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Abstract
Development of selective artificial metalloenzymes by combining the biological
concepts for selective recognition with those of transition metal catalysis has received
much attention during the last decade. Targeting covalent incorporation of
organometallic catalysts into proteins, we explored site-selective covalent coupling of
phosphane and N–containing ligands. The successful approach for incorporation of
phosphane ligands we report herein consists of site-specific covalent coupling of a
maleimide functionalized hydrazide into proteins, followed by coupling of aldehyde
functionalized phosphanes via a hydrazone linkage. Site selective incorporation of N–
containing ligands was obtained by coupling maleimide functionalized N–ligands to
proteins via Michael addition to the maleimide double bond. These two methods can
be easily applied to virtually any protein displaying a single reactive cysteine and
allows a wide range of possibilities in terms of cofactor design.
Site-specific covalent incorporation of transition metal complexes of phosphane
ligands into proteins was successfully obtained. The success of the approach is
influenced by several factors like the metal precursor, the phosphane type and the
protein scaffold.
Metal complexes of 5–maleimido–1,10–phenanthroline modified proteins were
formed in situ, via addition of a metal precursor to the phenanthroline modified
proteins or by coupling preformed metal complexes to proteins via Michael addition
of the thiol group from a cysteine residue to the maleimide double bond of the N-
ligand.
These successful coupling methods enable the use of a wide range of protein
structures as templates for the preparation of artificial transition metalloenzymes,
which opens the way to full exploration of the power of selective molecular
recognition of proteins in transition metal catalysis.
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1I. INTRODUCTION
I.1 Catalysis and sustainable chemistry
Waste-free, environmentally friendly production processes are an absolute necessity for
a sustainable society. The atom economic synthesis of many natural products has been
optimized by nature over millions of years and is realized by efficient biocatalysts,
enzymes. However, for the synthesis of many important and widely used
pharmaceuticals, agrochemicals, fine and bulk chemicals there are no enzymes
available. In industrial synthesis, several biological or bioinspired catalytic strategies
have been developed lately.1-2 Still, the number and diversity of these applications are
modest and the demand for new strategies remains high.
Catalysis is widely applied, from research laboratories to the chemical industry
(petrochemistry, bulk chemicals and fine chemicals industry). Also food processing and
many biological processes rely on catalysis. It is estimated that 90% of all chemical
products involve catalysis during different phases of their production.3 Catalytic
synthesis is superior to stoichiometric organic synthesis not only from an economic, but
especially from an environmental point of view. The amount of waste generated is
reduced as a result of improved selectivties and energy consumption is lowered by
reduction of reactions time and mildness of the reactions conditions.4 Therefore, a
solution to the environmental problems generated by chemical synthesis is the
development of new, highly selective catalysts, capable to catalyse a wide range of
chemical reactions and to improve reaction rates and yields.5
The idea of catalysed processes was first introduced by Jöns Jakob Berzelius in 1835,
who investigated systematically the previously recorded observations about changes in
substances when they were brought in contact with small amounts of species called
“ferments”.6-7 Wilhelm Ostwald, in 1894, was the first to give definition for a catalyst: a
substance that changes the rate of a chemical reaction but which is not consumed by the
reaction.8 According to Ostwald’s definition, a catalyst can also slow down a reaction.
Currently, a catalyst is defined as a substance that increases the rate of a reaction while
remaining itself unchanged. The catalyst affects only the rate of the reaction; it does not
2change the thermodynamics of the reaction and therefore not the equilibrium
composition.9
Catalysis can be divided into three distinct categories:
o heterogeneous catalysis – the area of catalysis involving substrates and catalyst
components in different phases. A heterogeneous catalytic reaction takes place
usually at the surface provided by the catalyst. A schematic mechanism is
represented by diffusion and adsorption of one or more reactants to the catalytic
surface, when the reactants bonds become weaker and allow product bonds
formation. This is followed by product desorption from the surface at the end of
the reaction, facilitated by the weak bonds existing between catalyst and
product, and diffusion of the product into the reactor environment.
o homogeneous catalysis - the substrates for reactions and the catalyst components
are in the same phase, most often the liquid phase. Homogeneous catalysis can
be further divided, corresponding to the nature of the catalysts, into nucleophilic
catalysis (using Lewis bases, Brønsted bases as catalysts), electrophilic catalysis
(using Lewis acids, Brønsted acids as catalysts), organocatalysis, which uses
simple organic molecules as catalysts and organometallic catalysis which deals
with transition metal complexes.
o enzymatic catalysis - catalysis that occurs due to the presence of enzymes or
complete microorganisms.
Homogeneous catalysis has been extensively used in organic synthesis. However,
limitations like a low selectivity or a reduced life time shown by some synthetic
catalytic systems, converted at the end in a low efficiency, require for major
improvements. The possibility of ligand tuning requires experience, a good knowledge
of the reactions mechanism and of the molecular modelling techniques, but also relies
on intuition and a great deal of trial and error.10 Moreover, in order to optimize the
catalyst performance, not only the steric and electronic properties of the ligand should
be considered, but also subtle experimental parameters like temperature, solvent or
presence of additives.10 Therefore, the methodologies used to develop new catalysts for
modern organic synthesis have to deal with all these problems.
Industrial application of biocatalysis for organic transformations has increased during
the last 20 years, mainly because of the high activity, chemo-, regio- and
enantioselectivity displayed by enzymes. The possibility to use some of them in organic
3solvents expanded also their applicability.11 The rapid progress in genomics, directed
enzyme evolution and the entire area of biotechnological engineering surpassed many
limitations of enzymes applicability.12 However, solutions still have to be found for its
remaining limitations like operational stability of enzymes and limited substrate and
reaction scope.12
An ideal catalyst seems to be the one capable of combining the best properties of both
areas: biocatalysis and homogeneous catalysis. It should demonstrate not only good
selectivity and high activity, but also high atom efficiency, low E-factor and industrial
applicability. An answer to these challenges could be represented by artificial
metalloenzymes, capable of combining the two domains and allowing using man-made
catalysts in organic synthesis under biological catalytic efficiency.
I.2 Enantioselective catalysis
The term enantiomers refer to stereoisomers that are nonsuperimposable complete
mirror images of each other. The differences in properties between enantiomers are not
displayed in regular environments, where enantiomers have identical physico-chemical
properties, but in asymmetric environments, like biological systems. The building
blocks of biological systems, amino acids and carbohydrates, are chiral and exist mainly
in single enantiomeric forms, consequently the chirality of the biological environments
is formed by them. In these chiral biological and living systems, chiral compounds like
drugs, fragrances, crop protectors, flavours etc. are recognized stereoselectively. The
difference in properties of two possible enantiomers could be the result of this
stereoselective interaction with chiral systems.13 Consequently, there is great scientific
and commercial interest for the preparation of enantiomerically pure compounds. For
example, the chiral drugs produced by the pharmaceutical industry needs to be tested for
the influence of chirality on all of their pharmacological, pharmacokinetic and
toxicological properties. This requirement is now a standard part of the drug research
and development process14 and is controlled by strict regulations.15 When a new chiral
drug is discovered, the development and commercialization of either a racemate or a
single enantiomer needs to be established from the first stages. Most often a single
enantiomer is developed, the opposite enantiomer being considered as an impurity that
is discarded when being detected.13
4A prime example of the impact of chirality on drugs safety is the thalidomide case. This
drug was widely prescribed to pregnant women in the late 1950's and early 1960's to
combat morning sickness. Before being released, the influence of chirality on drug
activity and safety was insufficiently tested. Thalidomide was used as a racemate, but
while the (R) enantiomer is effective against morning nausea, the (S) enantiomer is
teratogenic, resulting in severe birth malformations for the children of women who had
taken thalidomide during their pregnancies.16 The two enantiomers can interconvert in
vivo, therefore it is not possible to prevent the teratogenic effect by administration of
only one enantiomer.17
Considering the importance of chirality, efficient enantioselective technologies have
been developed for production and analysis of enantiomerically pure compounds.13
Three fundamentally different approaches are applied in order to obtain
enantiomerically pure compounds:18-19
- Resolution: separation of enantiomers by chemical and physical means – e.g. by
crystallization or liquid chromatography using chiral stationary phases. Also to
be mentioned is the interest during the last years in the development and
application of new miniaturized separation techniques, like
electrochromatography or nanotechnologies.13
- Chiral pool synthesis – the final chiral molecule is obtained from chiral
substrates, usually originating from natural products. The method can be applied
on a large scale only depending on the commercial availability of the starting
material.20
- Enantioselective synthesis, either stoichiometric or catalytic – preparation of
chiral compounds from achiral precursors, using chiral reagents or chiral
catalysts. Enantioselective catalysis is one of the most efficient methods in terms
of atom economy.21
I.2.a. Enantioselective homogeneous catalysis
Enantioselective organo- and organometallic catalytic reactions have been studied
intensively during the last forty years because of their high efficiency in producing
enantiopure compounds. The importance of work accomplished in this area was
recognized by a Nobel Prize awarded in 2001 to W.S. Knowles22 and R. Noyori23 for
5their contribution on chirally catalysed hydrogenation reactions and to K. B.
Sharpless24, for his contribution on chirally catalyzed oxidation reactions.
The history of enantioselective homogeneous catalysis starts in 1965 with the use of an
achiral catalyst: chlorotris-(triphenylphosphane)rhodium(I) - [RhCl(PPh3)3] by
Wilkinson and co-workers, as catalyst for the hydrogenation of olefins, demonstrating
for the first time the activation of molecular hydrogen by a metal complex (Figure 1).
Although homogeneous catalysts had been reported before, this was the first one having
rates comparable with those reported for the heterogeneous counterparts.25
3 3
3
3
3
3
3
3
3
3
3
3
3
- PPh3
Solvent (S)
Figure 1 Wilkinson’s hydrogenation cycle (mechanism investigated by Halpern and co-workers)5,26-27
In 1968, Knowles replaced the triphenylphosphane of Wilkinson’s catalyst with a chiral
equivalent, methyl(propyl)(phenyl)phosphane, and used this ligand for the rhodium-
catalysed hydrogenation of a prochiral olefin, α-phenylacrylic acid. The 15% 
enantiomeric excess (e.e.) reported, although modest, confirmed the possibility of
carrying out enantioselective catalytic reactions by using a metal (Rh) placed within a
chiral environment.28
6COOH COOH
RhClL3
H2
P
C6H5
CH3C3H7
L=
e.e. 15%
Figure 2 The first catalytic hydrogenation using a chiral phosphane ligand28
In the same year, Noyori and Nozaki discovered another example of asymmetric
catalysis, while trying to elucidate the mechanism of carbene reactions. Chiral
carbenoid species were obtained via decomposition of diazo compounds catalysed by a
chiral Cu(II) metal complex. One example is the decomposition of ethyl diazoacetate in
styrene in presence of bis[N-(R)-α-phenethylsalicylaldiminato] copper(II) or bis[N-(L)-
α-phenethylsalicylaldiminato] copper(II). An optically active mixture of cis and trans
cyclopropanecarboxylates is formed, with an enantiomeric excess of 6% and 10%
respectively (Figure 3).29
Figure 3 Asymmetric cyclopropanation of styrene using a chiral Cu(II) metal complex as catalyst29
Distinctive from Noyori’s catalyst, where the chiral centre is a carbon atom, the
Knowles catalyst contains a phosphorus stereogenic atom. When phosphanes having
two identical chiral alkyl side chains were tested, the enantioselectivity in
hydrogenation reactions was very low. Therefore it was hypothesized at this stage that,
to induce high selectivities, the chirality of the ligands should be located directly on
phosphorus.22
The substantial demand for the chemical L-dopa, a drug used in the treatment of
Parkinson disease, provided strong impetus for the further development of chiral
7phosphanes. The classical synthesis of this compound involved hydrogenation of a
prochiral enamide intermediate to protected DL-dopa, the racemic intermediate being
further resolved and deprotected to obtain L-dopa (Figure 4).22,30
COOH
NHCOC6H5
H2
Pd/C
HOOC
NHCOC6H5
DL mix
L form
deprotection
HO
O
HO
O
L-dopa
resolution
H3C H3C
HOOC
NHCOC6H5
HO
OH3C
HOOC
NH2
HO
OH3C
Figure 4 The former pathway of L-dopa synthesis (Hoffman-LaRoche process)
The next target was to find the right structure of a chiral phosphane able to catalyse the
hydrogenation of the enamine intermediate with very high enantioselectivity.
The enantioselective Rh-catalysed hydrogenation of a phenylalanine intermediate was
used as test reaction to study the efficiency and the structure-activity relationship of the
tested chiral phosphanes (Figure 5). The chirality induced by the initial ligand,
methyl(propyl)(phenyl) phosphane for this reaction was only 28%, but this provided a
promising starting point for a structure-activity study.
COOH
NHCOCH3
HOOC
NHCOCH3
Figure 5 Test reaction used to study the structure-activity relationship of chiral phosphanes developed for
the synthesis of L-dopa22
Initially the alkyl groups on phosphorus were varied by replacing the n-propyl with
more hindered isopropyl or cyclohexyl groups, but this did not yield a significant
improvement in enantioselectivity. The first enhancement resulted from the introduction
of the o-anisyl group, the enantioselectivity induced by PAMP - methyl(phenyl)(o-
anisyl)phosphane being increased up to 58%. Next, CAMP - methyl(cyclohexyl)(o-
anisyl)phosphane gave up to 88% e.e. for the test reaction, but also for the
8hydrogenation of the L-dopa precursor (Figure 6). Therefore its rhodium complex
[Rh(CAMP)2(COD)]+BF4- was used at the beginning in the Monsanto’s industrial
synthesis of L-dopa starting from vanillin.31 Knowles used an RhClL3 metal complex
for the first hydrogenation reaction studied. The replacement of chlorine by
cyclooctadiene (COD) in Monsanto’s process was justified by the improved solubility
and stability in air of the final metal complex.22
Figure 6 Series of chiral phosphane ligands synthesized by Knowles and co-workers by varying the
substituents on the phosphorus atom22
Initially it was hypothesized that the phosphane catalysts having the chirality on the
phosphorus are definitely superior. However, in 1972 Kagan introduced a diphosphane
ligand, which he called (R,R)-DIOP, with similar catalytic performances as CAMP, but
with the chirality provided by the carbon backbone (Figure 7).32 This discovery
introduced a new possibility to develop a whole series of diphosphane ligands with the
chirality located at the carbon backbone.
Figure 7 (R,R)-DIOP – phosphane ligand having the chirality induced by the carbon backbone32
Shortly afterwards, Knowles and co-workers reported the synthesis of a chelating
diphosphane ligand, called DIPAMP (Figure 6), with the chirality on the phosphorus
atom. This ligand replaced CAMP in the Monsanto L-dopa process where it displayed
enantioselectivity as high as 95% e.e.31 DIPAMP not only showed higher
9enantioselectivity, but it was easier to be synthesized than CAMP and it is a crystalline,
air-stable solid.22
The area of chiral phosphane ligands has expanded significantly after that and a large
number of versatile ligands are now readily available from commercial suppliers. For
example BINAP (2,2’-bis(diphenylphosphanyl)-1,1’-binaphtyl), a ligand with axial
chirality (Figure 8) introduced in the 1980s by Noyori and co-workers, was used
initially in combination with rhodium for catalytic hydrogenation of olefins,33 but it has
been used on a multitude of other reactions ever since.
Figure 8 BINAP - ligand presenting axial chirality
During the last two decades the area of asymmetric transition metal catalysis has been
developed significantly, becoming a common type of catalysis and allowing access to a
variety of compounds. However, a moderate number of asymmetric catalytic reactions
are used on an industrial scale today (e.g. hydrogenation, epoxidation, dihydroxylation,
isomerization, epoxide opening and addition reactions).34 This is due to several
problems associated with the production of chiral compounds on industrial scale. One
issue is the enantiopurity of the ligand, and consequently the enantioselectivity of a
chiral catalyst, which must be higher than 99% for pharmaceuticals and more than 80%
for agrochemicals and food products. The high price of chiral ligands and metal
precursors is also a limiting factor for their application on a large scale.
Generally, synthesis and optimization of a new catalyst involves a cyclic process which
includes three steps: (i) conception of a new catalyst, (ii) synthesis of the new catalyst
and (iii) testing its catalytic properties. The catalyst optimization consists of analysis of
the results obtained at the end of each cycle, followed by selection of the catalyst with
improved properties and the enhancement of its conception and synthesis for further
improvement. To obtain a highly active and selective catalyst, a very large number of
iterations may be required, making it a time-consuming process. These optimization
10
procedures have generally been applied to individual catalysts, known as the traditional
“one-catalyst-at-a-time” approach.10
In order to reduce the time and the costs of catalyst optimization, methods like
combinatorial chemistry and parallel synthesis can be applied in catalyst development.
These methods are used for simultaneous synthesis of different but structurally related
molecules. Combinatorial chemistry is a collection of methods that allow the
simultaneous chemical synthesis of a large number of compounds using a diversity of
starting materials. Multiple parallel synthesis is a related method used to prepare a
selected subset of molecules. The set of compounds prepared by multiple parallel
synthesis is more focused and less diverse than the large library resulting from
combinatorial techniques.35
Using the combinatorial chemistry and parallel synthesis methods, the synthesis and
optimization cycles can be applied simultaneously to a library of potential asymmetric
catalysts, rather than to each catalyst individually.10 In order to be applied, three main
conditions must be achieved:21,36
- existence of a source of diversity – represented by a library of ligands, of metal
precursors or a variety of reaction conditions;
- availability of methods to synthesize the catalysts fast and with a high purity;
- availability of methods for a high-throughput screening of the catalysts
performance.
The first condition, existence of a source of diversity, is not a limiting factor anymore.
A large variety of metal precursors and ligands is currently commercially available.37
However, even if methods for high-throughput screening of catalysts performance are
available nowadays (NMR, GC, HPLC or less often CE), this aspect still represents a
limiting factor not only presently, but probably also in the near future.10
Despite its significant progress, the area of asymmetric transition metal catalysis still
has important limitations. The energy difference involved in transition states leading to
both enantiomers is small. For that reason it is difficult to model or to calculate which
enantiomer of a desired product will be obtained for a catalytic reaction.38 In addition,
several subtle experimental parameters (solvent, counter ion, added salts etc), included
under the general term of second coordination sphere,39-41 exert an important influence
over the outcome of a reaction in homogeneous catalysis. However, the control over the
second coordination sphere is limited for the common enantiopure ligands because of
11
their relative small size. They are able to exert a considerable control only over the
hemisphere located around the catalytically active metal (known as the chiral ligand
hemisphere).39,41 Therefore, to induce a high enantioselectivity a catalyst should display
a higher control over the largest part of the second coordination sphere. In this way the
catalyst “shields” the active site and stabilizes the subtle experimental parameters which
influence the enantioselectivity of the reaction.41 However, even for catalysts displaying
high control over the second coordination sphere it still remains hard to predict the
enantioselectivity in a catalytic reaction.41
I.2.b. Enantioselective enzymatic catalysis
An alternative to enantioselective organometallic catalysis for the synthesis of
enantiomerically pure compounds is enzymatic catalysis. Enzymes are proteins that
possess catalytic activity and typically exhibit excellent regio-, chemo- and
enantioselectivity. Like all natural proteins, they are assembled from L-amino acids and
therefore they are chiral catalysts. Structurally an enzyme contains an active site which
is directly involved in selectively binding the substrate, creating the chiral environment
and carrying out the catalytic reactions. Frequently enzymes require cofactors (non-
protein organic or inorganic compounds) for catalytic activity. Cofactors can be divided
in two large groups: prosthetic groups and coenzymes, although there is not a sharp
division between these two.42-43 Generally, prosthetic groups form a permanent part of
an enzyme structure, being tightly bound to the apoenzyme, while coenzymes are
loosely bound organic molecules which carry chemical groups between enzymes and
can be released during the catalytic cycle. Two examples of compounds acting as
prosthetic group for some enzymes and coenzyme for others are thiamine diphosphate
(ThDP) and nicotinamide adenine dinucleotide (NAD+). ThDP is tightly bound in
transketolase or pyruvate decarboxylase, and less tightly bound in pyruvate
dehydrogenase. NAD+ also can be tightly bound in some enzymes, while it is loosely
bound in others.43
The catalytic mechanism of enzymes is explained by Pauling’s principle and consists of
lowering the activation energy of reactions by confining substrates in binding sites that
stabilize the transition state.44-46
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The use of biocatalysts provides several advantages. Enzymes display high selectivity
(chemo, regio and enantioselectivity) and high rates, resulting in a high quality product.
They supply a chiral first coordination sphere and a high control over the second
coordination sphere, being structurally able to shield the reactants and thus to prevent
possible side reactions.41 The molecular biology techniques could be applied in order to
obtain enzymes which satisfy supplementary requirements (e.g. broader reaction scope,
higher thermostability). Enzymes can be made readily available by expression in
adequate microorganisms, using recombinant DNA technology. Usually they act under
mild conditions and are used in aqueous media (but not always), therefore some
inherent problems of metal-catalysis (e.g. requirement for special equipments, undesired
side-reactions) are minimized. They are used in environmentally benign synthesis and
are biodegradable. The enzymatic reactions require few steps and in general there is no
need for protection of functional groups.
However, to fully exploit the advantages provided by enzymatic catalysis, it is
necessary to find solutions to overcome limitations of this area. One limitation is
represented by the small substrate scope exhibited in general by enzymes. Instability
under severe process conditions, substrate or product inhibition, high cost of production,
limited availability and lifetime durability, problems with product isolation due to
possible product contamination with catalyst are problems which can also be
encountered in biocatalysis. Enzymes have low volumetric productivities in general and
this requires high dilutions and complicated down-stream processing.
There are two ways to obtain enantiopure compounds using enzymes. One option is
biocatalysed asymmetric synthesis, in which an achiral substrate is converted to a chiral
product via enantioselective enzymatic conversion. The second option is the kinetic
resolution (KR) of a racemic mixture. In this process, one enantiomer from a racemic
mixture is converted, via enzymatic catalysis, with a higher reaction rate than the other
enantiomer. This means that the maximum yield is limited to 50%. A yield higher than
50% means that some of the other enantiomer has also reacted. However, Backvall and
co-workers demonstrated that full conversion of a racemic substrate to an
enantiomerically pure product can be achieved by combining enzyme catalysis for the
kinetic resolution with transition metal catalysis for racemization. By using a
racemization catalyst, the preferentially converted substrate enantiomer is replenished
during the course of the reaction, a process named dynamic kinetic resolution (DKR).47-
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49 This approach has been applied by several groups, for example for the
chemoenzymatic DKR of alcohols and amines.50-60
Currently enzymatic catalysis has become a valuable method for the synthesis of chiral
compounds not only in research laboratories, but also in pharmaceutical or
biotechnological industry. Commonly used enzymes are lipases for reactions involving
ester formation or hydrolysis,61-64 nitrilases for hydrolysis of cyanide group to acids65
and dehydrogenases for oxydoreduction of alcohols and ketones.66 The use of
dehydrogenases is limited sometimes by the cofactor (NAD(P)H or FADH)
regeneration.67-69
In other applications, like the enzymatic hydrogenation of enones and nitrolefins, it was
possible to use the whole microorganism which expresses the enzyme as catalyst
instead of the pure enzyme.70-71 This approach is more advantageous as the entire
process of enzyme purification is avoided. Another alternative is the combination of
reactions catalysed by whole microorganisms with reactions catalysed by enzymes. An
example, applied on industrial scale, is the two-step synthesis of vanillin from glucose,
by coupling a reaction catalysed by a microorganism (E. coli) with an enzymatic
reaction (Figure 9).72
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Figure 9 Synthesis of vanillin from glucose using E. coli (whole cells) and a pure enzyme72
Although the conventional use of enzymes at mild conditions in aqueous media brings
several advantages, it also presents limitations. The main disadvantages of using
aqueous media for synthesis reactions are the requirement of water soluble substrates,
occurrence of side reactions induced by water, degradation of common organic reagents
in aqueous media and the difficulties encountered sometimes in product recovery.11
Therefore a significant number of studies have been devoted to enzymatic reactions in
non-aqueous systems like organic solvents,11,73 ionic liquids, supercritical fluids,74
gases,75-76 eutectic mixtures77 or liquid crystals.11 Several enzymes have been used as
biocatalysts in biphasic systems like ionic liquids/supercritical fluids,78 ionic
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liquids/water,79 aqueous/oil phase80 or aqueous/organic phase.73 Enzymes have been
also used for conversions in solvent free systems.81-82
The long-standing dogma that enzymes have limited applicability in organic solvents
was initially justified by the conventional theory that they are denaturated in such
solvents.83 This theory holds when enzymes are investigated in aqueous-organic
mixtures, where water acts as a molecular lubricant.84-85 In such conditions, enzymes
have both the tendency to denature and also the conformational flexibility to do so.
However, in the absence of water enzymes become very rigid. As a result even if their
tendency to denature is higher in dry organic solvents, they don’t have the pliability for
denaturation.86
In general enzymes exhibit lower catalytic activity when they are used in organic
solvents.87 In hydrophobic solvents the enzymatic activity is usually higher than in
hydrophilic ones. This is because the hydrophilic solvents are capable of stripping the
tightly bound water, which is essential for catalytic activity.88 However, in organic
solvents enzymes can develop new properties like the ability to catalyse reactions which
are impossible or only marginal in water, solvent dependent selectivity and improved
thermostability. For example lipases and esterases are incapable of hydrolysing amides
but they are able to catalyse direct asymmetric acylation of racemic amines in organic
solvents,89-90 hence the industrial applicability for the preparation of chiral amines and
amides.91 Lipases and esterases have also been used for the synthesis of
enantiomerically pure alcohols, carboxylic acids or esters via enzymatic resolution of
their racemates in organic solvents.92-93 Regarding enzymes selectivity in organic
solvents, in particular substrate,94-97 enantio-98 and prochiral99 selectivity, was proved to
change remarkably when switching from one solvent to another.100-101 Enzymes showed
also improved thermostability in organic solvents. Three tested enzymes: porcine
pancreatic lipase,102 ribonuclease103 and α-chymotrypsin104 exhibited half-lives of
several hours in anhydrous solvents at 100ºC, while their deactivation in water requires
seconds at the same temperature.
Although the enzymatic catalysis in organic solvents has overcome some problems
encountered in the classical aqueous biocatalysis, the work in this area has involved so
far only a number of hydrolytic enzymes.93,105
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I.2.b.1 Directed evolution of natural enzymes
The approach of natural enzyme optimization through evolution was applied in
biochemistry as the directed evolution concept, to optimize and diversify natural
enzymes which are subsequently used as catalysts. The concept was first demonstrated
by Reetz in 1997 and several successful studies have been reported since then by both
academic and industrial groups.106-109 It is based on the appropriate combination of
random gene mutagenesis, expression of the enzyme mutants and high or medium
throughput screening for improvement of the desired properties10,110-115 (e.g. activity,
selectivity,107 organic solvents tolerance or improved thermostability).106 Importantly,
the concept can be applied to enzymes for which no structural information is available.
Together, these three steps represent a round of directed evolution. At the end of each
round the gene for the enzyme variant (hit) revealing the best properties is used as a
template for a new round of mutagenesis/expression/screening, a process which exerts
evolutionary pressure until the desired level for the improved properties is
reached.109,112,115-118
PCR (polymerase chain reaction) is a technique used to copy and amplify the
complementary strands of a DNA molecule without using living organisms. Several
techniques based on PCR have been used to create libraries of mutants. The most often
applied technique for mutagenesis is error-prone PCR (epPCR),119-120 in addition to
other methods like saturation mutagenesis121-122 and DNA shuffling.123-124
Error-prone PCR is based on introduction of random mutations, without being able to
control the location and the nature of the mutations. This is usually realised by using
error prone polymerases in the PCR process,125 but can also be realized by varying the
concentration of magnesium during the reaction, by using manganese salts or by using
an excess of certain oligonucleotides.126 Another possibility to introduce random
mutations without controlling their location and nature is to transform and grow the
plasmid containing the enzyme gene in “mutator” bacteria (bacteria with elevated
mutation frequencies).127-131
Saturation mutagenesis is a molecular biology method which restricts randomization to
predetermined sites in the enzyme. The result is represented by focused libraries,
created by replacing amino acid residues one by one, via mutagenesis, by the other 19
natural amino acids.128,132-133 The iterative saturation mutagenesis (ISM) method is a
more systematic approach for generation of focused libraries and it is a symbiosis of
rational design and combinatorial saturation mutagenesis. Using structural information
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of an enzyme, two or three amino acids are selectively chosen for saturation
mutagenesis, based on rational considerations.134-135
Two forms of ISM were developed, Combinatorial Active-site Saturation Test (CAST),
for controlling substrate scope and/or enantioselectivity,107-108,133 and the B-factor
saturation test (B-FIT) for increasing thermostability.106,135 Using these techniques, two
or three amino acids “hot spots” whose side chains are located next to each other and
close to the active site of the enzyme, are identified and randomized resulting in
libraries of mutants. The process is performed all around the active site of the enzyme.
The scheme can be applied in repetitive cycles, starting with mutagenesis in one
selected library, selecting the improved mutants and continuing successively to several
other libraries derived from improved mutants of the previous library. A powerful tool
to construct more focused enzyme libraries that requires considerably less screening
effort is the choice of the optimal codon degeneracy when modelling saturation
mutagenesis experiments. In this way, the size of focused libraries generated by targeted
mutagenesis is decreased and the quality, in terms of frequency of favourable variants
and the degree of catalyst improvement, is increased.136
In contrast with PCR, DNA shuffling is PCR without synthetic primers. It begins with
fragmentation of families of related genes with enzymes. The gene fragments then are
heated up to separate them into single-stranded templates. Some of these fragments will
bind to other fragments that share complementary DNA regions, which in some cases
are from other family members. At the end, new full length, shuffled genes are
constructed and multiplied by PCR.123
Even if important properties of enzymes (stability, selectivity, organic solvent tolerance,
substrate scope) could be engineered by applying the directed/designed evolution tools,
the overall process is time consuming, requires sophisticated equipment for high-
throughput screening and still has a very limited applicability.
I.2.c. Enantioselective hybrid catalysis
Biocatalysis and homogeneous asymmetric catalysis are both employed for the
production of enantiomerically pure compounds and these two areas of catalysis are
complementary in many essential aspects (Table 1).
17
Table 1 Comparison of typical characteristics of enzymatic and homogeneous catalysis38,137
Enzymatic catalysis Homogeneous catalysis
Reaction repertoire
Turnover number
Optimization
Second coordination sphere
Substrate scope
Enantiomers
Reaction medium
Reaction conditions
Recycling
Small
Large
Genetic
Well-defined
Limited
Single (usually)
Aqueous (mostly)
Mild
Immobilization protocols
Large
Modest
Chemical
Ill-defined
Large
Both
Organic (mostly)
Harsh
Rare
Hybrid catalysis is a relatively new area of asymmetric catalysis, aiming to combine the
most desirable properties of both parts, enzymatic and homogeneous catalysis. Artificial
metalloenzymes, as defined by Ward (2007), are catalysts resulting from the
introduction of an organometallic catalyst into a macromolecular host such as a protein,
DNA or an antibody, which provide a well-defined second coordination sphere and thus
induce the selectivity of the reaction.41
For a hybrid catalyst it is possible to optimize both the activity and the selectivity using
a chemogenetic approach.138 The activity can be optimized via a combinatorial approach
or parallel synthesis for the organometallic catalyst. The selectivity can be optimized via
molecular biology techniques for the host biomolecule.
The methods used to introduce a catalytic moiety into a host protein should be
optimized for the following aspects:
 Selectivity. All biomacromolecules possess a multitude of functional groups,
therefore the synthesis of well-defined systems by selective modification of a specific
site is not a trivial task.
 Compatibility with the host protein. The modified protein should be structurally
defined, therefore introduction of a ligand should not result in unfolding or denaturation
of the protein. The proper selection criteria should consider proteins presenting a robust
scaffold and ligands which are also active when they are located within the protein
environment.
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 Compatibility with coupling conditions and catalysis. Organometallic and organic
catalysts often require reaction conditions which are not compatible with proteins (high
temperatures, high pressure and presence of organic solvents).
A strategy is more beneficial when it can be applied for more than one protein and more
than one metal- or organocatalyst.
The strategies used to incorporate an artificial catalytic moiety within a
biomacromolecule host are the following:
 Supramolecular anchoring. The catalytic moiety acts like an anchor or is coupled to
an anchor which has supramolecular affinity for the host biomolecule. To ensure the
adequate localization of the ligand inside the binding pocket of the host molecule, a
very strong non-covalent guest-host couple should be selected. This condition comes as
a restriction of the method because of the limited number of suitable guest-host pairs
available.
 Dative anchoring. The artificial metalloenzyme is formed via coordination complex
formation of a metal ion of a catalytic moiety with amino acid residues of a protein,
which act as Lewis bases.
 Covalent anchoring of a catalytic moiety to a single, accessible functional group of
the host biomolecule. Typically the thiol group of a cysteine or the hydroxyl group of a
serine residue is used for covalent modification when proteins are used as host
biomolecule. However, selective incorporation of unnatural amino acids into proteins,
strategy developed mainly during the last ten years, allows further enhancement for the
covalent anchoring method. A variety of unnatural amino acids were incorporated into
recombinant proteins using specifically engineered bacterial strains.139-143 Those non-
natural amino acids possessing distinctive chemical reactivity create new possibilities
for bio-orthogonal conjugation of proteins with organic ligands. For example an azide
containing amino acid incorporated in a target protein has been selectively modified via
Staudinger ligation with triarylphosphane reagents. Importantly, this was performed
using a cell lysate mixture, in presence of all the other cellular proteins.144
 Cotranslational incorporation of multidentate metal-binding amino acids into
proteins. Schultz and co-workers reported the cotranslational incorporation of (2,2’-
bipyridin-5-yl)alanine into proteins. This approach opens additional possibilities to the
classical methods (covalent, dative and supramolecular anchoring) for artificial
metalloenzymes engineering.145
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I.3 Supramolecular anchoring
Biotin-(strept)avidin system
The most successful systems used for synthesis of artificial metalloenzymes based on
supramolecular anchoring of the catalyst are represented by biotin-avidin and biotin-
streptavidin couples. Both proteins, avidin and streptavidin, bind the vitamin biotin with
very high affinity and specificity. The affinity of streptavidin is lower (Ka ≈ 2.5x1013 M-
1) than that of avidin (Ka ≈ 1.5x1015 M-1), nevertheless these are the highest affinities
known in nature for a noncovalent interaction.146-147 Streptavidin has a deeper binding
pocket and it is a better chiral inducer than avidin,148 as host protein, and is very stable
in presence of denaturating agents.149-151
The biotin-avidin system was first used in 1978 by Wilson and Whitesides for creation
of artificial metalloenzymes. Their hybrid catalyst, formed by an achiral biotinylated
rhodium-diphosphane complex non-covalently coupled to avidin, was tested for the
hydrogenation of acetamidoacrylic acid. The 41% e.e. in favour of (S)-acetamidoalanine
was induced by the protein chirality.152
N
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H
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Figure 10 Whitesides diphosphane-rhodium biotin complex152
Figure 11 Enantioselective hydrogenation of acetamidoacrylic acid using a diphosphane-rhodium biotin
complex anchored to avidin152
Wilson and Whitesides achievement was strongly improved by Ward and co-workers.
They produced several efficient artificial metalloenzymes using initially avidin and later
streptavidin as host protein, in combination with biotinylated catalysts.148,153-165
As starting point the Whitesides rhodium-diphosphane biotin complex anchored into the
wild-type streptavidin was used for the hydrogenation of α-acetamidoacrylic and α-
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acetamidocinnamic acid. Two steps of chemogenetic engineering were applied.
Eighteen biotinylated rhodium-diphosphane complexes were screened throughout the
chemical optimization step and twenty mutants of streptavidin were tested during the
genetic optimization step. As a result, the enantioselectivity was improved to 94% e.e.
for the (R)-α-acetamidophenylalanine) and could be inverted to 88% e.e. for the (S)-α-
acetamidophenylalanine.155-156
Additional enhancements of the artificial metalloenzyme characteristics (selectivity,
reaction rates, solvent tolerance) were realized by applying the chemogenetic
approach138 again, in an extensive manner. The chemical optimization was done by
introducing chiral amino acid spacers (proline or phenylalanine) between the biotin
anchor and the diphosphane moiety and by varying the components of the metal
complex (metal, diphosphane ligand) and the chiral spacer. The genetic optimization
was done by introducing point mutations combined with saturation mutagenesis in the
protein scaffold in certain selected spots (Figure 12).
In this way the enantioselectivity was increased to 96% for the (R)-α-acetamidoalanine 
and 95% for the (S)-α-acetamidoalanine.148,157 In addition, the hybrid catalyst
containing the proline spacer showed enhanced stability towards organic solvents
(DMSO and ethyl-acetate, the latter under biphasic conditions).157-159
n
Figure 12 Schematic representation of the artificial metalloenzymes developed by Ward and co-workers
in enantioselective hydrogenation reactions148,155
Ward and co-workers were the first to genetically modify an artificial metalloenzyme.
For the optimization of the hybrid catalyst they used a combination of rational design
and combinatorial screening, an approach named designed evolution.137,166 The rational
design involved rational choices for the protein scaffold and for the mutation sites based
on structural information of the protein-biotin complex, and also for the chemical
components. The combinatorial screening included variation of the chemical
components and saturation mutagenesis for the protein.
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Reetz applied the concept of directed evolution of an artificial metalloenzyme,167-168 a
process fundamentally different from Ward’s designed evolution, for the optimization
of the hybrid catalysts based on biotin-streptavidin in hydrogenation of α-acetamido-
acrylic acid-methyl ester. By applying three cycles of random
mutagenesis/expression/screening, using Whitesides’ system as the starting point,
hybrids with improved and/or inverted selectivity were obtained. Starting from 23% e.e.
in favour of the (R) product before optimization, the enantioselectivity was enhanced up
to 65% e.e. for the (R) product and up to 7% e.e. for the (S) product).12,134 However, the
concept proved to be more difficult to apply for the hybrid catalysts than for the natural
enzymes. This was mainly due to problems associated with the protein expression
system and the air sensitivity of the metal complexes.
Following the application of the biotin-streptavidin based artificial metalloenzymes in
hydrogenation reactions, Thomas Ward’s group has focused on more challenging
reactions like transfer hydrogenation of ketone derivatives,153,160-161 oxidation of
secondary alcohols,162 allylic alkylation163 and sulfoxidation.164-165
Hybrid catalysts containing achiral biotinylated d6 piano-stool ruthenium complexes
[η6-(arene)Ru(biotin-ligand)Cl] bound to streptavidin were employed for
enantioselective transfer hydrogenation of ketones. After a first chemogenetic
optimization step, further improvements were realized by applying an additional
chemogenetic optimization based on the X-ray structure of a hybrid catalyst
variant.161,169 The nature of the capping arene (benzene or p-cymene) was found to have
a substantial influence on the reaction enantioselectivity.153,160
A similar approach based on biotinylated d6 piano-stool complexes embedded in
strept(avidin) was used for the reverse reaction, oxidation of racemic secondary alcohols
using tertbutylhydroperoxide (TBHP). In this case not only Ru-complexes were tested,
but also Ir and Rh-complexes, combined with both avidin and streptavidin as host
protein. Avidin and its mutants showed higher yields than streptavidin.162
Two types of streptavidin based hybrid catalysts were used by Ward and co-workers for
enantioselective sulfoxidation reactions: biotinylated manganese-salen complexes
incorporated in streptavidin as well as vanadyl-streptavidin.
Four achiral biotinylated manganese-salen complexes incorporated in streptavidin were
used as hybrid enantioselective catalysts for the aqueous sulfoxidation of thioanisole
with hydrogen peroxide, yielding moderate conversion (up to 56%) and low
enantioselectivities (maximum of 13% e.e.).165
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Although being optimized by nature to bind biotin with high affinity by combining both
hydrogen bonding and hydrophobic interactions, streptavidin can also bind a variety of
other ligands: (2-(4’-hydroxyphenyl-azo)benzoate (HABA), 1-anilino-8-naphthalene
sulfonate (ANS), different oligopeptides).146,150,164,170-171 Therefore, Ward and co-
workers considered the possibility of binding a catalytically active, small polar
coordination compound, the vanadyl ion, into the biotin-binding pocket of streptavidin.
Electron paramagnetic resonance (EPR) spectroscopy, docking studies, chemical
(addition of biotin) and genetic modification of the host protein suggested that
interactions between the active precatalyst [VO(H2O)5]2+ and the biotin binding pocket
are only via second coordination sphere. The resulting artificial metalloenzyme was
tested in enantioselective oxidation of prochiral sulfides using TBHP as oxidizing agent.
Good enantioselectivities were observed for both dialkyl and alkyl-aryl substrates (up to
93% e.e. for the sulfoxidation of methyl-2-naphtylsulfide).164
Serum albumins
Serum albumins have also attracted considerable interest in the area of artificial
enzymes based on supramolecular anchoring. Functioning as transport proteins, they
have a significant affinity for a variety of hydrophobic compounds like fatty acids,
steroids, thyroxine, porphyrins etc.172 Remarkably, serum albumins by themselves, and
in particular BSA, have been reported to induce moderate to good enantioselectivities in
several reactions, including sulfoxidation,173-177 epoxidation,178-180 reduction,181-182 and
Diels-Alder cycloaddition reactions.183
The first artificial metalloenzyme created via supramolecular incorporation of a metal
complex into serum albumin was reported by Watanabe in 2003. Two types of artificial
metalloenzymes containing a [CrIII-5,5’-tBu2-salophen] complex, one based on BSA
and the second on a myoglobin mutant, were tested for the enantiomeric sulfoxidation
of thioanisole. The hybrid catalyst based on BSA contained the CrIII complex bound
non-specifically, while in the myoglobin mutant it was bound via hydrogen bonding and
histidine (His 93) coordination to CrIII. The enantioselectivity and rate achieved with
[CrIII-5,5’-tBu2-salophen]-BSA were very low compared with those obtained using the
same CrIII-5,5’-tBu2-salophen complex incorporated within the myoglobin mutant. This
was assumed to be due to the non-specific binding of the metal complex to BSA and to
the absence of histidine coordination. No further characterization of the CrIII-5,5’-tBu2-
salophen binding positions to BSA has been reported.184
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Figure 13 CrIII-5,5’-tBu2-salophen complex inserted into BSA184
In 2009 Ménage and co-workers characterized three hybrid catalysts based on Mn-salen
complexes and HSA. As the hybrids crystallization was not successful, the localization
of the Mn-salen complexes within the cavity of HSA was assigned based on
spectroscopic characterization and on several competitive binding experiments.185 The
artificial metalloenzymes were tested in sulfoxidation of thioanisole by NaOCl. In
comparison with HSA alone, the artificial enzymes displayed higher efficiency
(conversion yield and rates) and chemoselectivity for sulfoxide over sulfone, but no
enantioselectivity was reported. In contrast with the metal complex alone, the hybrid
catalysts displayed inverted chemoselectivity. No oxidation was observed in presence of
hydrogen peroxide as oxidant. Considering the observation that for the epoxidation
reactions performed with hydrogen peroxide as oxidant, the reactivity of Mn-salen
complexes is highly improved when imidazole is coordinated in an apical position,186
this observation confirms that no histidine residue is involved in a dative interaction.185
Figure 14 Mn-salen complexes coupled to HSA via supramolecular interactions185
Antibodies
Another strategy to create artificial enzymes is based on non-covalent introduction of
catalytic activity into antibodies. This method exploits the capacity of the immune
system to generate specific monoclonal antibodies for particular molecules of interest.
In 1988 Schultz and Shokat reported reduction of Safranine T using an antibody-flavin
complex, a reaction that does not occur with free flavin. Antibodies were elicited
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against both the oxidized and the reduced form of the flavin cofactor. However the
oxidized flavin was bound with a 4x104 higher affinity than the reduced form to one of
the monoclonal antibodies. Based on the observation that enzymes could direct
substrate binding by non-covalent interactions,187 the idea was coined to incorporate
substrate binding sites adjacent to flavins to allow stereocontrolled chemical
reductions.188
Figure 15 Flavin cofactor used to generate antibody-flavin complexes: (a)oxidized form; (b)reduced
form188
In 1999 Keinan and Nimri were the first to report a catalytic antibody-porphyrin
assembly capable of catalyzing oxygenation reactions. Notably, this system exhibited
typical enzyme characteristics: oxidant and substrate selectivity, enantioselectivity and
Michaelis –Menten saturation kinetics. A structural analogue of the transition state of
sulfoxidation reactions was used as hapten for the production of monoclonal antibodies.
The highest enantioselectivity reported was 43% in favour of the (S)-sulfoxide
enantiomer, achieved for the sulfoxidation of thioanisole with iodosyl benzene (PhIO)
in presence of antibody SN37.4 and a Ru(II)porphyrin cofactor (Figure 16).189
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Figure 16 Rutenium (II) porphyrin cofactor coupled to antibody SN73.4 and used for enantioselective
sulfoxidation of thioanisole189
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Several other hemoabzymes (catalytic antibodies with a metalloporphyrin cofactor)
have been reported,190 exhibiting either peroxidase activity or monooxygenase activity.
However, all systems showed a relative low catalytic efficiency compared to natural
hemoenzymes. A possible explanation could be the fact that the selected antibodies lack
an amino acid residue like histidine or cysteine, which can coordinate axially to iron and
thereby enhances its redox potential. To address this problem the heme octapeptide
microperoxidase 8 (MP8), obtained by hydrolytic digestion of horse heart cytochrome c,
was used as hapten. MP8 contains the heme prosthetic group and also the amino acid
residues 14-21 of the cytochrome. The imidazole side chain of histidine 18 plays a
critical role by acting as a fifth axial ligand for iron. MP8 binding to amino acids of the
binding site occurs via four carboxylate substituents, two from propionate side chains of
the heme and two from the C-terminal glutamic acid Glu 21 of the octapeptide (Figure
17).190
Figure 17 Structure of microperoxidase 8
Using the catalytic system formed by the 3A3 monoclonal antibody and
microperoxidase 8 (3A3-MP8) for sulfoxidation of thioanisole using hydrogen peroxide
as oxidant, the enantiomeric excess was 45% in favour of the (R)-sulfoxide enantiomer.
This enantioselectivity is not only slightly higher than the one reported by Keinan et al.
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in 1999 for the same reaction, but is also inverted, as the (R) enantiomer is favoured
now.191
In 2006 Harada and coworkers elicited monoclonal antibodies against an achiral Rh
cyclooctadiene phosphane complex (Figure 18).
Figure 18 Structure of the achiral Rh complex used as hapten by Harada and co-workers192
Four catalytic systems based on four different monoclonal antibodies complexed with
this hapten were tested in asymmetric hydrogenation of amino acid precursors. One
combination (1G8-Rh complex) gave the enantiomer (S)-N-acetyl-L-alanine in 98% e.e.
for the hydrogenation of 2-acetamidoacrylic acid. In absence of antibodies, the achiral
Rh complex converted the substrate to racemic N-acetyl-alanine. The high
enantioselectivity obtained indicates that the attack over the double bond of the
substrate occurs only at one side of the alkene, the other side being blocked by the
antibody.
The Rh catalyst-antibody 1G8 complex also displayed substrate specificity, yielding no
conversion for larger substrates (2-acetamido-cinnamic acid and 2-acetamido-4-
methylpentenoic acid). This is caused by the control exerted by the bound antibody,
which does not allow accessibility of larger substrates to the Rh catalyst.192
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Figure 19 Schematic representation of the antibody 1G8 - Rh catalyst complex showing the substrate
specificity (P - diphenyl phosphane ligand; S - solvent molecules)192
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The previously reported antibody-based hybrid catalysts were based on cofactors
existing also in natural enzymes (flavins, porphyrins). In contrast, Harada’s catalytic
system employs a transition metal complex which is not found in natural enzymes, but
which has previously been applied in homogeneous catalysis for a variety of reactions
such as hydrogenation, hydroformylation and isomerization and was also used for the
synthesis of (strept)avidin based artificial metalloenzymes.148,152,155-156,158
I.4 Dative anchoring
The first artificial metalloenzyme created via dative anchoring strategy by Kaiser and
co-workers (1976) was based on the concept of replacing the native metal bound to the
active site of a metalloenzyme with a different one.193 By applying this concept, the
problems associated with synthesis of ligands and their couplings to proteins are
avoided. However, the high potential for unspecific binding of metals to proteins, most
probably to the side chains of cysteines, lysines and histidines, limits this approach.194-
196 For example, the Rh(II) complex [Rh2(carboxylate)4] binds weakly (K≈103) to serum
albumin in a molar ratio of about 8 rhodium atoms per serum albumin.197-198 Several
years after the first studies about the direct linkage of Rh(I) and Rh(II) complexes to
albumins, a complex formed by serum albumin and 30-fold molar excess of rhodium (I)
was tested in hydroformylation reaction, nevertheless no improved selectivity was
reported.199
Kaiser’s artificial metalloenzyme involved the carboxypeptidase A (CPA) as protein
host. This zinc containing metalloenzyme exhibits peptidase and esterase activity. By
replacing the active-site zinc by copper the CPA was transformed into an effective
catalyst for the oxidation of ascorbic acid to dehydroascorbic acid. The approach was
termed chemical mutation. The new artificial metalloenzyme showed neither peptidase
nor esterase activity, but was capable of binding the typical CPA inhibitors, such as β-
phenylpropionate and (rac)-α-benzylsuccinate. This property indicates the preservation 
of the native structure of the protein binding site.193
Later on, two different groups created an enantioselective oxidase by replacing the
active-site zinc in carbonic anhydrase with manganese. The hybrid catalyst was used for
enantioselective epoxidation of styrene with hydrogen peroxide. The reported
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enantioselectivity was moderate, but it was comparable to that of natural peroxidases.
Moreover, no unspecific binding of Mn ion was detected.200-201
A similar strategy was utilized by Sheldon and co-workers. They replaced the active site
zinc of the protease thermolysin with a tungstate, molybdate or selenate oxoanion
instead of another metal. This strategy differs from a simple replacement, as zinc and
the oxoanions have opposite charge and a different size. The resulting tungstate–
thermolysin hybrid catalyst was moderately active but not enantioselective in
sulfoxidation reaction.202
All methods described so far involved modification of the active site of metalloproteins.
Sheldon and co-workers introduced also a different approach based on incorporation of
metal ions in non-metalloproteins, in certain specific binding sites. Their strategy
exploited the structural similarity of vanadate to phosphate for the efficient inhibition of
the hydrolytic activity of a phytase and for generation of a vanadium-incorporated
phytase. Initially they used a phytase from Aspergillus ficuum, an enzyme which
mediates the hydrolysis of phosphate esters in vivo. The vanadium based semisynthetic
enzyme has been used for the enantioselective sulfoxidation of thioanisole. The choice
of the reaction was motivated by the phosphatase-like activity shown by natural
vanadium chloroperoxidases and also based on the structural similarity of vanadium
chloroperoxidases and the acid phosphatases (Figure 20).203 Although the metal free
phytase also catalyses this reaction, the vanadium-incorporated phytase increased the
conversion to 100% and the e.e. up to 66% (Figure 21).204 Furthermore, this
semisynthetic peroxidase was stable for more than three days at relative high
concentration of hydrogen peroxide, in contrast to heme-dependent peroxidases which
have the disadvantage of low operational stability. Slightly higher enantioselectivities
were observed when the same hybrid catalyst was tested for the enantioselective
sulfoxidation of ethyl-phenyl-sulphide and meta and para substituted thioanisoles under
the same conditions. Several other transition metal oxoanions were incorporated in the
active site of phytase and the catalytic properties of the hybrid catalysts were tested in
the same conditions, but only the vanadate-incorporated phytase showed genuine
peroxidase activity.205
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Figure 20 Schematic representation of the active sites of vanadium chloroperoxidase from C. inaequalis
(a) and vanadate modified phytase from A. ficuum (b)205
Figure 21 Sulfoxidation of thioanisole catalyzed by vanadium-modified phytase205
Following the phytase from A. ficuum, other phytases from different sources, but also
other enzymes (acid phosphatases, aminoacylases, albumins, phospholipases, sulfatases)
were tested for peroxidase activity with and without vanadate incorporation. In the
presence of vanadate, several enzymes exhibited peroxidase activity: the phytases from
A. fumigatus and A. nidulans, sulfatase from Helix pomatia and phospholipase D from
cabbage. In the absence of vanadate, only phytase from A. ficuum gave catalytic
enantioselective sulfoxidation of thioanisole.206
The first attempt to create a semisynthetic hydrogenase via the dative anchoring strategy
was performed by Zhu and co-workers (1993).207 Following Kaiser’s procedure, Zhu
and co-workers were successful in replacing the zinc ion of CPA with cobalt, nickel and
rhodium, metals known to catalyse hydrogenation reactions. However, Co-, Ni-, Rh-
CPAs and the native Zn-CPA did not show any activity as hydrogenation catalysts.207
Kazlauskas and co-workers created a semisynthetic hydrogenase capable of direct
hydrogenation of substrates with hydrogen, by replacing the active-site zinc of carbonic
anhydrase with rhodium. The problem of cofactor regeneration was surpassed by using
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molecular hydrogen. The Rh(I) – carbonic anhydrase was reported as an active and
selective catalyst for direct hydrogenation of olefins, showing a 20:1 selectivity for
hydrogenation of cis-stilbene over trans-stilbene. The enantioselectivity was less than
10% in the products, for preliminary experiments with prochiral substrates. Two
approaches were efficiently applied to minimize non-specific binding of rhodium to
protein while allowing its binding to the active site: site-directed mutagenesis and
combined site directed mutagenesis with chemical modification of histidines.196
Serum albumins
Serum albumins are a good choice for generation of enantioselective hybrid catalysts
because they are robust proteins, readily accessible and easy to handle.172 The first
enantioselective semisynthetic enzyme based on dative incorporation of a metal moiety
into a protein environment was based on BSA and it was reported by Kokubo and co-
workers (1983). They used a 1:1 complex of osmium tetroxide and BSA as catalyst in
cis dihydroxylation of alkenes using tertbutylhydroperoxide as oxidant. The anchoring
of OsO4 inside BSA was speculated to occur via two dative bonds with lysine residues.
The highest enantioselectivity achieved was 68% (S) for the dihydroxylation of α-
methylstyrene.208
It has been reported that sodium salts of di-, tri- and tetrasulfonic acid derivatives of
porphyrins, phthalocyanines and corroles bind strongly to serum albumins in a non-
covalent manner.209-213 The first assignment for structural localization of a hemin group
inside HSA was reported by Curry and co-workers.214
Figure 22 Albumin-conjugated corrole metal complexes as enantioselective catalysts in asymmetric
sulfoxidation215
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Mahammed and Gross anchored amphiphilic bis-sulfonated MnIII and FeIII corroles to
several serum albumins. The resulting hybrids were used for asymmetric oxidation of
prochiral sulfides to sulfoxides by hydrogen peroxide, with up to 74% e.e (Figure 22).
The albumin source had a significant influence on enantioselectivity. Five sources of
serum albumin were tested, the highest e.e. being obtained for conjugates of BSA.
Throughout the series of substrates and albumins, the results obtained with MnIII corrole
conjugates were significantly superior to those with FeIII corrole conjugates regarding
enantioselectivity, chemical yield and stability of the catalyst. The limited stability,
reflected by catalyst inactivation, is the main disadvantage for the related porphyrin-
based systems.216 However, no catalyst inactivation and/or protein oxidation was
observed for the oxidation reactions catalysed by albumin-conjugated manganese
corroles in presence of hydrogen peroxide.215
Reetz and co-workers used copper – phthalocyanine conjugates of serum albumins to
catalyze Diels-Alder reaction of azachalcones with cyclopentadiene in aqueous
conditions. High endo-selectivities (91-95%) and enantioselectivities (85-98% e.e.)
were reported (Figure 23). Among the six different serum albumins tested, the best
selectivities were achieved with BSA.217
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Figure 23 Serum albumin conjugated copper-phthalocyanines as enantioselective catalysts for Diels-
Alder reaction217
Serum albumins without additional metal complexes were previously used as catalysts
for sulfoxidation and Diels-Alder reaction (see sub-chapter I.3). However, for the
particular reactions tested by Gross and Reetz the catalytic activity of serum albumins
alone was negligible under identical conditions.217
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Curry and co-workers confirmed the binding of a hemin complex to HSA through axial
coordination of tyrosine Tyr161 to the iron ion.214 Therefore it is believed that binding
of MnIII and FeIII corroles (Figure 22) and Cu-phtalocyanine (Figure 23) to serum
albumins is realized via this tyrosine residue as well.137
Apomyoglobin
A novel strategy based on reconstitution of apomyoglobin (apo-Mb) and several
apomyoglobin mutants with symmetric MIII Schiff base complexes (M=Cr and Mn)
was reported by Watanabe and co-workers.184 Apo-Mb is an excellent candidate for
construction of artificial metalloenzymes because it possesses a cavity of 10Å which
accommodates the heme prosthetic group. The heme group is bound non-covalently to
the protein via hydrogen bonds and hydrophobic interactions and also via coordination
of histidine His93 to the heme iron.218 Additionally the apo-Mb reconstitution with
heme has been well studied.219-222
MIII Schiff base complexes (Figure 24) have been used as catalysts for several oxidation
reactions in organic solvents. On this basis the resulting artificial metalloenzymes were
used for enantioselective sulfoxidation of thioanisole with hydrogen peroxide. The
reactivity and enantioselectivity reported for the MIII-Schiff base complexes coupled to
the wild type apo-Mb were low.
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Figure 24 Schiff base complexes inserted into apomyoglobin223
Using a rational design approach based on the X-ray crystal structure data of metal
complex-protein hybrids, the reactivity and enantioselectivity were improved either by
site directed mutagenesis or by changing the position of the metal ion.224 The position of
the metal complex in apo-Mb is regulated by noncovalent interactions between the
ligand and surrounding protein and by the coordination of histidine His93 to the metal
ion. In addition, hydrophobic interactions between isoleucine Ile107 and the 3 and 3’-
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substituents on the salen/salophen ligand control the location of the Schiff base ligand in
the active site (Figure 25). Therefore it was possible to successfully control the
enantioselectivity by changing the size of the substituents at 3 and 3’ positions.
Moreover, the enantioselectivity was inverted by replacing the 3 and 3’ - methyl groups
with more bulky ethyl and n-propyl groups.223
Figure 25 Cartoon representation of the crystal structure of CrIII(3,3'-Me2-salophen)/apo-A71G Mb (PDB
ID 1J3F)224 (His 93 of apo-A71G Mb is represented in green)
The importance of the anchoring strategy for the catalytic properties of an artificial
metalloenzyme was highlighted by Lu and co-workers. To optimize the low e.e. of
sulfoxidation reactions catalyzed by MIII Schiff base complexes non-covalently attached
to the wild type myoglobin184,225 it was necessary to modify either the myoglobin
binding pocket by site directed mutagenesis or the Schiff base ligand by changing its
substituents.223 Using these strategies, the e.e. was increased up to 33% (S) and
27%(R).223 Another strategy which increased slightly the enantioselectivity (12%) was
the covalent incorporation, by single point attachment, of a Mn-salen complex into the
Y103C apo-Mb mutant.225 A similar e.e. (<10%) was reported by Reetz and co-workers
for a Mn-salen complex attached covalently to papain.12 The low enantioselectivities
reported for the single point covalent attachment strategy suggest that the metal
complex can adopt multiple conformations inside the binding site of the protein. This
hypothesis was corroborated by the significant increase in e.e. (51%) when the Mn-
salen complex (Figure 26) was incorporated into the L72C/Y103C myoglobin mutant
via two disulfide bridges. The dual anchoring limits the number of possible
conformational states of the metal complex inside the protein cavity and as a result
improves the e.e. The high enantioselectivity reported for the dual anchoring strategy
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was obtained without additional genetic mutations of myoglobin or modification of the
salen group. This suggests that the e.e. could be even further improved via
chemogenetic optimization.225
Figure 26 Mn-salen complex coupled to cysteines by methane thiosulfonate groups225
I.5 Covalent anchoring
Covalent anchoring is an alternative approach to create artificial metalloenzymes. The
most used method for covalent protein functionalization is the modification of the thiol
group of a cysteine. Modifications of other amino acid residues have also been
described. A number of groups (Reetz, van Koten) reported the synthesis of hybrid
catalysts based on modification of an activated serine residue of lipase.12,226-228 Lysine
covalent modification of proteins (BSA, lysozyme, avidin) with several organotransition
metal complexes was reported by Salmain and co-workers. However, protein labelling
was not site-selective and involved several binding sites, resulting in mixtures of
modified proteins.229-230 Specific labelling of a lysine residue of a protein (the aldolase
antibody 38C2) was reported by Janda and co-workers.231 Kaiser and co-workers used
the asparagine residues Asp-52 and Asp-101 of lysozyme for the synthesis of two
flavolysozyme isoenzymes via ester bond formation betwteen flavin analogues and
asparagines.232
Selective cysteine modification is a particularly useful bioconjugation reaction. It
exploits the high reactivity of the sulfhydryl group of cysteine but also the relatively
modest occurrence (1.7%) of cysteine in peptides and proteins.233-234 As a consequence,
the requirement of a unique cysteine for a selected protein can be easily accomplished
via site directed mutagenesis. The cysteine location and consequently the position of the
catalytic moiety within the protein cavity can also be adjusted via site directed
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mutagenesis. This can be a useful tool for controlling the enantioselectivity of a hybrid
catalyst.
Papain
Kaiser and co-workers were the first to report a semisynthetic enzyme created by
covalent modification of a cysteine residue of papain with an isoalloxazine derivative.235
The strategy of the initial concept was to combine the substrate specificity of the
enzyme with the characteristic chemical reactivity of the coenzyme analogue. By
alkylation of the active site cysteine-25 of papain with the flavin analogue 7α-
(bromoacetyl)-10-methylisoalloxazine (Figure 27- a) a semisynthetic oxidoreductase for
the oxidation of dihydronicotinamides was synthesized (Figure 27- d). The novel
synthetic enzyme exhibited saturation kinetics at low substrate concentrations and
significant rate accelerations relative to the model flavin 7-acetyl-10-
methylisoalloxazine.235-236
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Figure 27 Isoalloxazine derivatives covalently coupled to papain to generate semisynthetic flavoenzymes
for the oxidation of dihydronicotinamides237-238
Subsequently, two other flavopapain isoenzymes were created by alkylation of Cys-25
with 6α- and 8α-(bromoacetyl)-10-methylisoalloxazine (Figure 27- b and c). Even 
though the three parent isomers (6, 7 and 8-acetyl-10-methylisoalloxazine) have similar
chemical reactivity, the resulting flavopapains showed completely different rate
enhancements for catalysis of the oxidation of dihydronicotinamides (Figure 27- d) by
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oxygen. While flavopapain (c) showed no rate enhancement and flavopapain (a)
exceeds about 10 times the oxidation rate of the flavin prostethic group, flavopapain (b)
shows a catalytic rate enhancement of 100-fold to almost 1000-fold, which is
comparable to the activity exhibited by naturally occurring flavin containing
oxidoreductases.238
The three flavoenzymes were used also as catalysts for the oxidation of various dithiols
to disulfides, under anaerobic conditions. The most efficient catalyst was again the
flavopapain (b), with a catalytic rate enhancement of 100-fold relative to the model
flavin.239-240
The substantial differences in efficiency between the three flavopapains were assumed
to be the result of the differences in the flavin geometry at the active site. The flavin
orientation is determined by the hydrogen interactions to the neighbouring residues in
the protein backbone.
After Kaiser’s report, several other protein templates were covalently modified with
isoalloxazine derivatives to generate semisynthetic flavoenzymes.
Two flavolysozyme isoenzymes were created via ester bond formation between
bromoacetyl derivatives of isoalloxazines and the asparagine Asp-101 and respectively
Asp-52 of lysozyme. In this manner Kaiser’s initial concept was extended to proteins
that lack a highly reactive amino acid.232
A semisynthetic flavohemoglobin capable of carrying out aniline hydroxylation in a
similar mode with microsomal cytocrome P-450, was created by covalently attaching an
isoalloxazine moiety to hemoglobin in the vicinity of heme. The activity of NADPH-
dependent flavohemoglobin Fl-Hb3+ was similar to that of ferric hemoglobin Hb3+
reconstituted with NADPH-cytochrome P-450 reductase for this hydroxylation reaction.
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Another protein used to generate semisynthetic flavoenzymes was glyceraldehyde-3-
phosphate dehydrogenase (GAPDH).242 Two types of GAPDH were employed. The
first one was the rabbit muscle GADPH. The resulting flavo-enzyme was used as
catalyst for oxidation of NADH, NADPH and 1,4-dihydronicotinamides, showing a rate
acceleration of 120-fold for the oxidation of NADH.242 The second one was the
GADPH from Bacillus stearothermophilus. The subsequent flavo-GADPH showed
6000-fold rate acceleration for the oxidation of NADH by molecular oxygen at low
substrate concentration. It was also capable of catalysing the oxidation of
dihydronicotinamides at temperatures as high as 55°C.243
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Following Kaiser’s study on flavopapains, several other chemical modifications at the
active site sulfhydryl of Cys-25 of papain were reported, with coenzyme analogues or
with organic ligands.
Zhu and co-workers reported thiazolium modified papains as the first semisynthetic
enzymes capable of mediating carbon-carbon bond formation. The main reaction was
the dimerisation of 6-oxoheptanal (a) to 7-hydroxytetradecane-2,8,13-trione (b) and the
secondary reaction was cyclisation of 6-oxoheptanal (a) to 2-methylcyclohex-2-enone
(c) (Figure 28).244
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Figure 28 Thiazolium modified papains as hybrid catalysts for dimerisation and cyclisation of 6-
oxoheptanal244
De Vries and co-workers reported a papain-hybrid catalyst synthesized by covalently
coupling a monodentate phosphite ligand to the cysteine Cys-25 (Figure 29). The
artificial metalloenzyme was active in the hydrogenation of methyl 2-acetamidoacrylate
with hydrogen (100% conversion). However, no enantioselectivity was reported,
presumably because of the large flexibility of the catalyst or because of the catalyst
location far from the chiral environment of the enzyme. This study shows clearly that
active catalysts can be obtained via site specific modification of a cysteine residue in
proteins with transition metal complexes.245
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Figure 29 Papain based hybrid catalysts synthesized via covalent modification of Cys-25 with a
monodentate phosphite ligand and complexation with rhodium245
Reetz and co-workers modified Cys-25 of papain with a manganese-salen complex
(Figure 30- a) and with dipyridyl moieties (Figure 30- b) complexing copper, palladium
and rhodium. The Mn-salen hybrid catalyst was tested in epoxidation reactions and the
Rh-catalyst in hydrogenation, but in all cases the enantioselectivities were not higher
than 10%, confirming once again the lack of stereocontrol of the papain based hybrid
catalysts.12,246-247
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Figure 30 Covalent modification of the thiol group of Cys-25 of papain with a Mn-salen complex (a) and
with a dipyridyl moiety (b)12,247
Three organometallic maleimides (Figure 31) derived from ferrocene, ruthenocene and
cyrhetrene (η5-cyclopentadienyl tricarbonyl rhenium(I)) were synthesized and
covalently coupled to the Cys-25 of papain by Jaouen and co-workers. The transition
metal organic complexes were investigated as heavy-metal reagents for protein
structural determination by X-ray crystallography. This work confirms once again the
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possibility of chemospecific modification of proteins with transition metal complexes
via cysteine modification.248
n
n
n
n 3
Figure 31 Organometallic N-substituted maleimides coupled covalently to Cys-25 of papain248
FABPs (fatty acid binding proteins)
Kaiser’s approach for creation of semisynthetic enzymes by combining the substrate
specificity of naturally occurring enzymes with the characteristic reactivity of natural
cofactors was amended by Distefano and co-workers. Instead of using natural enzymes,
they employed carrier proteins to synthesize pyridoxamine (Px) conjugates (Figure 32-
a). Two fatty acid carrier proteins (FABP) had been tested, the adipocyte lipid binding
protein (ALBP) and the intestinal fatty acid binding protein (IFABP). The ALBP-Px
conjugate contains the pyridoxamine cofactor coupled via a disulfide bridge to the
unique cysteine residue Cys117. This artificial enzyme was shown to be an active and
enantioselective catalyst (up to 94% e.e.) for the reductive amination of a number of
alkyl, aryl and side-chain functionalized α-keto acids to α-amino acids (Figure 32- b).249
Moreover, it was possible to tune the rate, the enantioselectivity and the substrate
specificity of the semisynthetic transaminases. This was done by varying the position of
pyridoxamine inside the protein cavity, through changing the position of cysteine via
site directed mutagenesis.250 To increase the turnover numbers it was necessary to
overcome the pyridoxamine regeneration, the factor limiting turnover. This was solved
by using a second amino acid as an amine source (Figure 32- c).251
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Figure 32 FABP-Px used as hybrid catalysts for transamination reactions249-251
By replacing pyridoxamine with N-methylated pyridoxamine, a permanently positive
charge was placed on the cofactor. In this way a native transamination site was
mimicked, by stabilizing a cationic pyridoxamine ring system.252
A major step forward was achieved by the synthesis of 1,10-phenanthroline conjugate
of FABPs, thus enabling coordination of a metal ion within the defined protein cavity
(Figure 33- a). The ALBP-Phen-Cu(II) conjugate catalyzed the enantioselective
hydrolysis of several unactivated amino acid esters (with e.e.’s ranging from 31% to
86%) and the hydrolysis of amides (Figure 33- b and c).253
The rate and the selectivity of phenanthroline derivatives were enhanced by modifying
the location of phenanthroline ligand attachment within the protein cavity to three
different positions. In this way the cofactor orientation and the environment around the
catalytic metal centre were modified .251
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ester and amide hydrolysis253
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Figure 34 Cartoon representation of the crystal structure of ALBP-phenanthroline (PDB ID 1A18)254
Lipases
The hydroxyl group of serine has also been exploited for site specific modification with
organic ligands. To circumvent multiple modifications of serines, a successful idea was
to use lipases as protein backbone and phosphonate inhibitors as anchoring units, in
order to achieve a single site-directed modification. The phosphonate inhibitors are
capable of reacting covalently at the catalytically active serine site of a lipase,
selectively in the presence of other serine residues in the enzyme. The concept was
applied first by Reetz and co-workers. By using a dinitrophenol phosphonate
diphosphane, they incorporated a bidentate diphosphane ligand in the lipase from
Bacillus subtilis (Figure 35). However, the resulting hybrid was unstable and after 24 h
the inhibitor was cleaved hydrolytically in water167,246.
Figure 35 Bidentate diphosphane covalently coupled to the reactive serine residue in the active site of
lipase via a phosphonate inhibitor167,246
To prevent the hydrolysis of the second p-nitrophenol leaving group, van Koten and co-
workers replaced it by ethanol. A small series of phosphonate esters were synthesised
and covalently coupled to different ECE-pincer-type (ECE=[C6H3(CH2E)2-2,6]; E= NR2
or SR) metal complexes through a propyl tether (Figure 36- a). The organometallic
phosphonate-pincer-metal complexes were successfully coupled to the serine residue
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Ser120 of the lipase cutinase. The resulting hybrids were stable in aqueous buffer
solutions and tolerated aqueous dialysis purification conditions, but so far they were not
tested in catalysis.226
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Figure 36 Selective covalent modification of cutinase with different organometallic phosphonate-ECE
pincer-metal complexes226-227
The presence of the propyl linker placed the metal centre of the ECE pincer out of the
cutinase molecule, as was shown by the crystal structures of the modified cutinase.228
The location outside of the metal centre allowed different orientations of the metal
complex. Consequently, the chirality induced by the protein environment in the catalytic
reactions of the pincer-metal complex is anticipated to be low. To achieve a closer
contact between the pincer-metal group and the chiral protein environment, different
pincer-metal cutinase hybrids were synthesized in which the C3 linker was removed and
the pincer-metal complex was directly attached to the phosphonate group (Figure 36-
b).227
The nature of the ECE-pincer-metal group is also important, as was shown by the
crystal structures of the covalently modified cutinase. The ECE-pincer-platinum and
palladium inhibitors occupy different pockets in the active site of cutinase and impose
different stereochemistry on the phosphorus atom.228
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Seleno-subtilisin
Already in 1966, Polgar and Bender reported the preparation of a semisynthetic enzyme,
a thiol-subtilisin, by transforming the reactive serine residue Ser221 in the active site of
subtilisin to a cysteine residue.255-256 By applying this approach Hilvert and co-workers
achieved the synthesis of a seleno-subtilisin, through converting the active site serine
Ser221 into cysteine and subsequently into selenocysteine.257 The new semisynthetic
enzyme displayed novel acyl transferase properties as it favoured aminolysis over
hydrolysis, compared to the native subtilisin. In addition, it was capable of catalysing
the reduction of hydroperoxides by thiols, similar to the natural selenoprotein
glutathione peroxidase.258-259 Further investigations of Schreier and co-workers reported
enantioselective reduction of a variety of racemic hydroperoxides catalysed by seleno-
subtilisin. The catalytic efficiency of seleno-subtilisin was comparable to that of native
peroxidases. However, the semisynthetic enzyme exhibited the opposite sense in
enantioselectivity, suggesting that it may optimally complement the naturally available
peroxidases.260 Cross-linked microcrystals of seleno-subtilisin were synthesised using
glutardialdehyde as cross-linker. The microcrystals are insoluble in water and organic
solvents, can be easily recovered by centrifugation or filtration and recycled. Moreover,
the e.e.’s obtained using microcrystals are similar with those showed by the amorphous
seleno-subtilisin. The high activity of microcrystals was retained in organic solvents too
and remained high when recycled, due to their stability.261
Antibodies
The first covalent anchoring of an organic ligand to an antibody was reported in 2002
by Janda and co-workers. They synthesized an artificial metalloenzyme by coupling a
bis-imidazole cofactor to the aldolase antibody 38C2 (Figure 37- a). This antibody was
selected for modification because of its large hydrophobic pocket containing a highly
nucleophilic lysine residue, Lys H93, suitable for covalent modification. The choice of
the metal binding bis-imidazole cofactor was inspired by the active-site structures of a
number of natural metalloenzymes which possess a coordination sphere with two or
more histidine-derived imidazole ligands. The resulting 38C2 - bis-imidazole derivative
- Cu hybrid displayed esterase activity, being an active catalyst for the hydrolysis of a
picolinate ester (Figure 37- b).231
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Figure 37 Covalent modification of 38C2 antibody with a bis-imidazole cofactor (a) to generate a Cu-
complexed hybrid catalyst for the hydrolysis of 4-nitrophenyl picolinate (b)231
I.6 DNA-based asymmetric catalysis
Proteins are not the only source of chirality which have been used for generation of
enanioselective artificial metalloenzymes. Roelfes and Feringa reported the synthesis of
hybrid catalysts formed via non-covalent incorporation of copper complexes into DNA.
Two families of ligands have been investigated. Initially a metal complex of a non-
chiral ligand was connected through a spacer to a DNA intercalating moiety.262 Later
on, in an improved approach, bidentate ligands known to bind to DNA were used as
DNA binding moieties, omitting the requirement of a spacer.263-265 Enantioselectivities
up to 99% were obtained using Cu(II) complexes coupled to salmon testes DNA for the
Diels-Alder reaction of azachalcone with cyclopentadiene263 and for Michael
reactions.264 In addition, the role of DNA is not only as a chiral scaffold, as it was
proved for the Diels-Alder reaction. Both the enantioselectivity and the rate
enhancement of the reaction are dependent on the DNA sequence, as shown by
replacing the salmon DNA with synthetic oligonucleotides of defined sequence.265
Covalent modification of aminodeoxyuridines and amino-functionalized
oligonucleotides with phosphane ligands,266-267 but also with a Pd-phosphane complex
were recently reported.267 Another strategy used for DNA covalent modification
consists of Pd catalysed coupling of diphenylphosphane to 5-iodo-nucleosides and 5-
iodo-oligonucleotides.268 Covalent coupling of N-ligand complexes to DNA was also
reported. A Cu(II) complex of (2,2’-bipyridine)-5-carboxylic acid was covalently
coupled through an alkyl linker to a DNA double strand and was used as catalyst for the
Diels-Alder reaction.269
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I.7 Scope and outline of the thesis
As is clear from the overview above, the combination of biological concepts for
selective recognition with those of transition metal catalysis is a very promising
approach for the development of selective hybrid catalysts for important asymmetric
catalytic reactions for which there are no enzymes available. The long term objective of
this work is to synthesize novel artificial metalloenzymes based on the covalent site-
selective incorporation of organometallic catalysts into proteins, to use them for
asymmetric reactions and to tune their properties via chemogenetic optimization.
Targeting the development of transition metal complexes coupled covalently to
proteins, the initial objective was the introduction of metal binding ligands into proteins.
Phosphane ligands are an important class of ligands, not only in academic
organometallic chemistry, but also in catalytic reactions on industrial scale. Chiral
phosphane ligands are widely used in transition metal catalyzed asymmetric synthesis.
However, for a number of reactions the enantioselectivity achieved with these ligands
remains modest. Therefore, the need for novel, highly selective chiral phosphane-based
catalysts for asymmetric reactions remains high. However, high-throughput synthesis of
structurally diverse phosphane ligands toward catalysts optimization remains a
challenging and time-consuming process. By merging relatively simple achiral
phosphanes with protein scaffolds as chiral inducing environment, the powerful
methods of chemogenetic engineering and directed/designed evolution can be applied to
the optimization of phosphane-based catalysts.
Chapter II describes several strategies explored for covalent site-specific incorporation
of phosphane ligands into proteins. The first studied strategy was a thioester bond
formation between the thiol group of a unique cysteine of a protein and a carboxylic
group of a phosphane ligand. Problems encountered with the specificity of this method
led us to the second strategy, formation of a thioether bond between the thiol group of
cysteine and the double bond of a maleimide functionalized ligand. This method
demanded the use of protected phosphane ligands, as phosphanes react with the double
bond of maleimides. Several problems were encountered with phosphane deprotection.
Therefore, the successful strategy was to incorporate a maleimide functionalized
hydrazide into proteins and to couple several aldehyde functionalized phosphanes via
hydrazone linkage.
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Nitrogen ligands have also a large applicability in homogeneous catalytic reactions, due
to their distinctive advantages. Chapter III describes strategies explored for site-specific
covalent incorporation of this class of ligands into proteins. Covalent incorporation of a
carboxylic acid functionalized bipyridine was achieved after NHS (N-
hydroxysuccinimide) activation of the carboxylic group. The activated ligand was
coupled via thioester bond formation with a thiol group of a cysteine residue, however
low selectivity towards cysteine was observed for the proteins tested. Succesful site
selective incorporation of N-containing ligands was obtained by coupling maleimide
functionalized N-ligands to proteins via Michael addition to the maleimide double bond.
The final aim is construction of artificial metalloenzymes by coupling transition
organometallic catalysts into proteins. Therefore the fourth chapter contains several
strategies which have been explored in order to reach this target. Site-specific covalent
incorporation of transition metal complexes (Rh, Pd) of phosphane ligands into proteins
was successfully obtained.270-271 However, the success of the approach is influenced by
several factors like the metal precursor, the phosphane type and the protein scaffold. Pd
and Rh metal complexes of phosphane ligands proved to induce protein instability for
two particular proteins we investigated, ALBP and Δ98Δ. These problems were not 
encountered when metal complexes of maleimide functionalized N-ligands were tested.
Efficient and site selective covalent modification of a three different protein scaffolds
with metal complexes of 5-maleimido-1,10-phenathroline was obtained.
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II. Site-selective bioconjugation of phosphane ligands to structurally
diverse protein hosts
Abstract
A method for the site-selective introduction of phosphane-ligands in protein hosts
has been developed. Initially, carboxylic acid functionalized phosphanes were
coupled to proteins, but the chemoselectivity proved to be low for most proteins.
Borane protected maleimido-phosphanes were synthesised and coupled site-
selective to proteins. Unexpectedly, borane deprotection was not achievable under
conditions compatible with proteins in solution. An alternative approach reported
here consists of covalent coupling of 3-(maleimido)propionic acid hydrazide to the
thiol group of a cysteine residue of a protein, followed by coupling of aldehyde
functionalized phosphanes to the hydrazide group via a hydrazone linkage. This
method constitutes a valuable tool for the development of phosphane-containing
artificial metalloenzymes.
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II.1 Introduction
Natural enzymes have evolved over millions of years to catalyze biologically
relevant chemical reactions under mild reaction conditions with excellent rates and
enantio-, regio-, and chemoselectivity. These properties render enzymes attractive
synthetic tools as biocatalyst for the chemical industry. Moreover, the powerful
methods of directed evolution allow for significant improvements of the useful
properties of enzymes.1-2 However, for many synthetically important, transition-
metal catalyzed transformations, e.g., hydrogenation, allylic substitution and
hydroformylation, enzymes do not exist. Therefore these reactions are still confined
to the realm of homogeneous catalysis, relying on man-made organometallic
catalysts. Hybrid catalysts, consisting of a protein scaffold functionalized with a
synthetic transition metal catalyst, have emerged as a potential solution to this
limitation. This approach aims to combine the catalytic activity of transition-metal
complexes with the significant potential for selectivity-inducing interactions
between proteins and substrates. Inspired by the pioneering work of Kaiser3 and
Whitesides,4 several groups have developed artificial metalloenzymes, either by
non-covalent or covalent incorporation of catalytic moieties within a
macromolecular host. A particularly successful example of the non-covalent
approach is the work of Whitesides, Chan and particularly Ward, based on the well-
developed biotin-avidin technology. Chemical modification of biotin with
phosphorous ligands allows the introduction of transition metal catalysts in
(strept)avidin. Subsequent tuning of both the ligand structure and the protein
sequence has resulted in highly selective catalysts for the rhodium catalyzed
asymmetric hydrogenation of amino-acid precursors,5-11 transfer hydrogenation12-15
and more recently, palladium catalyzed asymmetric C-C bond formation.16
Moreover, Reetz subjected this system to directed evolution, demonstrating that this
method can also be applied to improve the performance of hybrid catalysts.17-18
Other examples of the non-covalent assembly of hybrid catalysts include antibodies
raised against transition metal complexes,19-20 and the reconstitution of apo-
myoglobin with CrIII Schiff base complexes.21
The covalent approach relies on the chemical modification of reactive residues in
proteins. Distefano modified adipocyte lipid binding protein with a CuII 1,10-
phenantroline complex by alkylation of a unique cysteine residue. The resulting
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conjugate catalyzed the enantioselective hydrolysis of amino-acid esters.22 The
cysteine of papain has been modified with maleimide modified manganese-salen and
rhodium-dipyridine complexes; the resulting hybrids were active as epoxidation and
hydrogenation catalysts, but showed no enantioselectivity.18 A hybrid of papain and
a rodium-phosphite complex was also active as a hydrogenation catalyst, but again
no stereocontrol was observed.23 The strategy of modifying the active site serine of
lipases has been employed to introduce palladium and platinum complexes of
nitrogen- and sulfur containing pincer ligands,24 and a free bidentate diphosphane
ligand.25-26
Phosphane ligands are ubiquitous in transition metal chemistry and afford extremely
reactive and versatile homogeneous catalysts. Several hybrid catalysts containing
phosphane-ligands have been created with the non-covalent approach, using the
biotin-avidin system4 and antibodies.20 To the best of my knowledge the only
example of covalent, site-selective introduction of a phosphane-ligand is the
aforementioned modification of the active site serine of a lipase with a diphosphane
coupled to a phosphonate inhibitor.25-26 However, the resulting linkage was
hydrolytically unstable. A general method for stable, covalent, site-selective
introduction of phosphane-ligands is desirable, as this would allow the
functionalization of structurally diverse proteins with this important class of ligands.
Because of the nucleophilic reactivity of its thiol side-chain and relative low
abundance in protein sequences, cysteine is a widely employed target for the site-
selective modification of proteins. Frequently used methods for the functionalization
of cysteine are disulfide bridge formation using thiols, and using electrophilic
moieties such as haloacetamides and maleimides.27 All three methods have been
employed in the synthesis of ligand modified proteins, e.g. Reetz introduced a small
library of nitrogen based chelating ligands and organocatalysts in a protein host
using maleimides.28
Because phosphanes are known to reduce disulfide bridges (e.g. tris(2-
carboxyethyl)phosphane is a well-known reducing agent), modification based on the
formation of a disulfide bridge is incompatible with phosphane ligands. The latter
two methods are incompatible with unprotected phosphanes due to their
nucleophilicity.
Because of the limitations of using the standard methods for cysteine modification
outlined above there is a need for alternative coupling methods for the introduction
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of phosphanes and transition metal phosphane complexes into proteins. Herein I
report on our exploration of different strategies, which led us to the development of
a highly efficient and selective method for site-selective covalent introduction of
unprotected phosphane ligands in different protein hosts.
II.2 Results and discussion
II.2.1 Engineering of protein hosts
Selectivity can be imparted on catalytic reactions by placing an achiral catalyst in
the constrained environment of a chiral cavity. Cavities that completely encapsulate
the catalyst will afford the highest potential for selectivity imparting interactions,
but may conversely impede access of substrates to the catalysts.
Figure 1 Structures of protein hosts used in this study.
(a) X-ray structure of I-FABP. The structural elements deleted in IFABP Δ98Δ are highlighted in cyan, 
the position of the introduced cysteine is highlighted in yellow. ALBP has the same fold as I-FABP. (b)
NMR structure of the BLUF domain of AppA.29 The mutated cysteines are highlighted in yellow; the
residues mutated to cysteines for modification are highlighted in blue. Residues 113-125 are omitted for
clarity.
Therefore proteins with different cavity structures, as hosts for artificial
metalloenzyme development, were used: (i) a protein containing a virtually
completely enclosed cavity; (ii) a protein containing a cavity with a large opening,
and (iii) a protein containing a deep cleft. For ease of purification of the proteins I
choose nickel-affinity chromatography as the purification procedure, using proteins
containing a hexa histidine-tag.
Fatty Acid Binding Proteins (FABPs) are a class of proteins that possess a large
apolar cavity. The cavity is formed by a β-barrel structure, capped by a α-helical lid, 
and completely encapsulates bound lipids. Thus FABPs contain a true protein cavity.
Cys110
Cys20
Cys19
Tyr21
Glu63Trp104
ba
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Two FABPs were used as hosts for modification with phosphane ligands: murine
adipocyte lipid binding protein (ALBP) and an engineered variant of rat intestinal
fatty acid binding protein (I-FABP), Δ98Δ. Both ALBP and I-FABP have previously 
been shown to be suitable scaffolds for the development of hybrid catalyst by
chemical modification with catalytic cofactors,22,30-32 but have so far not been
modified with phosphane-ligands.
Wild-type ALBP contains two native cysteines, at positions 1 and 117. Cys117 is
located inside the protein cavity and thus at a suitable position for modification.
Cys1, located on the surface of the protein, was replaced by alanine. Initially, ALBP
Cys1Ala containing an N-terminal histidine-tag was produced using a reported
expression system.30 However, the low yield (1-2 mg/l) in our hands prompted us to
investigate alternative expression conditions. Cloning of the DNA coding for ALBP
Cys1Ala into the vector pQE30 and expression in E. coli M15 pREP4 yielded a
satisfactory 80 mg of N-terminally his-tagged protein per litre of bacterial culture.
IFABP Δ98Δ is a genetically engineered all -sheet variant of IFABP, which lacks
the helices covering the cavity in the parent protein (Figure 1a). The protein has a
stable, well folded structure and has retained the ability to bind fatty acids. Deletion
of the helical cap has resulted in a cavity with a large opening, and thus easier access
for ligands and substrates compared to ALBP.33 IFABP Δ98Δ contains no native 
cysteine; therefore the IFABP Δ98Δ Tyr90Cys mutant was created, which contains a 
cysteine at a position structurally equivalent to ALBP Cys117. In addition, a stop-
codon, present in the initial expression construct between the IFABP gene and the
vector encoded His-tag was replaced by alanine, resulting in expression of the
protein with a C-terminal His-tag (hereafter referred to as 98).
The BLUF domain of the blue-light sensing flavoprotein AppA binds a flavin non-
covalently in a 12 Å deep cleft formed by two α-helices lying on top of a -sheet
(Figure 1b).34-36 I reasoned that if the flavin could be removed, anchoring catalysts
to the bottom of this cleft would ensure they are in close proximity to the chiral
environment of the protein. The BLUF domain used in this study (residues 5-125,
hereafter referred to as AppA) contains three native cysteines: Cys19, located buried
under a helix; Cys20, located on the solvent exposed surface of the -sheet and
Cys110, located in a loop outside the flavin-binding region. Based on sequence
comparison with other BLUF domains, I exchanged these cysteines for leucine,
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threonine and alanine, respectively.37 To introduce a cysteine at the bottom of the
cleft, the residues Tyr21, Glu63 and Trp104 were selected to be replaced
independently by cysteine, based on their location inside the protein cavity. In
addition, replacement of these amino acid residues is expected to disrupt the
hydrogen bonding interaction of the protein with the flavin, facilitating its
removal.36 Three mutant proteins: AppaA Y21C, AppA Q63C and AppA W104C,
suitable for chemical modification, resulted after cysteine introduction. All mutants
were purified with flavin bound, suggesting the mutations did not result in
significant structural changes. Coupling reactions to the cysteine should therefore be
performed under conditions which also result in flavin removal.
II.2.2 Conjugation of phosphanes to protein hosts
Our group reported recently a method for the site-selective conjugation of
phosphanes to the cysteine of PYP, an additional protein scaffold we employ in our
research program to develop artificial metalloenzymes.38 Here I explored the
suitability of this method for the site-selective conjugation of phosphane ligands to
the other protein hosts.
Figure 2 Site-selective protein modification using activated carboxylic acids. (a) DMF, o.n. (b) 50 mM
Tris-HCl/H2O, pH 8.0
The conjugates were analysed by mass spectrometry (MS) and the position of the
modification was confirmed by tryptic digestion. Due to their nucleophilicity, free
phosphanes react similarly with reagents used for the colorimetric detection of thiol
groups as free thiols (e.g. Ellman's reagent). This prohibited the use of such assays to
determine the specificity and efficiency of the coupling reactions. Instead, I relied on
MS to determine the extent of modification. To correct the MS data for differences
in ionization efficiency between unmodified and modified proteins, this difference
was assessed by comparing the MS spectra of samples of modified protein with and
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without the addition of 1 equivalent of unmodified protein. It should be noted that
although the MS measurements were done in air, very little oxidation of the
phosphane ligands occurred.
2
2
2
Figure 3 Structures of phosphane-carboxylic acids 1-4
ALBP was efficiently modified with ligand 3, but no coupling was observed for
ligands 1, 2 and 4. The latter ligands are possibly sterically more demanding than
ligand 3 and may be unable to enter the cavity to conjugate to the cysteine.
According to LC-MS analysis and considering the difference in ionization between
the modified and unmodified protein, the coupling efficiency of 3 to ALBP is higher
than 95%.
Purified 98 readily forms dimers via disulfide bridge formation, necessitating a
reduction step prior to the conjugation reactions.39 In contrast to ALBP, 98 could
be modified with all four ligands. This may reflect the fact that the latter protein
contains a more accessible cavity, and hence a more accessible cysteine. However,
the coupling efficiency was limited to 30-50% for single modification; attempts to
improve the modification levels by increasing the excess of ligand in the coupling
reactions resulted in the coupling of multiple ligands to the protein. The additional
sites of modification were identified as lysines, by trypsin digestion and MS
analysis. To prevent modification of lysines during the conjugation reactions, I
sought to protect their amine groups via amide or imine bond formation.40-44
Reaction of the protein with aldehydes, anhydrides or succinimide derivatives prior
to coupling of the phosphanes afforded some protection, but did not lead to a
sufficient increase in selectivity for phosphane-coupling. Also the replacement of
the most reactive lysines (K74 and K104, identified by tryptic digest analysis) with
glutamine did not yield a significant improvement in chemoselective modification of
the protein.
It was previously reported that the presence of high concentrations of imidazole
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(more than 2M) appears to cause the release of the flavin from AppA.45 Therefore to
facilitate the flavin removal during the conjugation reactions, phosphanes 1-4 were
coupled to AppA Y21C in presence of 3M imidazole. Again, it was not possible to
achieve efficient monomodification. Attempts to increase the coupling efficiency by
using a larger excess of ligands 1-4 led to unspecific incorporation of ligands. So the
chemoselectivity of bioconjugation of phosphanes via thioester formation is highly
dependent on the protein employed, prohibiting its implementation as a general
method for coupling of phosphanes to the cysteine of proteins.
Table 1 Coupling of activated carboxylic acids to protein hosts
Calculated
Mass (Da)
LC-MS Mass
found (Da)
ALBP - 3a 16893.1 16893.0±0.5
98-1a 13711.3 13711.20.9
98-2a 13711.3 13711.50.7
98-3a 13711.3 13710.40.5
98-4a 13946.2 13945.70.4
a Incomplete conversion
In search of a more chemoselective and efficient method I turned to the coupling of
phosphanes using maleimides, a standard strategy for highly selective cysteine
conjugation.46-47 However, since phosphanes are known to react with maleimides
leading to the formation of phosphonium-salts,48-49 the use of phosphane-protecting
groups is essential.
Initially I investigated a sulfur protected phosphane, diphenylphosphane sulfide
benzyl maleimide (Figure 4), which was incorporated with excellent
chemoselectivity into ALBP and 98. However, the standard Raney nickel
procedure for sulfur deprotection was not successful for the phosphane coupled to
protein, based on 31P NMR and MS data.50-51 No further methods for sulfur
deprotection were tested.
Figure 4 N-(4-(diphenylphosphane sulfide)benzyl) maleimide
A recent report on the synthesis of functionalized phosphanes using Cu(I)-catalyzed
azide-alkyne "click" cycloaddition, employing borane-protected phosphanes,
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prompted us to explore the synthesis of maleimide-functionalized phosphane-ligands
via click-chemistry.52
A number of alkyne and azide functionalized “building blocks” for the synthesis of
maleimide-functionalized phosphane ligands were synthesized (Figure 5).
3
2
3
2
3
3
Figure 5 Structures of azide and alkyne functionalized “building blocks” for the synthesis of borane-
protected maleimido-phosphanes
Using compounds 5-9 as building blocks, two strategies were available: (I) coupling
of maleimide alkynes and azide 5-7 to proteins first, followed by incorporation of
borane phosphanes via azide-alkyne click-reaction or (II) synthesis of maleimide
functionalized borane phosphanes via click-reaction followed by their covalent
incorporation into proteins and subsequent deprotection.
The maleimide functionalized alkynes 5, 6 and azide 7 were successfully
incorporated in three proteins: ALBP, 98 and AppA Y21C. Moreover, Michael
addition to maleimide functionalized ligands was highly chemoselective. Complete
selective modification with 5-7 was achieved for AppA Y21C and 98. The
incomplete modification (≈70%) of ALBP could be caused by the reduced 
accessibility of the thiol group of cysteine located deep inside the enclosed cavity of
the protein (Table 2).
The maleimide derivatives 5-9 were coupled to AppA Y21C in presence of 3M
imidazole, to help the flavin removal and also to improve the coupling efficiency.
Surprisingly, imidazole proved also to reduce unspecific coupling of maleimides.
This phenomenon initially observed for AppA, also applied to 98, but ALBP was
not stable in presence of 3M imidazole. When a large molar excess of maleimide
derivatives was used (25x or 50x), selective cysteine modification was only
observed when the reactions were performed in presence of 3M imidazole. Under
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similar conditions but without imidazole, multiple couplings were observed for
AppA Y21C and 98. The mechanism underlying this apparent protection against
lysine-modification is unclear at present.
An increase of the masses of proteins modified with ligands 5-7 with 18 Da and/or
16 Da was observed in time. The increase of 18 Da is likely due to hydrolytic
opening of the maleimide ring, affording maleamic acid adducts. This process is
known to be accelerated at basic pH.53 In addition the oxidation of methionine
residues can occur under Mass Spec conditions resulting in addition of 16 or 32 Da.
Table 2 Coupling of alkyne and azide maleimides 5-7 to proteins
Calculated
Mass (Da)
LC-MS Mass
found (Da)
ALBP-5a 16739.9 16757.00.7
ALBP-6a 16801.9 16819.20.4
ALBP-7a 16818.9 16836.40.4
98-5 13558.1 13575.50.5
98-6 13620.2 13638.50.4
98-7 13637.2 13654.90.6
AppA Y21C -5 15530.2 15530.21.8
AppA Y21C -6 15592.3 15592.21.7
AppA Y21C -7 15609.3 15609.21.7
aIncomplete conversion
After coupling of alkyne/azide functionalized maleimides 5-7 to proteins, the
coupling of borane-protected phosphanes 8 and 9 to the modified proteins via
copper-catalyzed azide-alkyne [3+2] “click” cycloaddition was attempted. Although
the click-reaction has previously been applied for bioorthogonal labelling of
proteins,54-55 our attempts to couple borane protected phosphanes to azide/alkyne
functionalized proteins via click-reaction proved unsuccessful. When the reactions
were performed in the absence of a ligand for the copper catalyst, no protein signals
were obtained during subsequent LC-MS analysis. Residual copper, possibly
coordinated to the protein, likely suppresses protein ionization. Extensive washing
procedures did not resolve this issue. Protein signals were restored when ligands
commonly used for coordination of copper during the click-reaction were
employed,55-56 but no protein modification was observed. This is likely due to the
fact that the azide or alkyne functionalities are located inside the protein cavities,
making them inaccessible for the copper catalysts. Indeed, the vast majority of
reports on bioconjugation using click-chemistry deal with labelling protein surfaces
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with fluorescent probes, involving reactions with limited steric demand and which
are typically solely analysed by fluorescence.54-55,57
Three maleimide functionalized borane phosphanes 10-12 were synthesized via
azide-alkyne click-reaction, using compounds 5-9 as building blocks.
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Figure 6 Maleimide functionalized borane-phosphanes synthesized via copper catalysed azide-alkyne
[3+2] “click” cycloaddition
All three click-products 10-12 were coupled chemo-specifically to proteins (Table
3). Once more, an addition of 18 and 16 Da to the masses of the modified proteins
was observed in time.
Table 3 Coupling of click-compounds 10-12 to proteins
Calculated
Mass (Da)
LC-MS Mass
found (Da)
ALBP-10 17023.0 17022.20.9
ALBP-11a 17057.0 17074.50.8
ALBP-12a 17085.1 17103.01.1
98-10 13841.2 13840.10.5
98-11 13875.2 13893.00.6
98-12a 13903.3 13903.10.6
AppA Y21C -10 15813.3 15812.30.9
AppA Y21C -11 15847.3 15864.90.6
AppA Y21C -12 15875.4 15893.10.8
aIncomplete conversion
Several reagents reported in literature for decomplexation of phosphane-borane
complexes (amines, KCN, CO)58-62 were tested for their ability to deprotect the
bioconjugated phosphane-boranes in aqueous conditions. The decomplexation
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conditions screened were only those deemed compatible with proteins in solution.
For all conditions tested removal of the BH3 protecting group from the ligands was
unsuccessful.
The phosphane-borane deprotection was initially assessed by LC-MS analysis of the
modified proteins after treatment. However, the MS resolution is not high enough to
clearly distinguish a mass difference of 2 Da for proteins of several kDa, so I could
not immediately differentiate between unprotected proteins and proteins that were
successfully deprotected but subsequently oxidized.
Previous studies reported the synthesis of Pd(0) or Rh(I) phosphane complexes by
reacting Pd(II) or Rh(III) salts with phosphane boranes, without previous
decomplexation, making use of the reductive properties of the borane group.63-64
Although reacting the phosphane-boranes 10-12 with RhCl3 or Pd(OAc)2 was
successful regarding borane decomplexation and metal complex formation, this was
accompanied by the reduction of the maleimide double bond, rendering the
complexes unsuitable for bioconjugation. Experiments are ongoing for the synthesis
of Pd(0) and Rh(I) metal complexes in situ, with borane protected maleimide-
phosphanes in presence of borane trapping agents, in order to protect the maleimide
double bond.
Previous studies reporting synthesis of protein conjugates via intermolecular
hydrazone linkage65-67 led us to a successful approach for phosphane ligand
incorporation into proteins.
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Figure 7 Structures of maleimide propionic acid hydrazide 13 and phosphane-aldehydes 14-18
First the maleimide propionic acid hydrazide13 was coupled covalently to ALBP,
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98, AppA Y21C and AppA Q63C, followed by incorporation of phosphane-
aldehydes 14-18 via hydrazone formation. Phosphane ligands incorporation was
confirmed by MS analysis (Table 4) and chemoselective modification of cysteine
was confirmed by partial digestion with trypsin followed by MS.
The hydrazone ligation of aldehyde functionalized phosphanes 14-16 to the four
proteins containing a hydrazide functionality was proved to be highly selective
(Table 4). The coupling efficiency was 100% and no secondary modification of the
NH2 group of lysines occurred, as determined by trypsin mediated partial digestion
combined with MS analysis. All the couplings conditions required were compatible
with proteins in solutions.
Phosphanes 17 and 18 were successfully coupled to AppA Y21C, AppA Q63C and
98, without being possible to reach complete modification. Once again it was not
possible to couple these ligands to ALBP, supporting the results obtained for ligand 4.
Table 4 Covalent incorporation of 13 into proteins via Michael addition, followed by incorporation of
phosphanes 14-18 via hydrazone ligation to 13
Calculated
Mass (Da)
LC-MS Mass
found (Da)
ALBP - 13 16787.9 16787.2±0.7
ALBP - 14 17060.2 17060.2±0.65
ALBP - 15 17060.2 17060.1±0.5
ALBP - 16 17060.2 17060.7±0.6
98-13 13606.1 13605.8±0.5
98-14 13878.4 13878.2±0.65
98-15 13878.4 13878.2±0.6
98-16 13878.4 13878.2±0.4
98-17a 14113.7 14114.0±1.9
AppA Y21C -13 15578.2 15578.2±0.6
AppA Y21C -14 15850.5 15850.6±0.6
AppA Y21C -15 15850.5 15850.9±0.6
AppA Y21C -16 15850.5 15850.0±0.5
AppA Y21C -17a 16085.8 16083.4±2.8
AppA Q63C -13 15613. 3 15612.80.6
AppA Q63C -14 15885.5 15900.20.8
AppA Q63C -15 15885.5 15884.80.6
AppA Q63C -16 15885.5 15884.60.8
AppA Q63C -17a 16120.8 16120.21.1
AppA Q63C -18a 16216.9 16216.10.9
a Incomplete conversion
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II.3 Conclusions
In conclusion a method for site specific covalent incorporation of phosphane ligands
into structurally different proteins was developed. The strategy is based on the
intermolecular hydrazone linkage between an aldehyde functionalized phosphane
and a hydrazide – maleimide precoupled to the thiol group of a cysteine residue of a
protein.
This concept of hydrazone ligation for incorporation of phosphane ligands into
proteins is a very powerful tool, making it possible to combine a large variety of
phosphane ligands and virtually any protein.
Next step will be the formation of metal complexes of hybrid proteins either by
complexation of metal precursors to the hybrid protein modified with phosphane or
by hydrazone ligation of a preformed metal complex of an aldehyde phosphane.
This first site-selective covalent coupling method of phosphane ligands enables the
modification of a wide range of structurally different proteins. Moreover, proteins
with improved properties like thermostability or organic solvents tolerance can be
used, potentially leading to artificial metalloenzymes with improved stability and
activity.
II.4 Experimental
II.4.1 General remarks
Chemicals were purchased from Aldrich and Fluka unless otherwise stated, and were
used as received. 3-maleimidopropionic acid hydrazide hydrochloride 13 was
purchased from Apollo Scientific. N,N-dimethylformamide was degassed and stored
on molsieves under an argon atmosphere. All air- and water-sensitive reactions were
carried out under dry, air free conditions using dry degassed solvents and standard
Schlenk techniques under an atmosphere of purified argon. NMR spectra were
recorded at room temperature on Bruker Avance 300, 400 and 500 spectrometers.
Positive chemical shifts () are given (in ppm) for high-frequency shifts relative to a
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TMS reference (1H and 13C) or an 85% H3PO4 reference (31P). 13C and 31P spectra
were measured with 1H decoupling.
Protein stability (apo and modified proteins) was assessed by Bradford assay68 and
SDS-PAGE .
Modified proteins were analysed by LC-MS (ES+), partial digestion with trypsin
followed by MS and Ellman Assay69 (where possible).
II.4.2 Whole protein mass spectrometry using ESI-TOF
The protein sample (20ul, 5 pM/ul) was desalted on-line through a XTerra MS C8
2.1 x 10 mm column, eluted with an increasing acetonitrile concentration (2%
acetonitrile, 98% aqueous 1% formic acid to 98% acetonitrile 2% aqueous 1%
formic acid) and delivered to an electrospray ionisation mass spectrometer (LCT,
Micromass, Manchester, U.K.) which had previously been calibrated using
myoglobin. An envelope of multiply charged signals was obtained and deconvoluted
using MaxEnt1 software to give the molecular mass of the protein. Standard
deviations were calculated manually from the raw MS data.
The sequence of ALBP reported by Bernlohr et al70 was used as reference for the mass
of ALBP C1A his-tagged mutant. For the mass of the 98 mutant, the 98 sequence
reported by Delfino et al33 was used as reference and for the mass of AppA mutants the
AppA sequence reported by Laan et al71 was used.
II.4.3 Protein tryptic digestion
The protein samples (5 μl, 10 pmoles/μl) were dialysed into ammonium bicarbonate (50 
mM, pH 8.0) using a membrane filter (Millipore, Billerica, MA) and trypsin (0.5 μl, 0.1 
μg, Promega, Madison, WI) was added, followed by incubation at 37C for 16 hours.
II.4.4 98 - reduction of disulfide bridges was performed every time before
modification with carboxylic acid or maleimide functionalized compounds. Prior to
the reduction reaction the protein solution was degassed by purging with argon for 8
hours. 6 μmol (6 eq.) of DTT were added from a freshly prepared stock solution of 
0.5 M in water to a solution of 1 μmol of protein (1 eq.) in Tris·HCl (50 mM, 10 ml, 
pH 8.0) in a Schlenk tube. The reaction mixture was stirred at room temperature for
1 hour. The reduced protein solution was used for the coupling reactions without
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further purification. For each coupling reaction the molar excess of modification
reagent was higher than 12-fold, to assure the right amount of modification reagent
for the potential modification of both the thiol groups of DTT and the thiol group of
the target cysteine.
II.4.5 Synthesis of modification reagents
Borane protected 3-(diphenylphosphane)benzenesulfonic acid
The borane protection of 3-(diphenylphosphane)benzenesulfonic acid was done
based on a literature procedure.72 A Schlenk tube containing a solution of 3-
(diphenylphosphane)benzenesulfonic acid (68.41 mg, 0.2 mmol) in
dimethylformamide (1 ml) was placed on an ice-bath (0ºC) and a 2M solution of
BH3SMe2 (759.5 mg, 10 mmol) in tetrahydrofuran was added slowly via syringe,
under stirring, into the ice cooled flask. After that the solution was allowed to reach
room temperature and the stirring was continued for 16 hours, when the reaction was
complete. The excess of BH3SMe2 was removed by adding toluene and evaporating
the solvent under vacuum; this process was repeated 3 times. The product was
obtained as a white solid and was used without further purification. Yield 98%
(69.81 mg). 31P {1H} (161.9 MHz, D2O): δ = 20.64 ppm (br). ESI-MS (ES+) 
m/z=356.14 ([M] C18H18BO3PS requires 356.18)
Oxidation of 3-(diphenylphosphane)benzenesulfonic acid - was performed
according to a literature procedure.73
3-(diphenylphosphane)benzoic acid (2) - this compound was prepared according to a
literature procedure74 and it was kindly provided by Dr Rene de Heeten (University of
Amsterdam).
4-(bis(2-(diphenylphosphane)-ethyl)amino-4-oxobutanoic acid (4) - this compound
was kindly provided by Dr Rene de Heeten (University of Amsterdam).75
CDI activation of phosphane carboxylic acids 1-4 – was performed according to a
literature procedure.76
N-(4-(diphenylphosphane sulfide)benzyl) maleimide – this compound was kindly
provided by Dr Yanmei Zhang (University of St Andrews).
N-(propargyl) maleimide (5) - this compound was prepared according to a literature
procedure77 and was kindly provided by Dr Gregorio Guisado (University of St
Andrews).
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N-(3-ethynylphenyl) maleimide (6) - this compound was kindly provided by Dr Nikos
Tsoureas (University of St Andrews).
N-(p-azidophenyl)-maleimide (7) - this compound was prepared according to a
literature procedure78 and was kindly provided by Dr Gregorio Guisado (University of
St Andrews).
Diphenyl(propargyl)phosphane borane complex (8) - this compound was prepared
according to a literature procedure.52
(3-Azidopropyl)diphenyl phosphane borane complex (9) - this compound was kindly
provided by Dr Gregorio Guisado (University of St Andrews).
Click-compounds 10-12
a. N-(1-((1-(3-(diphenyl(borane)phosphane)propyl)-1H-1,2,3-triazol-4-yl)methyl)
maleimide (10)
This compound was synthesized based on a literature procedure.79-80 To a solution of
(9) (94.41 mg, 0.333 mmol) in CHCl3 (1 ml) a solution of CuSO4x 5H2O (22.18 mg,
0.139 mmol) in water (0.5 ml) and a solution of sodium ascorbate (137.63 mg, 0.695
mmol) in water (0.5 ml) were added. Finally a solution of N-(propargyl)-maleimide
(37.55 mg, 0.278 mmol) in CHCl3 (1 ml) was added. The heterogeneous reaction
mixture was stirred at room temperature for 5 hours. After addition of H2O (10 ml)
the aqueous phase was extracted with CH2Cl2 (3x10 ml) and the combined organic
layers were washed with water (10 ml) and brine (10 ml). The organic phase was
dried over anhydrous Na2SO4, filtered and concentrated. Flash chromatography on
silica gel (CH2Cl2:EtOAc 4:1) afforded the product as a light yellow solid in 76%
yield (88.36 mg).
1H NMR (400 MHz, CDCl3): δ=7.3-7.65 (m, ar, 10H), 6.7 (s, 2H), 4.8 (s, 2H), 4.37 (t, 
J=6.44 Hz, 2H), 2.0-2.25 (m, 4H), 0.87 ppm (br m, 3H-BH3). 31P {1H} NMR (161.9
MHz, CDCl3): δ=15.75 ppm (br). 13C {1H} NMR (75 MHz, CDCl3): δ= 170.0 (2CO), 
142.8 (2C ar diφ), 134.3 (2CH, maleimide), 132.1, 132.0, 131.5, 129.0, 128.9 (10CH, ar 
diφ), 128.2 (1C triazole), 122.6 (1CH, triazole), 50.6-50.4 (d, 1CH2), 32.85 (1CH2 –
propargyl), 24.1 (1CH2), 22.8-22.3 ppm (d, 1CH2). HRMS (FTMS +): m/z calc. for
C22H25N4O2BP [M+H+]: 419.1803; found 419.1806.
b. N-(1-(4-(4-((diphenyl(borane)phosphane)methyl)-1H-1,2,3-triazol-1-yl)phenyl)
maleimide (11)
This compound was synthesized based on a literature procedure.52,79 To a solution of
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(7) (81.85 mg, 0.382 mmol) in CHCl3 (2ml), a solution of CuSO4x5H2O (30.48 mg,
0.191 mmol) in water (1 ml) and a solution of sodium ascorbate (189.18 mg, 0.955
mmol) in water (1 ml) were added. Finally the solution of (8) (109.19 mg, 0.458
mmol) in CHCl3 (2 ml) was added. The heterogeneous reaction mixture was stirred
at room temperature for 5 hours. After addition of H2O (10 ml) the aqueous phase
was extracted with CH2Cl2 (3x20 ml) and the combined organic layers were washed
with water (20 ml) and brine (20 ml). The organic phase was dried over anhydrous
Na2SO4, filtered and concentrated. Flash chromatography on silica gel
(CH2Cl2:EtOAc 4:1) afforded the product as light yellow solid in 92% yield (158.94
mg).
1H NMR (400 MHz, CDCl3): δ=7.4-7.8 (m, 15H), 6.9 (s, 2H), 3.8 (d, J=11.0 Hz, 2H), 
0.88 ppm (br m, 3H-BH3) . 31P {1H} NMR (161.9 MHz, CDCl3): δ=16.3 ppm (br). 13C
{1H} NMR (75 MHz, CDCl3): δ= 169.0 (2CO), 140.8 (2C ar diφ), 134.4 (2CH, 
maleimide), 132.5, 132.4 (4CH, ar diφ), 131.6 (2CH, ar), 129.0, 128.9 (6CH, ar diφ), 
127.7 (3C, 2 from ar, 1 from triazole), 126.9 (2CH, ar), 120.9 (1CH, triazole ring), 24.9-
24.4 ppm (d, 1 CH2). MALDI-MS m/z = 452.15 ([M] C25H22BN4O2P requires 452.25)
c. N-(1-(3-(1-(3-(diphenyl(borane)phosphane)propyl)-1H-1,2,3-triazol-4-yl)phenyl)
maleimide (12)
The compound was synthesized based on a literature procedure.79-80 To a solution of
(9) (249.82 mg, 0.882 mmol) in CHCl3 (3 ml) a solution of CuSO4x 5H2O (58.65
mg, 0.367 mmol) in water (1.5 ml) and a solution of sodium ascorbate (364 mg,
1.837 mmol) in water (1.5 ml) were added. Finally a solution of N-(3-
ethynylphenyl)-maleimide (145 mg, 0.735 mmol) in CHCl3 (3 ml) was added. The
heterogeneous reaction mixture was stirred at room temperature for 6 hours. After
addition of H2O (15 ml) the aqueous phase was extracted with CH2Cl2 (3x30 ml) and
the combined organic layers were washed with water (30 ml) and brine (30 ml). The
organic phase was dried over anhydrous Na2SO4, filtered and concentrated. Flash
chromatography on silica gel (CH2Cl2:EtOAc 4:1) afforded the product as cream
coloured, oily solid in 53% yield (187.10 mg).
1H NMR (300 MHz, CDCl3): δ=7.25-7.9 (m, 15H), 6.86 (s, 2H), 4.46 (t, J=6.03 Hz, 
2H), 2.1-2.3 ppm (m, 4H). 31P {1H} NMR (121 MHz, CDCl3): δ=15.31 ppm (br). 13C
{1H} NMR (75 MHz, CDCl3): δ=169.4 (2CO), 147.0 (1C-triazole ring), 134.4 (2CH), 
132.2 (2CH), 132.1 (2CH), 131.8 (d, 2C), 131.6 (1CH-triazole ring), 129.8 (1CH),
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129.0 (6CH), 128.3 (2C), 125.8 (1CH), 125.3 (1CH), 123.5 (1CH), 50.7 (d, 1CH2),
24.27 (1CH2), 22.5 ppm (d, 1 CH2). MALDI-MS m/z = 480.17 ([M] C27H26BN4O2P
requires 480.31)
3-(diphenylphosphane)benzaldehyde (15) - this compound was prepared according
to a literature procedure81 and was kindly provided by Peter Deuss (University of St
Andrews).
4-(diphenylphosphane)benzaldehyde (16) - this compound was prepared according
to a literature procedure82 and was kindly provided by Peter Deuss (University of St
Andrews).
N,N-bis(2-(diphenylphosphane)ethyl)-4-oxobutanamide (17) – this compound was
kindly provided Peter Deuss (University of St Andrews).83
4-(4,6-bis(diphenylphosphane)-phenoxazin-10-yl)butanal (18) - this compound was
kindly provided Peter Deuss (University of St Andrews).83
II.4.6 Protein engineering, expression and purification
Bacterial strains and media
Cloning was performed using E. coli XL1-Blue competent cells grown in LB
medium, following established protocols.84 For heterologous overexpression, E. coli
BL21(DE3) or M15 pREP4 cells harbouring the appropriate expression construct
were grown in PB medium (20 g l-1 tryptone, 10 g l-1 yeast extract, 5 g l-1 glucose, 5
g l-1 NaCl, 8.7 g l-1 K2HPO4, pH 7.0). Kanamycin and ampicilin were used at 50 and
100 mg l-1, respectively.
Site-directed mutagenesis
Mutations were introduced using the Quick-Change Site-Directed Mutagenesis Kit
(Stratagene). The following plasmids were used as templates for the PCR reactions:
pQE-AppA5-125 for AppA,71 pRSET-ALBP for ALBP,30,85 pET22b(+) ∆98∆ IFABP 
for ∆98∆.33
Following PCR reaction, the dam methylated plasmid templates were digested using
the Dpn I restriction enzyme (Stratagene) and the vectors containing the new
mutations were transformed into E. coli XL1-Blue and purified using QIAprep
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Miniprep kit (Qiagen). All mutations were verified by sequencing (The Sequencing
Service, Dundee, UK). The ALBP and AppA mutants verified by sequencing were
transformed to E. coli M15-pREP4 for protein overexpression, and the ∆98∆ 
mutants were transformed to E. coli BL21(DE3).
The mutagenic primers are specified in Tables 5-8.
Table 5 Sequences of primers used o introduce mutations in AppA. Mutated bases are indicated in bold.
Primer Mutation acquired Sequence
Primer1
Primer 2
C19L/C20T
TGCTGC/CTGACC
5’ GCTCGGATCTGGTTTCCCTGACCTACCGCAGCCTGGCGGC 3’
5’ GCCGCCAGGCTGCGGTAGGTCAGGGAAACCAGATCCGAGC 3’
Primer 3
Primer 4
C110A
TGC/GCG
5’ CACATGCAGCTCTCCGCGTCGGAGGCCGACATG 3’
5’ CATGTCGGCCTCCGACGCGGAGAGCTGCATGTG 3’
Primer 5
Primer 6
Y21C
TAC/TGC
5’ GTTTCCCTGACCTGCCGCAGCCTGGCG 3’
5’ CGCCAGGCTGCGGCAGGTCAGGGAAAC 3’
Primer 7
Primer 8
Q63C
CAG/TGC
5’ CAGGGCGTCTTCTTCTGCTGGCTCGAAGGCCAC 3’
5’ GTGGCCTTCGAGCCAGCAGAAGAAGACGCCCTG 3’
Primer 9
Primer 10
W104C
TGG/TGC
5’ CGCTTTGCGGGATGCCACATGCAGCTC 3’
5’ GAGCTGCATGTGGCATCCCGCAAAGCG 3’
Primer 11
Primer 12
L65R
CTC/CGT
5’ CTTCCAGTGGCGTGAAGGCCACC 3’
5’ GGTGGCCTTCACGCCACTGGAAG 3’
Primer 13
Primer 14
V75R
GTC/CGT
5’ CGTGGCGGAGCGTATGAGCCACATC 3’
5’ GATGTGGCTCATACGCTCCGCCACG 3’
Table 6 AppA mutants created by site-directed mutagenesis
AppA-BLUF domain mutant (Short) Name
AppA5-125 C19L/C20T/Y21C/C110A AppA Y21C
AppA5-125 C19L/C20T/Q63C/C110A AppA Q63C
AppA5-125 C19L/C20T/W104C/C110A AppA W104C
Table 7 Sequences for mutagenic primers used for C1A mutation in ALBP. Mutated bases are indicated
in bold.
Primer Mutation acquired Sequence
ALBP C1A-F
ALBP C1A-R
C1A
TGT/GCC
5’ CCTCGAAGGTTTACAAAATGGCCGATGCCTTTGTGGGAACC 3’
5’ GGTTCCCACAAAGGCATCGGCCATTTTGTAAACCTTCGAGG 3’
Table 8 Sequences for mutagenic primers used for single point mutations in 98. Mutated bases are
indicated in bold.
Primer Mutation acquired Sequence
Primer SC-F
Primer SC-R
Stop codon replaced with
alanine
TGA/GCC
5’ GAGTGGAGGCCAAGCGGGCCGGATCCGAATTCGAGC 3’
5’ GCTCGAATTCGGATCCGGCCCGCTTGGCCTCCACTC 3’
Primer RG-F
Primer RG-R
G base deleted
GCCGAT
5’ GCCAAGCGGGCCGATCCGAATTCGAG 3’
5’ CTCGAATTCGGATCGGCCCGCTTGGC 3’
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Primer 74 F
Primer 74 R
K74Q
AAG/CAG
5’ CGTGTAGACAATGGACAGGAGCTGATTGCTGTC 3’
5’ GACAGCAATCAGCTCCTGTCCATTGTCTACACG 3’
Primer 104 F
Primer 104 R
K104Q
AAG/CAG
5’ GCTCCGTCGACCAGCTTGCGGCCGC 3’
5’ GCGGCCGCAAGCTGGTCGACGGAGC 3’
Cloning
To clone the ALBP gene into pQE30, cDNA corresponding to the ALBP C1A
mutant was amplified by PCR using pRSET-ALBP C1A as template. The PCR
product was purified from agarose gel (Wizard SV Gel and PCR Clean-Up System,
Promega), digested with BamHI (Fermentas) and PstI (Fermentas) and ligated into
BamH I/Pst I digested pQE30 vector (Qiagen) using T4 DNA ligase (Fermentas).
The construct was verified by sequencing (The Sequencing Service, Dundee, UK).
Table 9 Primers used for cloning of the ALBP C1A segment. Restriction sites (BamH I or Pst I) are
underlined, the enterokinase site is given in italics.
Primer Sequence
Sc 1 5’-GCACGGATCCGATGACGATGACAAA ATGGCCGATGCCTTTGTGG-3’
Sc 2 5’-GCACCTGCAG TCATGCCCTTTCATAAACTCTTG-3’
Protein expression and purification
AppA
The AppA Y21C and AppA Q63C mutants were produced and purified according to
a literature procedure.71 Immobilized nickel affinity chromatography was performed
using a 5ml HisTrap™ FF column (GE Healthcare Life Sciences).
ALBP
E. coli M15 pREP4 transformed with pQE-ALBP C1A was grown at 37°C in PB
containing ampicillin and kanamycin. When the OD600 reached 3, protein expression
was induced by adding IPTG to a final concentration of 0.5 mM and growth was
continued for 16 hours at 20°C. The cells were then harvested by centrifugation
(4°C, 20 min, 3000 g) and resuspended in ice-cold lysis buffer (50 mM phosphate
buffer, 50 mM NaCl, 10% glycerol, 0.5% Nonidet P-40,86 pH 8.0) containing
protease inhibitor (Complete EDTA free, Roche). The cell-suspension was treated
with deoxyribonuclease (30 μg ml-1), ribonuclease (30 μg ml-1), and lysozyme (1 mg
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ml-1), held on ice for 30 min, sonicated (10 minutes with a 50% duty cycle) and
centrifuged (4°C, 30 min, 27000 g). The soluble fraction was applied to a 5ml
HisTrap™ FF column (GE Healthcare Life Sciences), the column was washed first
with washing buffer (50 mM phosphate, 150 mM NaCl, 20 mM imidazole, 10%
glycerol, pH 8.0) containing 0.5% detergent (Nonidet P-40),86 and then with an
equivalent volume of washing buffer without detergent. The protein was eluted with
elution buffer (50 mM phosphate, 150 mM NaCl, 500 mM imidazole, pH 8.0) and
dialyzed overnight at 4ºC against 50 mM phosphate, 50 mM NaCl, pH 8.0 and
stored at -20°C. Protein concentration was determined using the Bradford assay.68
Purity of the samples was checked by SDS-PAGE.
∆98∆
E. coli BL21(DE3), transformed with pET-22b(+)-∆98∆ IFABP was grown at 37°C 
in PB containing ampicillin. When the OD600 reached 0.6, the protein expression
was induced by adding IPTG (0.1 mM) and growth was continued for 16 hours at
25°C. The cells were then harvested by centrifugation (4°C, 20 min, 3000 g) and
resuspended in ice-cold lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 0.1% Triton-
X 100, 15% glycerol, pH 8.0) containing protease inhibitors (Pefabloc, Roche). The
cell-suspension was treated with deoxyribonuclease (30 μg ml-1), ribonuclease (30
μg ml-1), and lysozyme (1 mg ml-1), held on ice for 30 min, sonicated (10 minutes
with a 50% duty cycle) and centrifuged (4°C, 30 min, 27000 g). The soluble fraction
was applied to a 5ml HisTrap™ FF column (GE Healthcare Life Sciences), the
column was washed first with washing buffer (50 mM Tris-HCl, 500 mM NaCl, 20
mM imidazole, pH 8.0) containing 0.5% detergent (Nonidet P-40),86 and then with
an equal volume of the same washing buffer without detergent. The protein was
eluted using elution buffer (50 mM Tris-HCl, 500 mM NaCl, 500 mM imidazole, pH
8.0) and dialyzed at 4°C against 10 mM Tris-HCl, pH 8.0. After dialysis the protein
was stored at -20°C, in buffer (10mM Tris-HCl, pH 8.0) containing 10% glycerol.
Protein concentration was determined using the Bradford assay68 and the purity by
SDS-PAGE.
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II.4.7 Chemical modification of proteins
a. Conjugation with carboxylic acid functionalized phosphanes 1-4
ALBP
1. Conjugation with 3
Prior to coupling the protein solution was degassed by purging with argon for 8
hours.
2.5 μmol (25 eq.) of CDI activated 3 in 50 μl of dimethylformamide was added 
slowly to a solution of 100 nmol of protein (1 eq.) in Tris·HCl (50 mM, 1 ml, pH 
8.0) in a Schlenk tube. The cloudy reaction mixture was stirred at room temperature
for 16h. The insoluble fraction of the excess modification reagent was removed by
centrifugation (49,000 g, 4°C, 10 min). The supernatant was transferred to a
centrifugal concentrator (Amicon Ultra 15, 10,000 MWCO), diluted to 10 ml with
degassed Tris·HCl (50 mM, pH 8.0) and concentrated to 0.5 ml. This step was 
repeated four times after which the modified protein was concentrated to 1 ml and
stored at 4°C.
Figure 8 LC-MS (ES+) spectrum of ALBP -3
The difference in ionization efficiency between unmodified and modified ALBP was
assessed by comparing the MS spectra of modified protein with and without the
addition of 1 equivalent of unmodified protein. The ionization efficiency of
unmodified ALBP was found to be approximately 10x higher then the ionization
efficiency of the ALBP-3.
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multiple modification of the protein was 9 hours. The insoluble fraction of the
excess modification reagent was removed by centrifugation at 49,000 g at 4°C for 10
min. The supernatant was transferred to a centrifugal concentrator (Vivaspin 2,
10,000 MWCO), diluted to 2 ml with degassed Tris·HCl (50 mM, pH 8.0) and 
concentrated to 0.1 ml. This step was repeated four times after which the modified
protein was concentrated to 0.4 ml and stored at 4°C.
2. Conjugation with 2
Conjugation with 2 was performed as described for 1. 260 nmol (13 eq.) of CDI-
activated 2 in 5.2 μl of dimethylformamide were used for the coupling reaction. The 
reaction time was 4 hours, in order to achieve monomodification of the protein with
2.
3. Conjugation with 3
Conjugation with 3 was performed as described for 1. 280 nmol (14 eq.) of CDI-
activated 3 in 5.6 μl of dimethylformamide were used for the coupling reaction. The 
reaction time required to avoid multiple modification of the protein was 9 hours.
4. Conjugation with 4
Conjugation with 4 was performed as described for 1. 390 nmol (19.5 eq.) of CDI-
activated 4 in 7.8 μl of dimethylformamide were used for the coupling reaction. The 
reaction time required to avoid multiple modification of the protein was 9 hours.
It was not possible to accurately compare the ionization efficiency of unmodified and
modified 98, due to dimer formation observed by LC-MS (ES+).
Figure 11 LC-MS (ES+) spectrum of 98 modified with 1
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Figure 12 31P {1H} NMR (202 MHz, D2O) spectrum of 98-1 in 50 mM Tris·HCl (pH 8)
The sharp peak at +4.6 ppm is likely generated by traces of free phosphane 1 left in
solution after washing. The two broad peaks (around 0 ppm and -10 ppm) could be
generated either by the free phosphane 1 present inside the hydrophobic cavity of the
protein and by the phosphane 1 covalently coupled to protein, or by the migration of the
ligand 1 from the SH group to the NH2 group of a lysine residue. However the LC-MS
(ES+) spectrum of 98 modified with 1 revealed only monomodification of the
protein.
(a) (b)
Figure 13 LC-MS (ES+) spectrum of 98-2 (a, b). Unspecific modifications were obtained when high
excess ligand was used to improve the coupling efficiency (b).
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(a) (b)
Figure 14 LC-MS (ES+) spectrum of 98-3 (a, b). The attempt to improve coupling efficiency by
increasing the excess ligand led to unspecific modifications (b).
Figure 15 LC-MS (ES+) spectrum of 98-4
5. MALDI-MS analysis of tryptic peptides resulted from digestion of 98-1,
98-2 and 98-3
The digest solution (0.5 μl) was applied to the MALDI target along with alpha-cyano-4-
hydroxycinnamic acid matrix (0.5 μl, 10 mg/ml in 50:50 acetonitrile:0.1% TFA) and 
0.1% TFA (0.5 μl) and allowed to dry. MALDI MS was acquired using a 4800 MALDI 
TOF/TOF Analyser (Applied Biosystems, Foster City, CA) equipped with a Nd:YAG
355 nm laser and calibrated using a mixture of peptides. The spot was initially analysed
in positive MS mode between 800 and 4000 m/z, by averaging 1000 laser spots. The
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ion at m/z 2083.8 was associated to the mass of the unmodified peptide
(80)EISGNELIQTCTYEGVEAK(98) and the ion at m/z 2388.08 was found to correspond
to the peptide (80)EISGNELIQTCTYEGVEAK(98) modified with o, m or p-
(diphenylphosphinyl)-benzoic acid (Figure 16), proving that 98 is modified with the
ligands 1-3 at cysteine 90.
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Protection of the NH2 group of lysines (to prevent multiple modifications of 98
with phosphanes 1-4)
NH2 protection via imine bond formation
2
4
Figure 17 Lysines NH2 group protection via imine bond formation40
Reaction between the primary amino-group of a lysine and the carbonyl group of 4-
diethylamino 2-hydroxy benzaldehyde (S1) or pyridoxal 5’-phosphate (S2) leads to
formation of an imine bond,40 thereby protecting it from reacting with the activated
phosphino-carboxylic acids.
1 ml of protein solution (100 µM in phosphate buffer at pH 7.5) was treated with a 10x,
25x or 50x molar excess aldehyde S1 for 16 hours, at room temperature, under air,
followed by centrifugation and washing with phosphate buffer (pH 7.5) to remove the
excess S1. Subsequently, coupling of carboxylic acid functionalized phosphanes 1-4
was performed as described above for the unmodified protein.
The procedure for NH2 protection using S2 was performed as described for S1.
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Figure 18 LC-MS (ES+) spectrum of 98 modified with S1
Figure 19 LC-MS (ES+) spectrum of 98 modified with S1 and ligand 3
NH2 protection via amide bond formation
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Figure 20 Lysines NH2 group protection via amide bond formation (a) with N-hydroxysuccinimide ester
derivatives and (b) with anhydrides
The amide bond was formed using either N-hydroxysuccinimide ester derivatives or
anhydrides. Two esters were tested: 3-(4-hydroxyphenyl)-propionic acid N-
hydroxysuccinimide ester (S3)41 and nicotinic acid N-hydroxysuccinimide ester (S4),42
and two anhydrydes: acetic anhydride43 and 2,3 dimethyl maleic anhydride (S5).44
NH2 protection via amide bond formation was performed as described for S1.
Figure 21 LC-MS (ES+) spectrum of 98 protected with S3 (10x molar excess) and subsequently
modified with ligand 3 (5x molar excess)
13400 13600 13800 14000 14200 14400 14600 14800
mass
1.55e3
A:14287.45±1.07
B:13999.73±0.30
C:14724.11±1.07
A
14286.20B
13999.40
13993.10
13859.00
14000.70
14285.20
14148.60
14147.40
A
14287.40
14289.70
14290.30
14436.50
14576.20
C
14723.60
C
14724.30
14726.90
14860.40
14864.00
Calc Mass Observed
Mass
98+S3+3 13859.5 13859.00
98+(3)2 13999.6 13999.4
98+S3+(3)2 14147.8 14148.6
98+(3)3 14287.9 14287.4
98+S3+(3)3 14436.1 14436.5
98+(3)4 14576.2 14576.2
98+S3+(3)4 14724.4 14724.3
98+(3)5 14864.5 14864.0
Figure 22 LC-MS (ES+) spectrum of 98 protected with S3 (25x
modified with ligand 3 (5x molar exc
All tested compounds S1-S5 afforded proteins with vary
and modification of all the NH2 groups could not be ac
phosphane ligand was coupled to the protected protein, s
ligand were observed, in addition to the multiple imine/am
Figure 21, Figure 22).
Replacement of the most reactive lysines (K74 and K104)
This procedure was followed also by incomplete or m
protein with phosphanes 1-4.
AppA Y21C
Prior to couplings the protein solution was degasses b
hours.
1. Conjugation with 1
500 nmol (10 eq.) of CDI activated 1 in 10 μl of dimeth
solution of 50 nmol of protein (1 eq.) in buffer (50 mM
3M imidazole at pH 7.0. The reaction mixture was stir
13000 13250 13500 13750 14000 14250 14500 14750 15000
0
100
%
1.26e414148.00
14001.00
13713.00
13125.00
13697.0013140.00
13446.00
13860.00
14437.00
14295.00 14583.00
14726.00 14874.0
151Calc Mass Observed
Mass
98-3 13711.3 13713.0
98+S3+3 13859.5 13860.0
98+(3)2 13999.6 14001.0
98+S3+(3)2 14147.8 14148.0
98+(S3)2+(3)2 14295.9 14295.0
98+S3+(3)3 14436.1 14437.0
98+(S3)2+(3)3 14584.2 14583.0
98+S3+(3)4 14724.4 14726.087
molar excess) and subsequently
ess)
ing number of modifications
hieved. Moreover, when the
till multiple couplings of the
ide modifications (Figure 19,
with glutamine
ultiple modifications of the
y purging with argon for 8
ylformamide was added  to a 
 Tris·HCl, 1 ml) containing 
red at room temperature for
15250 15500 15750
mass
0
15847.00
45.00
15451.00
15161.00
15466.00
15514.00 15985.00
98+(S3)2+(3)4 14872.5 14874.0
88
16h. The insoluble fraction of the excess modification reagent was removed by
centrifugation at 49,000 g at 4°C for 10 min. The supernatant was transferred to a
centrifugal concentrator (Amicon Ultra 15, 10,000 MWCO), diluted to 10 ml with
degassed Tris·HCl (50 mM, pH 7.0) and concentrated to 0.5 ml. This step was 
repeated four times after which the modified protein was concentrated to 1 ml and
stored at 4°C.
2. Conjugation with 2, 3 and 4
Conjugation with 2, 3 and 4 was performed as described for 1.
(a) (b)
Figure 23 LC-MS (ES+) spectrum of AppA Y21C - 3. Coupling reaction done in absence of imidazole,
using a 10x (a) and a 50x (b) molar excess of ligand 3
When conjugation with carboxylic acid functionalized phosphanes was done in absence
of imidazole, very low coupling efficiency was observed, even when the molar excess
of ligand was as high as 50. Attempts to increase the conjugation efficiency by
increasing the excess ligand resulted in multiple unspecific modifications of the protein
(Figure 23).
The conjugation efficiency of ligands 1-4 was improved by performing the coupling
reactions in presence of 3M imidazole.45 However it was not possible to achieve
complete monomodification of the protein for any ligand.
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Figure 24 LC-MS (ES+) spectrum of AppA Y21C - 3.
Coupling reaction done in presence of 3M imidazole using 10x molar excess of ligand 3
Figure 25 LC-MS (ES+) spectrum of AppA Y21C - 4
Coupling reaction done in presence of 3M imidazole using 10x molar excess of ligand 4
b. Covalent modification with N-(4-(diphenylphosphane sulfide)benzyl)
maleimide
ALBP
5 μmol (50 eq.) of phosphane sulfide in 0.1 ml of dimethylformamide was added to a 
solution of 100 nmol of protein (1 eq.) in phosphate buffer (50 mM, 1ml, pH 7). The
cloudy reaction mixture was stirred at room temperature for 16 hours. The insoluble
excess modification reagent was removed by centrifugation (49,000 g, 4°C, 10 min).
The supernatant was transferred to a centrifugal concentrator (Amicon Ultra 15,
10,000 MWCO), diluted to 10 ml with degassed phosphate buffer (50 mM, pH 7.0)
and concentrated to 0.5 ml. This step was repeated four times after which the
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modified protein was concentrated to 1 ml and stored at 4°C.
Figure 26 LC-MS (ES+) spectrum of ALBP modified with N-(4-(diphenylphosphane sulfide)benzyl)
maleimide (dppsbm)
The LC-MS (ES+) spectrum of ALBP modified with N-(4-(diphenylphosphane
sulfide)benzyl) maleimide (Figure 26) indicates species corresponding to the protein
modified with the phosphane sulfide (17008.7), but also to the protein modified with the
phosphane oxide (16992.3). Most probable the sulfur deprotection and the consequent
phosphane oxidation occur during LC-MS analysis. This is suggested also by the NMR
analysis of 98 modified with the phosphane sulfide, which shows only the peak
corresponding to the phosphane sulfide modified protein, but no peak corresponding to
the phosphane oxide (Figure 27).
Raney nickel deprotection of N-(4-(diphenylphosphane sulfide)benzyl) maleimide
coupled to ALBP was tested according to a reported literature procedure.51,87 No mass
for the protein modified with the free phosphane was detected by LC-MS (ES+) after
the deprotection treatment.
98
Prior to coupling the protein solution was degassed by purging with argon for 8
hours. Reduction of protein disulfide bridges was performed using 6x molar excess
of TCEP.88 The reduction reaction proceeded for 1 hour at room temperature and the
protein solution was used directly for the next step, without further purification.
100 nmol (1 eq.) of phosphane sulfide in 2 μl of dimethylformamide was added to a 
solution of 100 nmol of protein (1 eq.) in Tris·HCl (50 mM, 1 ml, pH 7) in a 
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Schlenk-tube. The reaction mixture was stirred at room temperature for 16 hours.
The insoluble excess modification reagent was removed by centrifugation (49,000 g,
4°C, 10 min). The supernatant was transferred to a centrifugal concentrator (Amicon
Ultra 15, 10,000 MWCO), diluted to 10 ml with degassed Tris·HCl (50 mM, pH 7.0) 
and concentrated to 0.5 ml. This step was repeated four times after which the
modified protein was concentrated to 1 ml and stored at 4°C.
Figure 27 31P {1H} NMR spectrum of 98 modified with N-(4-(diphenylphosphane sulfide)benzyl)
maleimide
Figure 28 LC-MS (ES+) spectrum of 98 modified with N-(4-(diphenylphosphane sulfide)benzyl)
maleimide (dppsbm)
Raney nickel deprotection of N-(4-(diphenylphosphane sulfide)benzyl) maleimide
coupled to 98 was tested according to a literature procedure.51,87 No mass for the
protein modified with the free phosphane was detected by LC-MS (ES+). The mass at
13810, observed after the deprotection attempt, corresponds to the protein modified
with phosphane oxide, most probable formed during LC-MS analysis, as observed also
for ALBP (Figure 26).
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c. Coupling of maleimide functionalized azide and alkynes 5-7
ALBP
General procedure for coupling of maleimide derivatives 5-7 to ALBP
300 nmol (3 eq.) of maleimide derivative 5 in 6 μl of dimethylformamide was added to 
a solution of 100 nmol of protein (1 eq.) in Tris·HCl (50 mM, 1ml, pH 8). The cloudy 
reaction mixture was stirred at room temperature for 16 h. The insoluble excess
modification reagent was removed by centrifugation (49,000 g, 4°C, 10 min). The
supernatant was transferred to a centrifugal concentrator (Amicon Ultra 15, 10,000
MWCO), diluted to 10 ml with 50 mM Tris·HCl (pH 8.0) and concentrated to 0.5 ml. 
This step was repeated four times after which the modified protein was concentrated to
1 ml and stored at 4°C.
Coupling of maleimides 6 and 7 was performed as described for 5.
To compare the ionization efficiency of the modified and unmodified protein, 1 eq. of
unmodified protein was added to the reaction mixture after removal of excess
maleimides 5-7. No difference in ESI-MS ionization efficiency between the modified
and unmodified protein was observed for all three compounds.
An increase of 18 Da of the masses of ALBP-5, ALBP-6 and ALBP-7 was observed by
LC-MS (ES+). This is most probably caused by the hydrolytic opening of the
maleimide ring.
Figure 31 LC-MS (ES+) spectrum of ALBP - 5
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Figure 32 LC-MS (ES+) spectrum of ALBP - 6
Figure 33 LC-MS (ES+) spectrum of ALBP - 7
MALDI-MS analysis of the peptides resulted from digestion of ALBP-5 with
trypsin
Figure 34 MALDI MS spectrum of tryptic peptides resulted from digestion of ALBP-5
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The digest solution (0.5 μl) was applied to the MALDI target along with alpha-cyano-4-
hydroxycinnamic acid matrix (0.5 μl, 10 mg/ml in 50:50 acetonitrile:0.1% TFA) and 
0.1% TFA (0.5 μl) and allowed to dry. MALDI MS was acquired using a 4800 MALDI 
TOF/TOF Analyser (Applied Biosystems, Foster City, CA) equipped with a Nd:YAG
355 nm laser and calibrated using a mixture of peptides. The spot was initially analysed
in positive MS mode between 800 and 4000 m/z, by averaging 1000 laser spots. The ion
at m/z 1073.67 found in the spectrum of digested ALBP-5 was assigned to the peptide
(131)LVVECVMK(38) modified with the maleamic acid adduct of 5 (Figure 34).
MALDI-MS/MS analysis of the peptide at m/z 1073.67
Figure 35 MALDI MS/MS spectrum of
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assuming up to one missed cleavage, carbamidomethyl modification of cysteines as a
fixed modification and methionine oxidation selected as a variable modification.
MALDI-MS analysis of the peptides resulted from digestion of ALBP-6 with
trypsin
Figure 36 MALDI MS spectrum of tryptic peptides from ALBP-6
MALDI MS of the ALBP-6 digest solution was performed as described for ALBP-5.
The ion at m/z 1135.6 found in the spectrum of digested ALBP-6 was assigned to the
peptide (131)LVVECVMK(138) modified with the maleamic acid adduct of 6 (Figure 36).
MALDI-MS/MS analysis of the peptide at m/z 1135.6
Figure 37 MALDI MS/MS spectrum of peptide Leu131-Lys138-6
The MALDI MS/MS analysis of the peptide Leu131-Lys138-6 (performed as described
for Leu131-Lys138-5) confirmed cysteine modification (Figure 37).
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98
General procedure for coupling of maleimide derivatives 5-7 to 98
1.5 μmol (15 eq.) of maleimide derivative 5 in 30 μl of dimethylformamide was added 
to a solution of 100 nmol of protein (1 eq.) in Tris·HCl (50 mM, 1 ml, pH 8) containing 
DTT (6 eq.) in a Schlenk-tube, followed by stirring at room temperature for 16 hours.
The insoluble excess modification reagent was removed by centrifugation (49,000 g,
4°C, 10 min). The supernatant was transferred to a centrifugal concentrator (Amicon
Ultra 15, 10,000 MWCO), diluted to 10 ml with degassed 50 mM Tris·HCl (pH 7.0) and 
concentrated to 0.5 ml. This step was repeated four times after which the modified
protein was concentrated to 1 ml and stored at 4°C.
Coupling of maleimides 6 and 7 was performed as described for 5.
An increase of 18 Da of the mass of 98 modified with the ligands 5-7 was observed
by LC-MS (ES+), most probably caused by the hydrolytic opening of the maleimide
ring.
Figure 38 LC-MS (ES+) spectrum of 98 - 5
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Figure 39 LC-MS (ES+) spectrum of 98 - 6
Figure 40 LC-MS (ES+) spectrum of 98 - 7
MALDI-MS analysis of the peptides resulted from digestion of 98-5 with trypsin
MALDI MS of the digest solution was performed as described for ALBP-5. The ion at
m/z 2218.1 found in the spectrum of digested 98-5 was assigned to the peptide
(80)EISGNELIQTCTYEGVEAK(98) modified with 5 and the ion at m/z 2236.8 was
assigned to the same peptide modified with the maleamic acid adduct of 5 (Figure 41).
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Figure 41 MALDI MS spectrum of tryptic peptides resulted from digestion of 98-5
MALDI-MS/MS analysis of the peptide at m/z 2236.8
Figure 42 MALDI MS/M
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added to a solution of 100 nmol of protein (1 eq.) in buffer (Tris·HCl 50 mM, 1ml) 
containing 3M imidazole at pH 7.0. The cloudy reaction mixture was stirred at room
temperature for 4 h. The insoluble excess modification reagent was removed by
centrifugation (49,000 g, 4°C, 10 min). The supernatant was transferred to a
centrifugal concentrator (Amicon Ultra 15, 10,000 MWCO), diluted to 10 ml with
50 mM Tris·HCl (pH 7.0) and concentrated to 0.5 ml. This step was repeated four 
times after which the modified protein was concentrated to 1 ml and stored at 4°C.
Coupling of maleimides 6 and 7 was performed as described for 5.
98
General procedure for coupling of maleimide derivatives 5-7 to 98 in presence of
3M imidazole
3.7 μmol (37 eq.) of maleimide derivative 5 in 74 μl of dimethylformamide was 
added to a solution of 100 nmol of protein (1 eq.) in buffer (Tris·HCl, 50 mM, 1 ml) 
containing 3M imidazole, at pH 7, in a Schlenk-tube. The reaction mixture was
stirred at room temperature for 16 hours. The insoluble excess modification reagent
was removed by centrifugation (49,000 g, 4°C, 10 min). The supernatant was
transferred to a centrifugal concentrator (Amicon Ultra 15, 10,000 MWCO), diluted
to 10 ml with degassed 50 mM Tris·HCl (pH 7.0) and concentrated to 0.5 ml. This 
step was repeated four times after which the modified protein was concentrated to 1
ml and stored at 4°C.
Coupling of maleimides 6 and 7 was performed as described for 5.
(a)
10000 12000 14000 16000 18000
mass0
100
%
15530.10
13708.3012425.00
15665.70
15682.50
15800.70 17602.30 19672.80
Calc Mass Observed Mass
AppA Y21C-5 15530.2 15530.1
AppA Y21C-(5)2 15665.4 15665.7
AppA Y21C-(5)3 15800.6 15800.7
101
(b)
Figure 43 LC-MS (ES+) spectrum of AppA Y21C - 5 in absence (a) and in presence (b) of 3M imidazole
(a)
(b)
Figure 44 LC-MS (ES+) spectrum of AppA Y21C - 6 in absence (a) and in presence (b) of 3M imidazole
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Figure 45 LC-MS (ES+) spectrum of AppA Y21C - 7 in absence (a) and in presence (b) of 3M imidazole
(a)
10000 12000 14000 16000 18000
mass0
100
%
13557.80
10395.10 13542.20
11878.40
13574.90
13710.40
13845.30
13863.50
17103.6015062.30 18638.80
10000 12000 14000 16000 18000
mass0
100
%
15609.30
15590.70
10406.00 12856.10 14692.50
15822.70
15841.20
16054.20
19209.9016073.40
10000 12000 14000 16000 18000
mass0
100
%
15609.80
15591.40
10406.40 14790.8012291.30
15627.50
Calc Mass Observed Mass
AppA Y21C-7 15609.3 15609.3
AppA Y21C-(7)2 15823.5 15822.7
AppA Y21C-(7)3 16037.7 16054.2
Calc Mass Observed Mass
98-5 13558.1 13557.8
98-(5)2 13693.3 13710.4
98-(5)3 13828.5 13845.3
AppA Y21C-7
Calc Mass 15609.3
Observed Mass 15609.8
AppA Y21C
(b)
Figure 46 LC-MS (ES+) spectrum of 98 - 5 in absence (a) and in presence (b) of 3M imidazole
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Figure 47 LC-MS (ES+) spectrum of 98 - 6 in absence (
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Multiple couplings to AppA Y21C were detected by LC-MS (ES+) when a 25-fold
molar excess of 5-7 was used for the coupling reactions. However, when the reactions
were done in presence of 3M imidazole, selective monomodification of cysteine was
observed, despite of the high molar excess of maleimide.
To check the influence of imidazole in multiple modifications prevention, the
maleimides 5-7 were coupled to 98 in presence and in absence of 3M imidazole,
using also a large excess of modification reagent. Once again selective
monomodification of 98 was observed when the reactions were performed in
presence of imidazole, while multiple couplings were noticed for the same excess of
modification reagent in absence of imidazole.
Similar results were found when a different maleimide functionalized compound, tert-
butyl phenyl maleimide, was coupled to AppA Y21C and 98 in presence and in
absence of imidazole using a large excess of modification reagent.
d. Attempts to introduce BH3 protected phosphanes into alkyne and azide
functionalized proteins via click- reaction
Several reported literature procedures were adapted in order to modify our library of
alkyne/azide functionalized proteins via click- reaction.
1. A procedure reported by Hatzakis and co-workers89 for protein labelling was
adapted to test the incorporation of alkyne functionalized phosphane borane 8 to ALBP-
7 and 98-7.
0.5 μmol (20 eq.) of phosphane-borane 8 in 50 μl of tetrahydrofurane was added to a 
solution of 25 nmol of azide modified protein (1 eq.) in phosphate buffer (20 mM, 0.5
ml, pH 7.2), followed by the addition of catalyst solution (2.5 μmol of CuSO4x5H2O,
12.5 μmol of Na-ascorbate) in phosphate buffer (20 mM, 0.2 ml, pH 7.2). The reaction 
mixture was stirred for 24 hours. The insoluble excess modification reagent and Cu(II)
salts were removed by centrifugation (49,000 g, 4°C, 10 min). The supernatant was
transferred to a centrifugal concentrator (Amicon Ultra 15, 10,000 MWCO), diluted to
10 ml with degassed 20 mM phosphate buffer (pH 7.2) and concentrated to 0.5 ml. This
105
step was repeated four times after which the modified protein was concentrated to 0.75
ml and stored at 4°C.
LC-MS was performed before and after the washing step, but no protein signal could be
detected. 50% of the initial amount of 98 and 25% of the initial amount of ALBP
was found in solution after the washing step (Bradford assay68).
2. A procedure reported by Finn and co-workers involves the water-soluble ligand S6
(sulfonated bathophenanthroline) as promoter of Cu(I) mediated azide-alkyne
cycloaddition.56 This procedure was tested for incorporation of phosphane-boranes 8
and 9 to ALBP and 98 modified with 5, 6 or 7.
33
0.8 μmol (10 eq.) of phosphane-borane 8 in 5 μl of tetrahydrofurane was added to a 
solution of 80 nmol of azide modified protein (1 eq.) in 50 mM Tris·HCl (1.232 ml, pH 
8), followed by the addition of preformed catalyst solution, synthesized by mixing 40
μmol of CuBr in 0.288 ml acetonitrile with 120 μmol of ligand S6 in 0.480 ml Tris·HCl, 
pH 8, under argon. The reaction mixture was stirred for 16 hours.
Proteins stability was verified at the end of the reaction by SDS-PAGE and Bradford
assay. Both proteins proved to be stable under the reaction conditions. However, LC-
MS of the reaction mixture did not indicate any protein signal.
The precipitated Cu(II) salts and the insoluble excess phosphane were removed by
centrifugation (49,000 g, 4°C, 10 min). The supernatant was desalted on a PD 10
column (GE Healthcare) and eluted with demineralised water (3.5 ml). The eluent was
transferred to a centrifugal concentrator (Amicon Ultra 15, 10,000 MWCO), diluted to
10 ml with 20 mM EDTA solution90 in 50 mM Tris·HCl (pH 8) and concentrated to 0.5 
ml. This step was repeated two times. After that the protein solution was diluted twice
to 10 ml with 50 mM Tris·HCl (pH 8), concentrated to 0.5 ml and characterised by 
Bradford assay (64% of the initial amount of protein was left in solution), SDS-Page
and LC-MS (ES+).
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The attempt to couple the phosphane-borane 9 via click-reaction to alkyne modified
proteins was performed as described for 8.
Figure 48 LC-MS (ES+) spectrum of 98 - 5, after the click-reaction done in presence of S6 followed
by washing with EDTA
The only masses detected by LC-MS (ES+) after the click reaction done according to
this procedure were the ones corresponding to the mass of apo-proteins and of the
protein modified with the maleimide functionalized compounds 5-7 (Figure 48).
3. A procedure used by Finn and co-workers for the modification of an alkyne/azide
functionalized virus via Cu(I) catalyzed azide-alkyne [3+2] cycloaddition is involving
the ligand S7 (tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine).55 I adapted this
procedure in an attempt to incorporate the phosphane-borane 9 to ALBP modified with
5 or 6.
400 nmol (10 eq) of phosphane-borane 9 in 4 μl of tetrahydrofurane was added to a 
solution of 40 nmol of alkyne modified ALBP (1 eq.) in 50 mM Tris·HCl (1 ml, pH 8), 
followed by the addition of 2 μmol of TCEP in 0.200 ml Tris·HCl and 2 μmol of S7 in
40 μl dimethyl sulfoxide. 1 μmol of CuSO4 in Tris·HCl (250 μl, pH 8) was then added. 
The reaction mixture was stirred for 16 hours. The precipitated Cu(II) salts and the
insoluble excess phosphane were removed by centrifugation (49,000 g, 4°C, 10 min).
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The supernatant was desalted on a PD 10 column (GE Healthcare) and eluted with
demineralised water (3.5 ml). The eluent was transferred to a centrifugal concentrator
(Amicon Ultra 15, 10,000 MWCO), diluted to 10 ml with 20 mM EDTA solution90 in
50 mM Tris·HCl (pH 8) and concentrated to 0.5 ml. This step was repeated two times. 
After that the protein solution was diluted twice to 10 ml with 50 mM Tris·HCl (pH 8) 
and concentrated to 0.5 ml. At the end the protein was characterised by Bradford Assay
(46% of the initial amount of protein was left in solution), SDS-PAGE and LC-MS
(ES+). LC-MS spectra showed only the peak corresponding to the alkyne modified
protein.
(a)
(b)
Figure 49 LC-MS (ES+) spectrum of ALBP - 6 before (a) and after (b) the click-reaction done in
presence of S7
In conclusion, when the attempts to couple the phosphane-boranes 8 and 9 to the
modified proteins via click-reaction were performed in presence of Cu(I) it was not
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possible to asses the product formation via LC-MS, due to possible suppression of the
protein signal by Cu(I). The use of nitrogen ligands capable to coordinate and stabilize
the metal appears to prevent this suppression during the LC-MS analysis, however
masses corresponding to the click modified proteins were not observed. This suggests
that either the click reaction did not work for the tested conditions, or the click modified
proteins were not stable for the tested reaction conditions.
e. Covalent modification with maleimide functionalized phosphane-boranes 10-
12
ALBP
Prior to coupling the protein solution was degassed by purging with argon for 8
hours.
1. Conjugation with 10
312.5 nmol (25 eq.) of click-compound 10 in 6.25 μl of dimethylformamide was 
added to a solution of 12.5 nmol of protein (1 eq.) in Tris·HCl (50 mM, 0.25 ml, pH 
8). The reaction mixture was stirred at room temperature for 5h. The insoluble
fraction of excess ligand was removed by centrifugation (49,000 g, 4°C, 10 min).
The supernatant was transferred to a centrifugal concentrator (Vivaspin 2, 10,000
MWCO), diluted to 2 ml with degassed Tris·HCl (50 mM, pH 8.0) and concentrated 
to 0.1 ml. This step was repeated four times after which the modified protein was
concentrated to 0.25 ml and stored at 4°C.
2. Conjugation with 11 and 12
Conjugation with 11 and 12 was performed as described for 10.
Figure 50 LC-MS (ES+) spectrum of ALBP - 10
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Figure 51 LC-MS (ES+) spectrum of ALBP - 11
Figure 52 LC-MS (ES+) spectrum of ALBP - 12
98
1. Conjugation with 10
1.85 μmol (37 eq.) of click-compound 10 in 37 μl of dimethylformamide was added 
to a solution of 50 nmol of protein (1 eq.) in Tris·HCl (50 mM, 1 ml, pH 8.0) 
containing DTT (6 eq.) in a Schlenk-tube, followed by stirring at room temperature
for 9 h. The insoluble excess modification reagent was removed by centrifugation
(49,000 g, 4°C, 10 min). The supernatant was transferred to a centrifugal
concentrator (Amicon Ultra 15, 10,000 MWCO), diluted to 10 ml with degassed
Tris·HCl (50 mM, pH 8.0) and concentrated to 0.5 ml. This step was repeated four 
times after which the modified protein was concentrated to 1 ml and stored at 4°C.
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2. Conjugation with 11 and 12
Conjugation with 11 and 12 was performed as described for 10.
Figure 53 LC-MS (ES+) spectrum of 98 - 10
Figure 54 LC-MS (ES+) spectrum of 98 - 11
Figure 55 LC-MS (ES+) spectrum of 98 - 12
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AppA Y21C
Prior to coupling the protein solution was degassed by purging with argon for 8
hours.
1. Conjugation with 10
312.5 nmol (25 eq.) of click-compound 10 in 6.25 μl of dimethylformamide was 
added to a solution of 12.5 nmol of protein (1 eq.) in buffer (Tris·HCl 50 mM, 0.25 
ml) containing 3M imidazole at pH 7.0. The reaction mixture was stirred at room
temperature for 5h. The insoluble fraction of excess ligand was removed by
centrifugation (49,000 g, 4°C, 10 min). The supernatant was transferred to a
centrifugal concentrator (Vivaspin 2, 10,000 MWCO), diluted to 2 ml with degassed
Tris·HCl (50 mM, pH 7.0) and concentrated to 0.1 ml. This step was repeated four 
times after which the modified protein was concentrated to 0.25 ml and stored at
4°C.
2. Conjugation with 11 and 12
Conjugation with 11 and 12 was performed as described for 10.
Figure 56 LC-MS (ES+) spectrum of AppA Y21C - 10
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Figure 57 LC-MS (ES+) spectrum of AppA Y21C – 11
Figure 58 LC-MS (ES+) spectrum of AppA Y21C - 12
f. Procedures tested for deprotection of phosphane-boranes coupled to proteins
Ethanolamine58
ALBP
a. A solution of 12.5 nmol of protein modified with 10 in 50 mM Tris·HCl 
(0.25 ml, pH 8) was transferred to a centrifugal concentrator (Amicon Ultra
15, 10,000 MWCO), diluted to 15 ml with degassed 20 mM ethanolamine in
50mM Tris-HCl (pH 8) and concentrated to 0.5 ml. The procedure was
repeated and the protein solution was finally concentrated to 0.25 ml and
analysed by LC-MS (ES+).
b. 15 ml of degassed 100 mM ethanolamine in 50mM Tris-HCl (pH 8) were
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added to a solution of 12.5 nmol of protein modified with 10 in 50 mM
Tris·HCl (0.25 ml, pH 8) in a Schlenk-tube. The reaction was stirred for 2 
hours at room temperature. The protein solution was concentrated to 0.25 ml
and analysed by LC-MS (ES+).
c. 15 ml of degassed 200 mM ethanolamine in 50mM Tris-HCl (pH 8) were
added to a solution of 12.5 nmol of protein modified with 10 in 50 mM
Tris·HCl (0.25 ml, pH 8). The reaction was stirred for 24 hours at room 
temperature. The protein solution was concentrated to 0.25 ml and analysed
by LC-MS (ES+).
No mass corresponding to the protein modified with free phosphane was
observed by LC-MS after all the tested procedures.
Figure 59 LC-MS (ES+) spectrum of ALBP - 10 after decomplexation reaction with 200 mM
ethanolamine.
TCEP
ALBP
a. A solution of 12.5 nmol of protein modified with 10 in Tris·HCl (50 mM, 
0.25 ml, pH 8) was transferred to a centrifugal concentrator (Amicon Ultra
15, 10,000 MWCO), diluted to 15 ml with degassed 20 mM TCEP in Tris-
HCl (50mM, pH 8) and concentrated to 0.5 ml. The procedure was repeated
and the protein solution was finally concentrated to 0.25 ml and analysed by
LC-MS (ES+).
b. 15 ml of degassed 100 mM TCEP in Tris-HCl (50mM, pH 8) were added to a
solution of 12.5 nmol of protein modified with 10 in Tris·HCl (50 mM, 0.25 
ml, pH 8) in a Schlenk-tube, followed by stirring for 2 hours at room
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temperature. The protein solution was finally concentrated to 0.25 ml and
analysed by LC-MS (ES+).
c. 15 ml of degassed 200 mM TCEP in Tris-HCl (50mM, pH 8) were added to a
solution of 12.5 nmol of protein modified with 10 in Tris·HCl (50 mM, 0.25 
ml, pH 8) in a Schlenk-tube, followed by stirring for 24 hours at room
temperature. The protein solution was finally concentrated to 0.25 ml and
analysed by LC-MS (ES+).
No mass corresponding to protein modified with free phosphane was observed
by LC-MS for any of the tested procedures.
Figure 60 LC-MS (ES+) spectrum of ALBP - 10 after decomplexation reaction with TCEP (200 mM).
DABCO59
ALBP, 98
a. 15 ml of degassed 100 mM DABCO in phosphate buffer (50mM, pH 9.5)
were added to a solution of 12.5 nmol of protein modified with 10 in
Tris·HCl (50 mM, 0.25 ml, pH 8) in a Schlenk-tube, followed by stirring for 
5 hours at room temperature. The protein solution was finally concentrated to
0.25 ml and analysed by LC-MS (ES+).
b. The same procedure was tested using a 200 mM DABCO in phosphate buffer
(50mM, pH 9.9).
No mass corresponding to protein modified with free phosphane was observed by
LC-MS after the tested procedures.
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Figure 61 LC-MS (ES+) spectrum of ALBP - 10 after decomplexation reaction with DABCO
DABCO treatment under denaturating conditions59
ALBP
15 ml of degassed 200 mM DABCO and 6M GuCl in phosphate buffer (50mM, pH
9.9) were added to a solution of 12.5 nmol of protein modified with 10 in Tris·HCl 
(50 mM, 0.25 ml, pH 8) in a Schlenk-tube, followed by stirring for 16 hours at room
temperature. The protein solution was finally concentrated to 0.25 ml and analysed
by LC-MS (ES+). No mass corresponding to protein modified with free phosphane
was observed.
Figure 62 LC-MS (ES+) spectrum of ALBP - 10 after decomplexation reaction with DABCO under
denaturating conditions (6M GuCl)
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DABCO treatment in presence of KF60,91
ALBP
15 ml of 200 mM DABCO and 6M GuCl in phosphate buffer (50mM, pH 9.9) and
0.15 ml of saturated KF in water were added to a solution of 12.5 nmol of protein
modified with 10 in Tris·HCl (50 mM, 0.25 ml, pH 8) in a Schlenk-tube, followed 
by stirring for 16 hours at room temperature. The protein solution was finally
concentrated to 0.25 ml and analysed by LC-MS. No mass corresponding to protein
modified with free phosphane was observed.
Figure 63 LC-MS (ES+) spectrum of ALBP - 10 after decomplexation with DABCO under denaturating
conditions, in presence of KF
Imidazole
ALBP, 98
a. 15 ml of degassed 0.5 M imidazole in Tris-HCl (50 mM, pH 8.5) were added to
a solution of 12.5 nmol of protein modified with 10 in Tris·HCl (50 mM, 0.25 
ml, pH 8) in a Schlenk-tube, followed by stirring for 16 hours at room
temperature. The protein solution was finally concentrated to 0.25 ml and
analysed by LC-MS (ES+).
b. The same procedure was tested for 1M imidazole concentration (in Tris-HCl, 50
mM, pH 8.5).
No mass corresponding to the protein modified with free phosphane was observed in
both cases.
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Figure 64 LC-MS (ES+) spectrum of ALBP - 10 after decomplexation treatment with 1 M imidazole.
Tris(hydroxymethyl)phosphane
ALBP
15 ml of degassed 100 mM P(CH2OH)3 in Tris-HCl (50mM, pH 8) were added to a
solution of 12.5 nmol of ALBP modified with 10  in Tris·HCl (50 mM, 0.25 ml, pH 8.0) 
in a Schlenk-tube, followed by stirring for 5 hours at room temperature. The protein
solution was finally concentrated to 0.25 ml.
This same procedure was tested also using a 200 mM P(CH2OH)3 solution, as described
for the 100 mM P(CH2OH)3 solution.
No protein (modified or unmodified) was present in solution at the end of the
decomplexation reaction (Bradford assay68).
Hydroxylamine
ALBP
15 ml of degassed 100 mM hydroxylamine in Tris-HCl (50mM, pH 8) were added to a
solution of 12.5 nmol of ALBP modified with 10 in Tris·HCl (50 mM, 0.25 ml, pH 8) in 
a Schlenk-tube, followed by stirring for 16 hours at room temperature. The protein
solution was finally concentrated to 0.25 ml and analysed by LC-MS (ES+).
This same procedure was tested also using a 200 mM hydroxylamine solution, as
described for the 100 mM hydroxylamine.
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Figure 65 LC-MS (ES+) spectrum of ALBP - 10 after decomplexation attempt with hydroxylamine (200
mM).
Multiple additions of a mass varying from 14 to 16 to the mass of both unmodified and
modified protein were observed after the decomplexation attempt.
Morpholine (0.5 M)61
ALBP, 98, AppA Y21C
15 ml of degassed 0.5 M morpholine in Tris-HCl (50mM, pH 9) were added to a
solution of 12.5 nmol of protein modified with click-phosphane in Tris·HCl (50 mM, 
0.25 ml, pH 8) in a Schlenk-tube, followed by stirring for 16 hours at room temperature.
The protein solution was finally concentrated to 0.25 ml and analysed by LC-MS ES(+).
Figure 66 LC-MS (ES+) spectrum of ALBP - 11 after decomplexation attempt with 0.5 M morpholine
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Figure 67 LC-MS (ES+) spectrum of 98 - 11 after decomplexation treatment with 0.5M morpholine
(a)
(b)
Figure 68 LC-MS (ES+) spectrum of AppA Y21C modified with 12 after decomplexation treatment with
0.5 M morpholine (a) and neat morpholine (b)
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No mass of the protein modified with free phosphane was observed after the
decomplexation treatment, for all the three proteins.
Morpholine (neat)61
AppA Y21C
The borane decomplexation with neat morpholine was also tested. 15 ml of degassed
morpholine were added to 12.5 nmol of AppA Y21C modified with phosphane 12 in
Tris·HCl (50 mM, 0.25 ml), in a Schlenk tube. The reaction was stirred for 3 hours at 
room temperature. After that the reaction mixture was transferred to a centrifugal
concentrator (Amicon Ultra 15, 10,000 MWCO), concentrated to 0.5 ml, diluted to
10 ml with Tris-HCl (50 mM, pH 8.0) and concentrated to 0.2 ml. This step was
repeated four times after which the modified protein was concentrated to 0.2 ml and
analysed by LC-MS (ES+). No mass corresponding to protein modified with free
phosphane was observed (Figure 68b).
KCN
ALBP, 98, AppA Y21C
The BH3 decomplexation attempt using KCN was performed based on a literature
procedure.58
5 ml of degassed 100 mM KCN in Tris-HCl (50mM, pH 8) were added to a solution of
10 nmol of protein modified with 10 in Tris·HCl (50 mM, 0.2 ml, pH 8) in a Schlenk-
tube, followed by stirring for 16 hours at room temperature. After that the reaction
mixture was transferred to a centrifugal concentrator (Amicon Ultra 15, 10,000
MWCO), diluted to 10 ml with degassed Tris-HCl (50 mM, pH 8.0) and
concentrated to 0.2 ml. This step was repeated four times after which the modified
protein was concentrated to 0.2 ml and analysed by LC-MS ES(+). No mass
corresponding to the protein modified with free phosphane was detected by LC-MS
after decomplexation treatment.
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(a)
(b)
Figure 69 LC-MS (ES+) spectrum of ALBP - 10 before (a) and after (b) decomplexation attempt with
KCN
Figure 70 LC-MS (ES+) spectrum of 98 - 10 after decomplexation with KCN
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CO
The attempt to deprotect the phosphane-borane 10 coupled to ALBP, 98 and AppA
Y21C using CO was performed following a modified literature procedure.62
A solution of 25 nmol of protein modified with 10 in Tris·HCl (50 mM, 0.5 ml, pH 8.0) 
was maintained for 16 hours under 30 bars CO pressure at room temperature.
LC-MS (ES+) spectrum of modified ALBP, treated with CO for borane deprotection,
shows an addition of a mass of 56 to the mass of modified protein (Figure 71), which
could correspond to the mass of two molecules of CO. When one equivalent of
unmodified protein was added to the modified protein after CO decomplexation, the
same addition of a mass of 56 was observed for the freshly added apo-protein (Figure
72).
Figure 71 LC-MS (ES+) of ALBP - 10 after decomplexation with CO
Figure 72 LC-MS (ES+) of ALBP - 10 after decomplexatio
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Figure 73 LC-MS (ES+) of 98 - 10 after decomplexation treatment with CO
However, the addition of 56 was not observed for 98 and AppA Y21C, were no
changes in the mass of the modified protein were noticed after the CO decomplexation
attempt.
The question was posed if the protein environment, in particular the NH2 groups of
the lysine residues, have the ability to induce BH3 deprotection and consequent
oxidation of phosphane-boranes in aqueous solutions. To verify this hypothesis I
chose 3-(diphenylphosphane)benzenesulfonic acid, a phosphane available on large
scale. I tested the borane decomplexation of its BH3 complex in aqueous solutions,
in presence and in absence of ALBP. The decomplexation was followed by 31P {1H}
NMR. According to the 31P NMR spectra, after 16 hours only phosphane-borane and
phosphane oxide were observed and no free phosphane. Also the ratio between
phosphane-borane and phosphane oxide was the same for both solutions, with or
without protein, and remained the same after 24 hours. Therefore I concluded that
for this particular borane-phosphane the protein environment did not promote BH3
deprotection and consequent phosphane oxidation.
The mass difference of only 2 Da between the proteins modified with phosphane
oxide and with phosphane borane made difficult to evaluate the borane deprotection
of precoupled phosphanes to proteins via LC-MS. To be able to compare between
the masses of the two types of proteins, the maleimide functionalized phosphane
oxide S8 was synthesized via click-reaction and coupled to all three proteins.
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After a statistically relevant number of coupling reactions of the phosphane-boranes
10-12 and of the phosphane-oxide S8 to proteins it was possible to distinguish
between the masses of the two types of modified protein. In general, for the proteins
modified with phosphane-borane the observed mass is 0.5-0.9 Da higher than the
calculated mass. In the case of phosphane-oxide, an average mass of the modified
protein 0.03 Da higher than the calculated mass (protein+phosphane-oxide) was
obtained, thus 2.03 Da higher than the calculated mass for phosphane-borane
modified protein.
Figure 74 Maleimide functionalized phosphane-oxide synthesized via azide-alkyne cycloaddition
The mass difference between the modified protein after borane deprotection and the
calculated mass of the protein modified with phosphane-borane, observed by MS
analysis, was in general no higher than 1 Da, but every time lower than 2 Da.
Therefore I concluded that the decomplexation of phosphane-boranes precoupled to
proteins, using the procedures outlined above, was unsuccessful for the tested
conditions.
g. Coupling of phosphane ligands via hydrazone linkage
Conjugation with 3-maleimidopropionic acid hydrazide
ALBP
2.5 μmol (10 eq.) of 13 in 50 μl of dimethylformamide was added to a solution of 
250 nmol of protein (1 eq.) in potassium phosphate buffer (50 mM, 5 ml, pH 7),
followed by stirring at room temperature, for 16 hours, under air. To remove the
unreacted compound 13 the reaction mixture was dialyzed for 16 hours against
potassium phosphate buffer (50mM, pH 7) after which the modified protein was
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stored at 4°C.
98
5.5 μmol (22 eq.) of 13 in 0.11 ml of dimethylformamide was added to a solution of
250 nmol of protein (1 eq.) in Tris·HCl (50 mM, 5 ml, pH 8.0) containing DTT (6 
eq.) in a Schlenk-tube, followed by stirring for 16 hours at room temperature. To
remove the unreacted compound 13 and the side products, the reaction mixture was
dialyzed for 16 hours against potassium phosphate buffer (50 mM, pH 7) after which
the modified protein was stored at 4°C.
AppA Y21C
2.5 μmol (10 eq.) of 3-maleimidopropionic acid hydrazide in 50 μl of 
dimethylformamide was added to a solution of 250 nmol of protein (1 eq.) in
Tris·HCl (50 mM, 5 ml) containing 3M imidazole at pH 7, followed by stirring at 
room temperature under air for 16 hours. To remove the imidazole and the unreacted
compound 13, the reaction mixture was dialyzed for 16 hours against potassium
phosphate buffer (50 mM, pH 7) after which the modified protein was stored at 4°C.
AppA Q63C
Coupling of 13 to AppA Q63C was performed as described for coupling of 13 to
AppA Y21C.
Conjugation with aldehyde functionalized phosphanes 14-17 via intermolecular
hydrazone ligation
ALBP, 98, AppA Y21C, AppA Q63C
Prior to coupling reactions the solution of the proteins modified with 3-
maleimidopropionic acid hydrazide were degassed by purging with argon for 8
hours.
1. Conjugation with 14
500 nmol (10 eq.) of aldhyde functionalized phosphane 14 in 10 μl of 
dimethylformamide was added to a solution of 50 nmol of protein modified with 3-
maleimidopropionic acid hydrazide (1 eq.) in potassium phosphate buffer (50 mM, 1
ml, pH 7) . The reaction mixture was stirred at room temperature for 24 hours. The
insoluble fraction of the excess phosphane ligand was removed by centrifugation
(49,000 g, 4°C, 10 min). The supernatant was transferred to a centrifugal
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concentrator (Amicon Ultra 15, 10,000 MWCO) diluted to 10 ml with degassed
potassium phosphate buffer (50 mM, pH 7.0) and concentrated to 0.5 ml. This step
was repeated four times after which the modified protein was concentrated to 1 ml
and stored at 4°C.
2. Conjugation with 15-17
Conjugation with phosphanes 15-17 was performed as described for 14.
2. Conjugation with 18
Conjugation with phosphane 18 was performed as described for 14. 1 μmol (20 eq) 
of phosphane aldehyde 18 in 40 μl dimethylformamide was used for the coupling 
reaction.
ALBP
Figure 75 LC-MS (ES+) spectrum of ALBP - 13
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Figure 76 LC-MS (ES+) spectrum of ALBP modified with 14 via hydrazone linkage
Figure 77 LC-MS (ES+) spectrum of ALBP modified with 15 via hydrazone linkage
Figure 78 LC-MS (ES+) spectrum of ALBP modified with 16 via hydrazone linkage
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nLC-ESI-MS/MS analysis of the peptides resulted from digestion of ALBP (apo-
protein and protein modified with (13+15)) with trypsin
The peptides were acidified with TFA and then separated using an UltiMate nanoLC
(LC Packings, Amsterdam) equipped with a PepMap C18 trap & column. A 60 minutes
gradient of increasing acetonitrile concentration containing 0.1 % formic acid was used
(5-35% acetonitrile in first 35 minutes, 35-50% in a further 20 minutes, followed by
95% acetonitrile to clean the column). The eluent was sprayed into a Q-Star XL tandem
mass spectrometer (Applied Biosystems, Foster City, CA) and analysed in Information
Dependent Acquisition (IDA) mode, performing 1 sec of MS followed by 3 sec MS/MS
analyses of the 2 most intense peaks seen by MS. These masses are then excluded from
analysis for the next 60 sec. MS/MS data for doubly and triply charged precursor ions
was converted to centroid data, without smoothing, using the Analyst QS1.1 mascot.dll
data import filter with default settings. The MS/MS data file generated was analysed
using the Mascot 2.1 search engine (Matrix Science, London, UK) against an internal
database containing the protein sequence of interest. The data was searched with
tolerances of 0.2 Da for the precursor and fragment ions, trypsin as the cleavage
enzyme, one missed cleavage, and (oxidized) ligand modification of cysteine, and lysine
and methionine oxidation, selected as variable modifications.
An ion at m/z 460.2 corresponding to the double protonated peptide Leu131-Lys138 was
observed in the MS spectrum of digested ALBP (Figure 80a) and ALBP-(13+15). An
ion at m/z 705.3 corresponding to the double protonated peptide Leu131-Lys138 modified
with the maleamic acid adduct of oxidised hydrazone phosphane (13+15) was observed
in the MS spectrum of digested ALBP-(13+15) (Figure 79b, Figure 80b). MS/MS of
peptide Leu131-Lys138-(13+15) confirmed cysteine modification (Figure 81).
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Figure 82 LC-MS (ES+) spectrum of Δ98Δ - 13
Figure 83 LC-MS (ES+) spectrum of 98 modified with 14 via hydrazone linkage
Figure 84 LC-MS (ES+) spectrum of 98 modified with 15 via hydrazone linkage
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Figure 85 LC-MS (ES+) spectrum of 98 modified with 16 via hydrazone linkage
Figure 86 LC-MS (ES+) spectrum of 98 modified with 17 via hydrazone linkage
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MALDI-MS analysis of the peptides resulted from digestion of 98 (apo-protein
and protein modified with (13+15) and (13+16)) with trypsin
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Figure 88 LC-MS (ES+) spectrum of AppA Y21C - 13
Control of AppA Y21C-13 cysteine modification (control reaction between AppA
Y21C-13 and DTNB)92
AppA Y21C and Ellman’s reagent (DTNB)
2
2
500 nmol (10 eq.) of 5,5'-dithiobis-(2-nitrobenzoic acid) in 50 μl of Tris·HCl (50 
mM, pH 7) was added to a solution of 50 nmol of AppA Y21C (1 eq.) in buffer (50
mM Tris·HCl, 1 ml), containing 3M imidazole, at pH 7, followed by stirring at 4°C 
for 5 minutes. Modified protein was analysed directly by LC-MS (ES+). Only the
mass of protein modified with 5-thio-(2-nitro benzoic acid) was detected (Figure
89).
Figure 89 LC-MS (ES+) spectrum of A
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AppA Y21C-13 and Ellman’s reagent (DTNB)
500 nmol (10 eq.) of 5,5'-dithiobis-(2-nitrobenzoic acid) in 50 μl of Tris·HCl (50 mM, 
pH 7) was added to a solution of 50 nmol of AppA Y21C-13 (1 eq.) in buffer (50 mM
Tris·HCl, 1 ml), containing 3M imidazole, at pH 7, followed by stirring at 4°C for 5 
minutes. Modified protein was analysed directly by LC-MS (ES+). Only one protein
species was detected by LC-MS, corresponding to the AppA Y21C modified with 13.
This result indicates that all cysteines of the apo-protein are modified with maleimide
13.
Figure 90 LC-MS (ES+) spectrum of AppA Y21C -13 after the treatment with DTNB
Figure 91 LC-MS (ES+) spectrum of AppA Y21C modified with 14 via hydrazone linkage
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Figure 92 LC-MS (ES+) spectrum of AppA Y21C modified with 15 via hydrazone linkage
Figure 93 LC-MS (ES+) spectrum of AppA Y21C modified with 16 via hydrazone linkage
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Figure 95 LC-MS (ES+) spectrum of AppA Q63C - 13
Control of AppA Q63C -13 cysteine modification (control reaction between AppA
Q63C-13 and DTNB)92
AppA Q63C and Ellman’s reagent (DTNB) – this reaction was performed as described
for AppA Y21C and Ellman’s reagent. LC-MS (ES+) spectrum indicates the presence
of only one species of protein, AppA Q63C modified with 5-thio-(2-nitro benzoic acid)
(Figure 96).
Figure 96 LC-MS (ES+) spectrum of AppA Q63C - TNB
AppA Q63C-13 and Ellman’s reagent (DTNB) – this reaction was performed as
described for AppA Y21C–13 and Ellman’s reagent. Only the mass of the protein
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modified with hydrazide (AppA Q63C-13) was detected by LC-MS (ES+). This
indicates complete cysteine modification with 13.
Figure 97 LC-MS (ES+) spectrum of AppA Q63C - 13 after the treatment with DTNB
Figure 98 LC-MS (ES+) spectrum of AppA Q63C modified with 14 via hydrazone linkage
Figure 99 LC-MS (ES+) spectrum of AppA Q63C modified with 15 via hydrazone linkage
10000 12000 14000 16000 18000
mass0
100
%
15613.20
15577.90 15626.80
15654.50
10000 12000 14000 16000 18000
mass0
100
%
15884.60
15611.8010599.50
15902.00
15917.50 18267.90
10000 12000 14000 16000 18000
mass0
100
%
15901.20
15885.20
15599.8010600.40 12459.00
15916.50
15930.00
15942.20 17650.10
19876.00
AppA Q63C-13+DTNB
Calc Mass 15613.3 / 15627.3
Observed Mass 15613.2
AppA Q63C
AppA Q63C-14
Calc Mass 15885.5
Observed Mass 15885.2
15901.2
15916.5
AppA Q63C
AppA Q63C-15
Calc Mass 15885.5
Observed Mass 15884.6
AppA Q63C
Figure 100 LC-MS (ES+) spectrum of AppA Q63C modified with 16 via hydrazone linkage
Figure 101 LC-MS (ES+) spectrum of AppA Q63C modified with 17 via hydrazone linkage
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III. Site-selective bioconjugation of nitrogen-containing ligands to
structurally diverse protein hosts
Abstract
A strategy for site-specific covalent incorporation of nitrogen-containing ligands into
several protein hosts is described.
Covalent incorporation of 2,2’-bipyridine-5-carboxylic acid into three protein hosts was
accomplished after N-hydroxysuccinimide activation of the carboxylic acid group.
However the lack of specificity towards cysteine resulted in unspecific protein
modifications and incomplete conversion. Site-specific covalent modification of
cysteine was achieved by using maleimide functionalized nitrogen-ligands. Complete
site-selective chemical modification of three structurally different protein hosts with two
maleimide functionalized nitrogen-containing ligands (5-maleimido-1,10-
phenanthroline and 3-(N-maleimido)-(N,N-bis(2-picolyl))-propanamide) was obtained
via Michael addition to the maleimide double bond.
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III.1 Introduction
The wide application scope of nitrogen-containing ligands (N-ligands) in asymmetric
catalysis stems from several distinctive advantages of this class of ligands. They are
largely available in enantiomerically pure form, either from the chiral pool or as cheap
industrial intermediates.1 Even if chirality on nitrogen atom is difficult to obtain due to
instantaneous epimerization of a chiral nitrogen atom at room temperature, formation of
a stable chiral centre on a nitrogen atom could be obtained by using bicyclic structures.2
Unlike phosphines, N-ligands are very stable in aqueous solutions and do not react with
atmospheric oxygen. Consequently, their preparation and long term storage are
simplified. The large diversity of this class of ligands, sometimes used as part of
chelating systems which also involve other donor atoms, such as C, O, P or S, allows
their adaptation to different types of reactions and metals.2 In particular the interactions
with transition metals could be varied by involving X-type ligands (amides,
sulfonamides) or L-type ligands (amines, imines).2-3 Amines are considered as “hard” in
classical hard/soft acid/base theory4 and usually bind less polarizable metal centres in
higher oxidation states. Imines and pyridines are both good σ donors and π acceptors, 
therefore are of “borderline” hardness. Consequently they have a great flexibility in
binding a wide variety of metals, in a range of oxidation states. However, phosphines
and carbenes could be better suited ligands for some catalytic processes involving low
oxidation states of the transitional metal centre.5 The effectiveness of N-ligands for
asymmetric catalytic reactions with less expensive transition metals makes them
applicable for distinctive reactions, complementary to those catalysed by phosphine-
based catalysts. In addition, they could afford alternative catalysts for reactions where
the efficiency of phosphines has already been established.6
Among the N,N chelating ligands, the derivatives of 2,2’-bipyridine and the structurally
similar 1,10-phenanthroline have received special attention, mainly because of their
particular coordination chemistry.7-8 Over the last decades, 2,2’-bipyridine complexes of
virtually every transition metal in the periodic table have been described.7-8 Moreover,
transition-metal complexes of chiral 2,2’-bipyridines have found widespread use in
asymmetric homogeneous catalysis.9 1,10-phenanthroline is of particular importance for
organometallic chemistry as a very rigid ligand capable of coordinating various metal
ions.10-11 Metal complexes of 1,10-phenanthroline have been used for a broad range of
catalytic reactions, such us aryl and alkenyl aminations and amidations,12-16 oxidation of
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alcohols,17 conjugate addition reactions,18-19 and cyclopropanations20. Applications of
chiral 1,10-phenanthroline derivatives in asymmetric catalysis are still modest, but
include Pd-catalysed allylic alkylation of allylic acetates,10,21-23 Cu-catalysed
cyclopropanation of styrenes,24-26 Rh-catalysed asymmetric hydrosilylation27 and
transfer hydrogenation of ketones,28 Cu-catalysed allylic oxidation of alkenes29, Sc and
Ir catalysed ring-opening reactions of meso-epoxides and Cu-catalysed amination of -
keto esters.30
Aqua complexes of 2,2’-bipyridine and 1,10-phenanthroline31-34 have the particular
advantage of displaying good stability, activity and solubility for the conditions required
by proteins in solution (aqueous media, mild temperatures, atmospheric pressure). Ogo
and co-workers reported the synthesis of water soluble [Cp*-IrIII(bpy)(OH2)]2+ and [(6-
C6Me6)-RuII-(bpy)(H2O)]2+ catalyst precursors for transfer hydrogenation of carbonyl
compounds in aqueous conditions.31-32 Notably, the activity of these catalysts displayed
a strong pH dependence. The catalysts developed by Ogo were exploited by Ward and
co-workers to synthesize artificial transfer hydrogenases, via supramolecular anchoring
of biotinylated [6-(C6Me6)Ru(Biot-bipy)H2O]2+ into streptavidin, for the asymmetric
reduction of acetophenone in water.35 Also for pH-dependent transfer hydrogenation of
carbonyl compounds, Süss-Fink and co-workers explored the catalytic potential of
seven [(6-arene)Ru(N∩N)(OH2)]2+ complexes, involving 1,10-phenanthroline or its 5-
NO2 or 5-NH2 derivatives as N∩N ligand.33-34 So far, these organometallic catalysts
have not been used in the synthesis of artificial metalloenzymes.
Artificial metalloenzymes based on nitrogen-containing metal complexes and DNA36-44
or proteins45-64 as chiral environment have been previously reported in literature. Mainly
two types of nitrogen-ligands have been used for the synthesis of artificial
metalloenzymes. One category is formed by large heterocyclic tetradentate ligands like
symmetric MIII Schiff-base complexes or ligands related structurally to porphyrins
(corroles, phthalocyanines).49-59,64 Their metal complexes were introduced either to
myoglobin, a protein possessing a heme prosthetic group suitable for replacement or to
serum albumins, proteins which possess a natural high affinity for hydrophobic
compounds.
MIII Schiff-base complexes (Figure 1) were incorporated into apo-myoglobin mutants,
via dative anchoring50,57-58 or covalent anchoring.59 Even if the enantioselectivities
147
obtained for sulfoxidation of thioanisole using these artificial metalloenzymes were not
very high (up to 33% e.e. for dative incorporation and up to 51% e.e. for covalent
anchoring), these results proved that asymmetric reactions could be performed by
employing chiral protein cavities and symmetric metal complexes.
Figure 1 Schiff-base complexes inserted into apo-myoglobin mutants50,57-59
A drawback for dative incorporation of symmetric MIII Schiff-base complexes into
proteins is the requirement of histidine coordination to the metal ion, in order to control
and stabilize the metal complex location inside the protein cavity. This requirement
added to the requirement of supramolecular affinity between the protein scaffold and
symmetric MIII Schiff-base complexes tremendously limits the number of suitable
proteins for this strategy.
Artificial metalloenzymes based on serum albumins and porphyrin related ligands
(MnIII and FeIII corroles,55 copper-phthalocyanines56) displayed up to 74% e.e. for
asymmetric oxidation of prochiral sulfides to sulfoxides by H2O255 and 85-98% e.e. for
Diels-Alder reactions.56 However, the applicability of this strategy is also limited.
The second category of nitrogen-ligands used for the synthesis of artificial
metalloenzymes is represented by bidentate chelating nitrogen ligands, for example
derivatives of 2, 2’-bipyridine, sulfonated diamines or 1,10-phenanthroline. Their metal
complexes were coupled via covalent or supramolecular anchoring to proteins35,45-48,60-62
or DNA.36-44
Iodoacetamido-1,10-phenanthroline was used by Distefano and co-workers to modify
the cysteine residue of two proteins: ALBP and IFABP (Figure 2). Enantioselectivities
varying from 31% to 86% e.e. were reported for the hydrolysis of several unactivated
amino acid esters and the hydrolysis of amides catalysed by ALPB-Phen-Cu(II).61
Genetic optimization - site directed mutagenesis applied in order to change the cysteine
location inside protein’s cavity - was used to enhance the rate and selectivity of the
hybrid catalysts.62
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Figure 2 Cu(II)-Phenanthroline conjugates of fatty acid binding proteins used as hybrid catalysts for ester
and amide hydrolysis61
Reetz and co-workers reported covalent incorporation of a Pd complex of N-(di(pyridin-
2-yl)methyl)-maleimide (Figure 3a) and a Rh-complex of 5-maleimido-1,10-
phenanthroline (Figure 3b) into the protein tHisF-C9AD11C, a thermostable enzyme
from Thermotoga maritima.65-66 The artificial metalloenzyme containing the Rh
complex was tested for the reduction of benzoyl formic acid to mandelic acid, but low
activity was obtained. Moreover, unspecific modifications of the protein host with the
rhodium complex were observed, most probably due to undesired direct interaction of
the protein with the rhodium centre rather than unspecific covalent modification of
protein with the metal complex.65 The Pd complex of N-(di(pyridin-2-yl)methyl)-
maleimide (Figure 3a) was coupled to papain. The resulting artificial metalloenzyme
was used as catalyst for the hydrogenation of dimethyl itaconate, but low activity and no
enantioselectivity were obtained.60
2
Figure 3 Pd complex of N-(di(pyridin-2-yl)methyl)-maleimide (a) and Rh-complex of 5-maleimido-1,10-
phenanthroline (b) covalently coupled to tHisF-C9AD11C65-66
A biotinylated Rh complex of a di(pyridin-2-yl)methane derivative (Figure 4) was
coupled to streptavidin and tested by Reetz and co-workers for the enantioselective
transfer hydrogenation of acetophenone, ethyl pyruvate and α,α,α trifluoro-
acetophenone. The catalyst was active, but low enantioselectivities (<5% e.e.) were
obtained for the tested reactions.67
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Figure 4 Biotinylated Rh complex of di(pyridin-2-yl)methanamine which was coupled to streptavidin and
used as catalyst for transfer hydrogenation reactions67
Ward and co-workers synthesized and chemogenetically optimised transfer
hydrogenases based on biotinylated d6-piano stool complexes of N-ligands [n-
(CnRn)M(Biot-L)] (M=Ru, Rh or Ir) incorporated to streptavidin mutants, for the
enantioselective transfer hydrogenation of prochiral ketones.45-46,68-69 The first studies
involved biotinylated Ru-bipyridine complexes. However, high temperature and low pH
were required in order to obtain good activity and enantioselectivity with these
complexes.35 The problem was overcome by replacing the bipyridine ligand with ortho-,
meta- and para- biotinylated sulfonamides (Figure 5), which afford metal complexes
highly active and enantioselective under conditions compatible with proteins in
solution.45-46,68-69
2
Figure 5 Ortho-, meta and para- biotinylated amino-sulfonamides used for the synthesis of streptavidin
based artificial metallo-enzymes45-46,68-69
DNA has also been exploited as chiral biomolecule for the development of hybrid
catalysts of bidentate chelating nitrogen ligands. The first generation of DNA-based
catalysts was based on ligands containing a metal-binding domain linked through a
spacer to a DNA intercalator.36 For the second generation of DNA catalysts, the DNA
binding moiety was integrated into the metal-binding domain.41 Cu(II) complexes of
2,2’-bipyridines and 1,10-phenanthroline, known to bind to DNA in a non-covalent
manner, were employed for the synthesis of this type of catalysts, displaying high
enantioselectivities (up to 99%) for Diels-Alder reactions37 (Figure 6) and Michael
additions38 in water. The scope of DNA-based catalysis was extended and high
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enantioselectivities were reported for Friedel-Crafts alkylations,42 fluorination
reactions43 and epoxide hydrolysis.44
Figure 6 Cu-(4,4’-dimethyl-2,2’dipyridine(NO3)2)-DNA catalyzed Diels-Alder cycloaddition37
Reprinted from E.W. Dijk, B.L. Feringa and G. Roelfes, Tetrahedron: Asymmetry, 2008, 19 (20), 2374-2377.
Copyright 2008, with permission from Elsevier.
A Cu(II) complex of (2,2’-bipyridine)-5-carboxylic acid covalently coupled through an
alkyl linker to a DNA double strand was used as enantioselective catalyst for the same
Diels-Alder reaction (Figure 6). The hybrid catalyst containing the Cu-bipyridine
complex covalently coupled to DNA showed similar conversion, but significantly
higher enantioselectivity than the one having the Cu(II) complex coupled non-
covalently, for the same DNA strand. This clearly demonstrates the advantage of the
covalent coupling strategy in the synthesis of a well defined hybrid catalyst.40
As observed, 1,10-phenanthroline, 2,2’-bipyridine and di(pyridin-2-yl)methane
derivatives have been used for the synthesis of protein or DNA based hybrid catalysts
and tested for enantioselective catalytic reactions. In particular the hybrid catalysts
formed by 1,10-phenathroline-FABPs and 1,10-phenanthroline- and 2,2’-bipyridine -
DNA proved to be good chiral inducers for several catalytic reactions. The wide
applicability of this type of N-ligands in homogeneous catalytic reactions allows the
applicability of the resulting class of hybrid catalysts to a potential large number of
reactions. Moreover, covalent anchoring of this type of ligands into proteins or DNA
allows a large flexibility in terms of varying the protein/DNA scaffold or of the
ligand/metal complex design. Nevertheless, the number and applicability of the artificial
metalloenzymes based on N-ligands reported has been limited so far.
Considering the promising results previously reported for hybrid catalysts based on
1,10-phenanthroline and 2,2’-bipryridine ligands, I explored covalent incorporation of
this type of ligands into three different protein structures (ALBP, Δ98Δ and AppA). 
Two strategies were tested for covalent incorporation of N-ligands: via thioester bond
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formation between a thiol group of a cysteine residue and an activated carboxylic acid
group of an N-ligand and via Michael addition to the maleimide double bond of a
maleimide functionalized ligand.
III.2 Results and Discussion
III.2.1 Coupling of carboxylic acid functionalised N-ligands
Ward and co-workers were the first to show incorporation of bipyridine ligands into a
protein scaffold and to investigate the catalytic properties of the resulting artificial
metalloenzyme. They synthesized artificial transfer hydrogenases by supramolecular
anchoring of biotinylated [6-(C6Me6)Ru(Biot-bipy)H2O]2+ into streptavidin.35 Inspired
by these studies and also considering the wide range of applications of the bipyridine
ligands,9,70 I explored the covalent incorporation of carboxylic acid functionalized 2,2’-
bipyridine in several protein scaffolds.
The three proteins previously used for covalent incorporation of phosphine ligands
(mutants of ALBP, Δ98Δ and AppA, see Chapter II) were also used for incorporation of 
(2,2’-bipyridine)-5 carboxylic acid via thioester bond formation. The choice of the
proteins was based again on the possibility of comparing the activity and the selectivity
of artificial metalloenzymes having different cavity structures and subsequently
different degrees of encapsulation of the organometallic catalyst into the protein
scaffold.
Scheme 1 Carbonyl diimidazole activation of 2,2’-bipyridine-5-carboxylic acid
The first method tested for covalent coupling of (2,2’-bipyridine)-5 carboxylic acid was
the reaction between the active imidazolide derivative 2 formed upon CDI activation of
1 (Scheme 1) and the thiol group of a selected protein. Still, the coupling efficiency of
an imidazolyl derived from a pyridine based carboxylic acid was very low, compared to
the benzoic acid derived imidazolyl compounds, used previously for phosphine
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incorporation (see Chapter II). No significant differences in coupling efficiency were
observed regarding the protein scaffold involved. The highest efficiency, about 20%
according to LC-MS (ES+) analysis, was found for AppA Y21C. These values were not
corrected for the difference in ionization efficiency between the modified and
unmodified proteins. Attempts to quantify this difference were not successful, because
of the low coupling efficiency.
When proteins were modified covalently with CDI activated benzoic acid derivatives
(see Chapter II), good coupling efficiencies were obtained.71 This result allowed us to
conclude that the rate of hydrolysis of CDI activated benzoic acids is slower than the
rate of their coupling to proteins, which is an overnight reaction. However, considering
the very low coupling efficiency of CDI activated bipyridine-carboxylic acids, two
hypotheses were formulated. The first possibility was that the imidazolide 2 formed as
product of the reaction between 2,2’-bipyridine 5-carboxylic acid and CDI in
dimethylformamide is highly reactive and, although it is stable in dimethylformamide,
hydrolyses rapidly in aqueous conditions. Consequently its coupling efficiency is very
low. A second possibility was that the hydrolysis rate of 2 is lower than its coupling rate
to proteins and the coupling efficiency to proteins is high, but the modified proteins are
not stable and the bipyridine-carboxylic acid 1 hydrolyses rapidly after its coupling to
proteins. Therefore the stability of the imidazolide 2 in presence of water was
investigated. After addition of 0.5 ml of D2O to CDI activated 2,2’-bipyridine 5-
carboxylic acid in 0.5 ml of DMF-d6, 40% of the imidazolide 2 was hydrolysed during
the first three minutes, as observed by 1H NMR, complete hydrolysis being achieved
after the first hour of the reaction. Therefore I concluded that the hydrolysis rate of the
imidazolide 2 is higher than the rate of the covalent modification of protein with 2,
which is usually an overnight reaction, causing the very low efficiency of protein
modification.
Figure 7 Structure of the N-succinimidyl ester of 2,2’-bipyridine-5-carboxylic acid
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The N-succinimidyl ester 3 of the ligand 1 is more stable under aqueous conditions than
the imidazolide derivative 2 and therefore its hydrolysis rate might be lower than the
rate of coupling to proteins. Consequently, its coupling efficiency to proteins is
significantly improved. However, incorporation of the NHS activated carboxylic acid
bipyridine into proteins was not selective toward cysteine modification. It was not
possible to obtain complete protein mono-modification and the attempts to improve the
coupling efficiency by increasing the molar excess of modification reagent resulted in
multiple modifications of the protein host (Figure 8).
Figure 8 LC-MS (ES+) spectrum of ALBP - 3
(unspecific modifications of the protein were obtained when higher molar excess of modification reagent
was used for the coupling reaction)
Considering the efficient coupling of 3 to ALBP in 50 mM Tris buffer at pH 7-8, I can
assume that the hydrolysis rate of 3 for the conditions tested is lower than protein
modification. However, when coupling of 3 to the AppA mutants was done in 50 mM
Tris buffer, in presence of 3M imidazole required to facilitate the flavin cofactor
removal from the enzyme active site, no coupling was observed irrespective of the
molar excess of ligand used. One cause could be the rapid hydrolysis of the NHS
activated acid induced by the high concentration of nucleophilic imidazole, in addition
to the increased reactivity of the ester bond induced by the electron withdrawing effect
of pyridine ring. Indeed, when coupling of 3 to AppA was done in absence of
imidazole, the coupling efficiency was highly improved. The AppA mutants were first
maintained in 3M imidazole buffer solution to facilitate the flavin removal, and then the
imidazole was removed by over-night dialysis against 50 mM Tris buffer. Subsequent
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coupling of 3 resulted in efficient, but unspecific coupling of the NHS-activated ligand,
for both Y21C and Q63C mutants of AppA.
Figure 9 LC-MS (ES+) spectrum of AppA Y21C - 3, after imidazole treatment of the unmodified protein
LC-MS (ES+) analysis revealed formation of the dimer of AppA Y21C. Potential
changes in the mutant folding generated by flavin removal following the imidazole
treatment and dialysis, could expose the thiol of cysteine 21 to the surface and facilitate
the dimer formation via a disulfide bridge. Consequently the dimer possesses no free
cysteine. Nevertheless, efficient coupling of 3 to the AppA Y21C dimer was observed
by LC-MS (ES+), proving the lack of specificity towards cysteine of the method (Figure
9).
Figure 10 LC-MS (ES+) spectrum of AppA Q63C
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The dimer formation was not observed for the AppA Q63C mutant. Yet incomplete
conversion and multiple modification of the protein with 3 were observed (Figure 10)
when 7.5-fold excess ligand was used for the coupling reaction.
Flavin cofactor removal might be also possible to achieve after its reduction, firstly,
followed by its removal, based on reported literature procedures,72 in the reduced form.
In conclusion, although CDI activation of benzoic and aliphatic carboxylic acid
functionalized phosphine ligands is compatible with aqueous coupling conditions,71 this
method was not suitable for the bipyridine ligand having the carboxylic group attached
to a pyridine ring. The reactivity of the imidazolide intermediate of a carboxylic acid
functionalized pyridine is higher than that of a benzoic or aliphatic carboxylic acid
derivative. Consequently, hydrolysis of pyridine based carboxylic acid-imidazolides is
faster than that of benzoic acid imidazolides or aliphatic carboxylic acid imidazolides.
On the other hand, the reactivity of NHS activated carboxylic acid functionalised
pyridines is lower than the reactivity of the CDI activated ones, and subsequently their
hydrolysis occurs at a lower rate. As a result a higher coupling efficiency of the NHS
activated ligands was obtained.
Regarding the nature of the ligand (phosphine or nitrogen-containing), for the same
molar excess ligand (e.g. 25-fold excess for ALBP modification), monomodification
with p-diphenylphosphino-benzoic acid was obtained, while multiple modifications
were obtained when 2,2’-bipyridine-5-carboxylic acid was coupled. The electron
withdrawing effect of pyridine is higher compared to that of the benzoic acid ring. As a
result, the acidity of (bi)pyridine carboxylic acids is higher than that of benzoic acids
and consequently the reactivity of activated bipyridine carboxylic acids is higher. This
can explain the reduced selectivity towards cysteine of the activated bipyridine
carboxylic acids, which are more reactive than phosphine carboxylic acids and,
therefore, more prone to react with the NH2 group of lysines.
As observed, the main drawback of the covalent incorporation of carboxylic acid
functionalized ligands in proteins via thioester bond formation with a cysteine residue
seems to be the lack of specificity. Nevertheless, selective and efficient protein
modification with benzoic acid and aliphatic acid functionalized phosphine ligands and
their metal complexes was reported in our group.71 These results suggest that the
selectivity of this method depends on the host-protein structure, in particular on the
number and the reactivity of the lysine residues.
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III.2.2 Coupling of maleimide functionalised N-ligands
The lack of selectivity towards cysteine of the carboxylic acid functionalized nitrogen-
containing ligands prompted us to explore a different method for covalent incorporation
of this class of ligands into proteins. Among the common methods used for selective
cysteine modification, Michael addition to maleimide functionalized ligands was
selected. This method was previously applied for covalent incorporation of a library of
N-ligands and their metal complexes into proteins by Reetz and co-workers.60,65-66
Applications of chiral phenanthroline derivatives in asymmetric catalysis have been
previously reported.30 Based on these facts, but also considering the successful covalent
incorporation of 1,10-phenanthroline derivatives in ALBP61 and tHisF-C9AD11C65 and
the good enantioselectivities induced by ALBP as protein scaffold for the hydrolytic
reactions catalysed by the ALPB-Phen-Cu(II) complex,61 I investigated the covalent
incorporation of 5-maleimido-1,10-phenanthroline to ALBP, Δ98Δ and AppA mutants.  
Ru-complexes of the type [(6-arene)Ru(N∩N)(Cl)]+ containing N,N-chelating
dipyridylamine ligands (Figure 11) were reported as efficient catalysts for transfer
hydrogenation of aryl ketones in water.73
6 6
3 6 3
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Figure 11 Structure of the dipyridylamine-Ru complexes used as catalyst for transfer hydrogenation of
aryl ketones73
Inspired by this study, the 3-(N-maleimido)-(N,N-bis(2-picolyl))-propanamide ligand
(Figure 12) was synthesized in our group and its covalent incorporation in the above
mentioned proteins was tested. The choice for a dipicolylamine over a dipyridylamine
derivative was motivated by the higher flexibility of the third N atom, which would
allow its potential coordination to the metal centre and subsequent stabilization of metal
complexes. In addition, the synthesis of ligand 5 could be easily achieved via
DCC/HOBt coupling of 3-maleimidopropionic acid to the commercially available di-(2-
picolyl)amine.
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Figure 12 Structure of the 3-(N-maleimido)-(N’,N’-bis(2-picolyl))-propamide
The chemical modification of proteins was performed according to standard conditions
reported in literature for other systems66,74 and the bioconjugates were characterized by
LC-MS (ES+).
Figure 13 Reaction of (modified) proteins with Ellman’s reagent (DTNB) as a method for the
quantification of the cysteine modification via Michael addition to maleimide functionalized N-ligands75
Cysteine conversion upon Michael addition to maleimide functionalized N-ligands was
tested by subsequent treatment with Ellman’s reagent75-76 followed by LC-MS (ES+)
analysis. Under the same reaction conditions, treatment with Ellman reagent76 converts
the unmodified proteins to the corresponding 5-thio-(2-nitro benzoic acid) conjugates
(Table 1), while the modified proteins, displaying no free cysteine, show no
modification with DTNB (Figure 13, Figure 14, Figure 15).
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Table 1 Chemical modification of apo-proteins with DTNB
Calculated
mass (Da)
LC-MS mass
found (Da)
ALBP-TNB 16802.0 16802.0
D98D-TNB 13620.2 13620.2
AppA Q63C-TNB 15627.3 15627.2
AppA Y21C-TNB 15592.3 15592.2
Contrary to the covalent coupling of carboxylic acid functionalized ligands, the
incorporation of maleimide functionalized ligands into proteins via thioether bond
proved to be highly selective towards cysteine. This was evidenced by the complete
mono-modification of proteins obtained for the ligands 4 and 5 (Table 2 and Table 3).
The high selectivity was observed for all the four proteins tested for chemical
modification.
In conclusion, Michael addition to maleimide functionalized ligands turns out to be a
suitable method for selective modification of virtually any protein displaying a single
accessible, reactive cysteine.
Table 2 Proteins chemical modification with 4
(a) (b)
Figure 14 (a) LC-MS (ES+) spectrum of AppA Y21C - 4; (b) LC-MS (ES+) spectrum of AppA Y21C-4
after treatment with Ellman’s reagent
Calculated
mass (Da)
LC-MS mass
found (Da)
ALBP-4 16880.1 16880.1±0.5
Δ98Δ-4 13698.3 13698.6±0.6
AppA Y21C-4 15670.4 15670.0±0.5
AppA Q63C-4 15705.4 15704.9±0.6
10000 12000 14000 16000 18000
mass0
100
%
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15715.90
10000 12000 14000 16000 18000
mass0
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15670.00
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15696.70
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Table 3 Chemical modification of proteins with 5
Calculated
mass (Da)
LC-MS mass
found (Da)
ALBP-5 16955.2 16955.0±0.2
Δ98Δ-5 13773.4 13773.5±0.9
AppA Y21C-5 15745.5 15745.4±0.4
AppA Q63C-5 15780.4 15779.5±0.6
(a) (b)
Figure 15 (a) LC-MS (ES+) spectrum of ALBP - 5; (b) LC-MS (ES+) spectrum of ALBP-5 after the
reaction with Ellman’s reagent
III.3 Conclusions
Incorporation of carboxylic acid functionalized 2,2’-bipyridine into proteins, in aqueous
conditions and at room temperature, could be easily achieved by NHS activation of the
carboxylic group followed by covalent coupling of the activated ligand. However, the
selectivity towards thioester bond formation is low, multiple chemical modifications of
proteins or incomplete conversions were obtained. The low selectivity could be
explained by the increased reactivity of the activated bipyridine carboxylic acids
compared to the benzoic acids, due to the difference in the inductive effect of the two
aromatic rings. The NHS activated 2,2’-bipyridine 5-carboxylic acid is stable in
aqueous conditions, but in presence of high concentrations of the nucleophilic
imidazole, the stability appears to be low.
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CDI activation of carboxylic acid functionalized bipyridines proved not to be an
efficient method for coupling this class of ligands to proteins. The imidazolide
intermediate of 2,2’-bipyridine 5-carboxylic acid formed upon activation with CDI in
dimethylformamide is highly reactive and hydrolyses rapidly under aqueous conditions,
before coupling to proteins.
Bioconjugation with maleimide functionalized N-ligands can be easily achieved and it
is very selective towards cysteine modification, as was demonstrated for the three
structurally different proteins. This method can be easily applied to virtually any protein
displaying a single reactive cysteine and allows a wide range of possibilities in terms of
cofactor design. Herein, selective incorporation of two maleimide functionalized N-
ligands having different heterocyclic structures: a 1,10-phenanthroline derivative and a
tridentate N,N-bis(2-picolyl))-amide derivative was demonstrated.
The coordination properties of 1,10-phenanthrolines are well-known, however their
applications as chiral ligand templates in asymmetric catalysis are still limited.11 The
typical way for synthesis of chiral 1,10-phenanthrolines is the introduction of chiral
groups in the peripheral region of the phenanthroline heterocycle. However, by using
this method the stereogenic centre is located far from the aromatic ring and
consequently far from the metal complex centre. This disadvantage is potentially
overcome by embedding an achiral phenanthroline heterocycle within a chiral protein
environment, thus having a higher control over the first and second coordination sphere
of the metal complex and subsequently over the enantioselectivity. As a result of this
project, the number of proteins modified with 1,10 phenanthroline derivatives, initially
limited to FABP61-62 and tHisF-C9AD11C,66 is now enriched with another three
different protein scaffolds: Δ98Δ, AppA Y21C and AppA Q63C. The synthesis of 
Cu(II) complexes of 1,10-phenanthroline modified proteins is straightforward61-62 and
their catalytic properties could be subsequently tested for the hydrolytic reactions
reported by Distefano and co-workers61 or for other Cu(II) catalysed reactions like
Michael additions,38 Diels-Alder reactions,37 Friedel-Crafts alkylations42 or epoxide
hydrolysis.44 The library of metal complexes of modified proteins and their use in
asymmetric homogeneous catalytic reactions can be further expanded to other
enantioselective reactions catalysed by metal complexes of chiral bipyridines or
phenanthrolines. I reported successful incorporation of a Ru complex of 1,10
phenanthroline to ALBP and AppA mutants (see Chapter IV).
161
III.4 Experimental
III.4.1 General remarks
Chemicals were purchased from Aldrich and Fluka and were used as received. NMR
spectra were recorded at room temperature on Bruker Avance 400 and 300
spectrometers. Positive chemical shifts (δ) are given (in ppm) for high-frequency shifts 
relative to a TMS reference (1H and 13C). 13C spectra were measured with 1H
decoupling. Multiplicities are indicated by: s (singlet), d (doublet), dd (doublet of
doublets), and m (multiplet).
Protein stability (apo and modified proteins) was assessed by Bradford assay77 and
SDS-PAGE. Modified proteins were analysed by LC-MS (ES+). Quantification of
cysteine modification was done by reaction with Ellman’s reagent (DTNB).75
III.4.1.a Whole protein mass spectrometry using ESI-TOF
The protein sample (20 μL, 5 pM/μL) was desalted on-line through a XTerra MS C8 2.1 
× 10 mm column, eluted with an increasing acetonitrile concentration (2 % acetonitrile,
98 % aqueous 1 % formic acid to 98 % acetonitrile 2 % aqueous 1 % formic acid and
delivered to an electrospray ionisation mass spectrometer (LCT, Micromass,
Manchester, U.K.) which had previously been calibrated using myoglobin. An envelope
of multiply charged signals was obtained and deconvoluted using MaxEnt1 software to
give the molecular mass of the protein.
The sequence of ALBP reported by Bernlohr et al78 was used as reference for the mass
of ALBP C1A his-tagged mutant. For the mass of the 98 mutant, the 98 sequence
reported by Delfino et al79 was used as reference and for the mass of AppA mutants the
AppA sequence reported by Laan et al80 was used.
II.4.1.b 98 - reduction of disulfide bridges was performed every time before
modification with carboxylic acid or maleimide functionalized compounds. Prior to
the reduction reaction the protein solution was degassed by purging with argon for 8
hours. 6 μmol (6 eq.) of DTT were added from a freshly prepared stock solution of 
0.5 M in water to a solution of 1 μmol of protein (1 eq.) in Tris·HCl (50 mM, 10 ml, 
pH 8.0) in a Schlenk tube. The reaction mixture was stirred at room temperature for
1 hour. The reduced protein solution was used for the coupling reactions without
further purification. For each coupling reaction the molar excess of modification
reagent was higher than 12-fold, to assure the right amount of modification reagent
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for the potential modification of both the thiol groups of DTT and the thiol group of
the target cysteine.
III.4.2 Synthesis of modification reagents
2,2’ – bipyridine-5-carboxylic acid (1)
This compound was synthesised according to a reported literature procedure.81
[2,2'-bipyridin]-5-yl(1H-imidazol-1-yl)methanone (2)
[2,2'-bipyridin]-5-yl(1H-imidazol-1-yl)methanone was synthesised according to a
modified literature procedure.82-83
In a Schlenk-tube, 2,2’–bipyridine-5-carboxylic acid (10mg, 50 μmol) and N,N’-
carbonyldiimidazole (24.3 mg, 150 μmol) were dissolved in 1 ml dimethylformamide 
and the reaction mixture was stirred for 30 min at room temperature. The CDI activated
ligand thus obtained was used directly for the chemical modification of proteins,
without further purification.
1H NMR (400 MHz, d7-DMF): 9.17 (d, J=1.9Hz, 1H), 8.81-8.82 (d, J=4.5Hz, 1H), 8.68-
8.70 (d, J=8.2Hz, 1H), 8.57-8.59 (d, J=7.8Hz, 1H), 8.47-8.49 (dd, J=2.3, 8.1Hz, 1H),
8.42 (s, 1H), 8.13 (d, 1H), 8.12 (d, 1H), 8.06-8.11 (m, 1H), 7.57-7.60 (m, 1H); 13C
NMR (101 MHz, d7-DMF): δ=165.0, 159.2, 154.5, 150.4, 149.9, 138.8, 137.6, 128.5, 
125.2, 124.8, 121.5, 120.2, 118.2 ppm
[2,2'-bipyridin]-5-yl(1H-imidazol-1-yl)methanone hydrolysis
To follow the ligand 2 hydrolysis in time, in presence of water, the 2,2’ – bipyridine-5-
carboxylic acid was activated with CDI, in d7-dimethylformamide, as described above.
After that, 0.5 ml of D2O was added to the CDI activated ligand in d7-
dimethylformamide (1ml) and the hydrolysis reaction was followed by 1H and 13C
NMR.
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As a result of imidazolide hydrolysis, three minutes after D2O addition the following
NMR peaks corresponding to 2 were shifted to the corresponding peaks of the acid 1:
1H NMR (400 MHz, d7-DMF, D2O): δ=9.07 (d, J=1.3, 1H) was shifted to δ=9.10 (d, 
J=1.4, 1H); 8.72(d, J=4.8Hz, 1H) was shifted to 8.65(d, J=4.2Hz, 1H); 8.49 (d, J=7.9Hz,
1H) was shifted to 8.40 (d, J=8.2 Hz, 1H); 8.44(dd, J=2.0,8.3Hz, 1H) and 8.39(d, 1H)
were shifted to 8.22-8.27 (m, 2H); 8.04 (m, 1H) was shifted to 7.98 (m, 1H); 7.60 (m,
1H) was shifted to 7.52 ppm (m, 1H). 13C NMR (101 MHz, d7-DMF, D2O):  δ=165.4 
was shifted to 168.9; 157.3 was shifted to 154.4; 155.9 was shifted to 152.9; 148.5 was
shifted to 148.3; 147.8 was shifted to 147.5; 137.7 was shifted to 136.9; 136.8 was
shifted to 136.6; 129.3 was shifted to 131.5; 128.5 remained at 128.5; 124.0 was shifted
to 123.2; 120.8 was shifted to 120.2 ppm.
N-hydroxysuccinimide 2,2-bipyridine-5-carboxylate (3)
This compound was synthesised according to a reported literature procedure.40
5-maleimido-1,10-phenanthroline (4)
This compound was synthesised according to a reported literature procedure 65,84.
3-(N-maleimido)-(N,N-bis(2-picolyl))-propanamide (5)
This compound was kindly provided by Peter Deuss (University of St Andrews, UK).
III.4.3 Chemical modification of proteins
Chemical modification with [2,2'-bipyridin]-5-yl(1H-imidazol-1-yl)methanone
ALBP
1.25 μmol (25 eq.) of 2 in 25 μl of dimethylformamide was added slowly to a solution 
of 50 nmol of protein (1 eq.) in potassium phosphate buffer (50 mM, 1 ml, pH 7.0). The
cloudy reaction mixture was stirred at room temperature for 16h. The insoluble excess
modification reagent was removed by centrifugation (49,000 g, 4°C, 10 min). The
supernatant was transferred to a centrifugal concentrator (Amicon Ultra 15, 10,000
MWCO), concentrated to 0.5 ml and then diluted to 10 ml with potassium phosphate
buffer (50 mM, pH 7.0). This step was repeated four times after which the protein
solution was concentrated to 1 ml and stored at 4°C.
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Figure 17 LC-MS (ES+) spectrum of Δ98Δ after the reaction with 2
AppA Y21C
1.25 μmol (25 eq.) of 2 in 25 μl of dimethylformamide was added slowly to a solution 
of 50 nmol of AppA Y21C (1 eq.) in buffer (Tris·HCl 50 mM, 1ml) containing 3M 
imidazole, at pH 7.0. The cloudy reaction mixture was stirred at room temperature for
16h. The insoluble excess modification reagent was removed by centrifugation (49,000
g, 4°C, 10 min). The supernatant was transferred to a centrifugal concentrator (Amicon
Ultra 15, 10,000 MWCO) and concentrated to 0.5 ml, followed by dilution to 10 ml
with Tris·HCl (50 mM, pH 7.0). This step was repeated four times after which the 
protein solution was concentrated to 1 ml and stored at 4°C.
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Chemical modification with N-hydroxysuccinimide 2,2-bipyridine-5-carboxylate
ALBP
150 nmol (3 eq.) of 3 in 3.0 μl of dimethylformamide was added slowly to a solution of 
50 nmol of protein (1 eq.) in potassium phosphate buffer (50 mM, 1 ml, pH 7.0). The
cloudy reaction mixture was stirred at room temperature for 5h. The insoluble excess
modification reagent was removed by centrifugation (49,000 g, 4°C, 10 min). The
supernatant was transferred to a centrifugal concentrator (Amicon Ultra 15, 10,000
MWCO), concentrated to 0.5 ml and then diluted to 10 ml with potassium phosphate
buffer (50 mM, pH 7.0). This step was repeated four times after which the protein
solution was concentrated to 1 ml and stored at 4°C.
AppA Y21C
50 nmol of protein (1 eq.) was maintained for 4 hours in buffer (Tris·HCl 50 mM, 1ml) 
containing 3M imidazole, at pH 7.0 and was further dialysed against Tris·HCl (50 mM, 
pH 7.0) to remove the imidazole. 375 nmol (7.5 eq.) of 3 in 7.5 μl of 
dimethylformamide was added to the protein solution after dialysis. The reaction
mixture was stirred at room temperature for 5h. The insoluble excess modification
reagent was removed by centrifugation (49,000 g, 4°C, 10 min). The supernatant was
transferred to a centrifugal concentrator (Amicon Ultra 15, 10,000 MWCO) and
concentrated to 0.5 ml, followed by dilution to 10 ml with Tris·HCl (50 mM, pH 7.0). 
This step was repeated four times after which the protein solution was concentrated to 1
ml and stored at 4°C.
AppA Q63C
Coupling of 3 to AppA Q63C was performed as described for coupling of 3 to AppA
Y21C.
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850 nmol (17 eq.) of 4 in 17 μl of dimethylformamide was added slowly to a degassed 
solution of 50 nmol of reduced Δ98Δ (1 eq.) in Tris·HCl (50 mM, 1ml, pH 8.0) 
containing DTT (6 eq.), in a Schlenk-tube, followed by stirring at room temperature for
5h under inert atmosphere. The insoluble fractions from the excess modification reagent
were removed by centrifugation (49,000 g, 4°C, 10 min). The supernatant was
transferred to a centrifugal concentrator (Amicon Ultra 15, 10,000 MWCO) and
concentrated to 0.5 ml, followed by dilution to 10 ml with Tris·HCl (50 mM, pH 8.0). 
This step was repeated four times after which the modified protein was concentrated to
1 ml and stored at 4°C. Yield: 100%.
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Coupling of 4 to AppA Q63C was performed as described for coupling of 4 to AppA
Y21C. Yield: 100%.
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Figure 23 LC-MS (ES+) spectrum of Δ98Δ - 5
AppA Y21C
312.5 nmol (25 eq.) of 5 in 6.25 μl of dimethylformamide was added to a solution of 
12.5 nmol of AppA Y21C (1 eq.) in buffer (Tris·HCl 50 mM, 0.25 ml) containing 3M 
imidazole, at pH 7.0. The reaction mixture was stirred at room temperature for 5h. To
remove the excess modification reagent, the reaction mixture was transferred to a
centrifugal concentrator (Vivaspin 2, 10,000 MWCO), diluted to 2 ml with Tris·HCl (50 
mM, pH 7.0) and concentrated to 0.1 ml. This step was repeated four times after which
the modified protein was concentrated to 0.25 ml and stored at 4°C. Yield: 100%.
Figure 24 LC-MS (ES+) spectrum of AppA Y21C - 5
AppA Q63C
Coupling of 5 to AppA Q63C was performed as described for coupling of 5 to AppA
Y21C. Yield: 100%.
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AppA Q63C
Coupling of 5,5'-dithiobis-(2-nitrobenzoic acid) to AppA Q63C was performed as
described for the chemical modification of AppA Y21C with 5,5'-dithiobis-(2-
nitrobenzoic acid). Only the mass of protein modified with 5-thio-(2-nitro benzoic acid)
was detected.
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Figure 27 LC-MS (ES+) spectrum of (a) Δ98Δ-4 and (b) AppA Q63C-4 after the reaction with Ellman’s
reagent
Control reaction between 5-modified proteins and DTNB
The control reaction between DTNB and 5-modified proteins was performed as
described for chemical modification of apo-proteins with DTNB. Only one protein
species was detected by LC-MS ES(+), corresponding to the 5-modified proteins. This
result indicates that all cysteines of the apo-proteins are modified with the maleimide 5.
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Figure 28 LC-MS (ES+) spectrum of (a) Δ98Δ-5, (b) AppA Y21C-5 and (c) AppA Q63C –5 after the
reaction with Ellman reagent
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IV. Site selective bioconjugation of transition metal complexes to
structurally different protein hosts
Abstract
Site-selective covalent incorporation of metal complexes of CDI activated carboxylic
acid functionalized phosphane ligands into protein scaffolds can be efficiently
accomplished.1-2 However, for some protein structures, problems related to modified
proteins’ stability or unspecific multiple modifications were encountered. Highly
efficient and selective coupling of phosphane ligands to proteins was achieved via a
hydrazone linkage between an aldehyde functionalized phosphane and 3-
(maleimido)propionic acid hydrazide modified proteins. Using this strategy, hybrid
transition metal protein adducts can be formed in situ from metal precursors and
phosphane modified proteins,3 or by coupling preformed metal complexes of aldehyde
functionalized phosphanes to 3-(maleimido)propionic acid hydrazide modified proteins.
Cu and Ru complexes of 5-maleimido-1,10-phenanthroline were incorporated highly
efficiently and site selectively into proteins via Michael addition of the thiol group from
a cysteine residue to the maleimide double bond. Cu(II) complexes were formed in situ,
by adding CuSO4 to phenanthroline modified ALBP and 98. Preformed Ru
complexes of 5-maleimido-1,10-phenanthroline were efficiently and selectively coupled
to ALBP, AppA Y21C and AppA Q63C.
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IV.1 Introduction
It has been known for decades that artificial metalloenzymes can be synthesised through
covalent or non-covalent incorporation of transition metal complexes into protein
hosts.4-5 In this way, the chirality of proteins could be transferred to achiral transition
metal catalysts with important applications in organic synthesis.
Covalent incorporation of catalytic functionalities into proteins, first applied by Kaiser
and co-workers,6 and by several other groups after that,5,7-19 allows a wide range of
possibilities for choosing the protein structure or the catalyst. The catalytic moiety
inside the protein cavity can be attached at a well-defined position, due to the precise
location of a unique cysteine of the protein. This is a particular advantage of the
covalent anchoring strategy. Moreover, catalytic systems having different catalytic
properties can be created via covalent anchoring, using the same protein scaffold –
catalyst couple, simply by varying the location of cysteine inside protein’s cavity, as it
was proved by Distefano and co-workers.19 In other words, genetic optimization is an
efficient and easy to apply tool for the covalent approach. Also by using the covalent
strategy, an organometallic catalyst can be coupled to virtually any protein scaffold
displaying a unique, reactive and accessible cysteine.
The non-covalent incorporation of transition metal complexes into proteins has been
applied for the synthesis of several artificial metalloenzymes, but this concept has the
disadvantage of a limited structural diversity of the protein. So far this concept has been
successfully and extensively applied for the biotin-(strept)avidin couple.4,20-33 It was
also applied for serum-albumins,34-35 displaying high affinity for a variety of
hydrophobic compounds, for apomyoglobin34,36-37 capable of binding symmetric Schiff-
base complexes non-covalently and for antibodies38-42 raised against compounds
displaying a similar structure to the specific antigens.
Amongst the common methods reported for chemoselective thiol modification,
maleimide and haloacetamide reagents have been used for covalent anchoring of
organometallic catalysts into proteins, for the synthesis of artificial metalloenzymes.
The haloacetamide derivatives have good chemoselectivity towards cysteine at slightly
alkaline pH when low excess of modification reagent relative to the number of
sulfhydryl groups present is used.43 De Vries and co-workers applied this method for
selective covalent incorporation of a phosphite ligand into papain via a phenacyl
bromide moiety (Figure 1). The resulting artificial metalloenzyme, formed by treating
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the modified protein with excess [Rh(COD)2]BF4, was an active catalyst for the
hydrogenation of methyl 2-acetamidoacrylate, but no enantioselectivity was obtained.14
2 2 3
2 2 3
Figure 1 Monodentate phosphite ligand coupled covalently to papain via a phenacyl bromide moiety14
The same method was used by Davies and Distefano for chemoselective covalent
incorporation of 5-iodoacetamido-1,10-phenanthroline into two structurally related fatty
acid binding proteins (FABPs): ALBP5 and IFABP19 (Figure 2a). The Cu(II) complex of
the 1,10-phenanthroline modified proteins was subsequently formed. Good
enantioselectivities of 31-86% were reported for the hydrolysis of several unactivated
amino acid esters (Figure 2b) using the FABP-CuII-Phen,5 which were enhanced to 94%
e.e. after genetic optimization of the catalyst. Three different catalytic systems were
created by placing the phenanthroline catalyst into three different locations inside
IFABP cavity. The three catalytic systems displayed different rates and selectivities for
the hydrolysis reaction. This proves that the catalytic properties of an artificial
metalloenzyme created via covalent anchoring can be modified by changing the
attachment site of the metal complex into the protein cavity.19
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Figure 2 Cu(II)-Phenanthroline conjugates of fatty acid binding proteins (a) used as hybrid catalysts for
ester hydrolysis (b)
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Distefano’s work shows clearly the possibility of synthesizing highly active and
selective artificial metalloenzymes by attaching transition metal complexes covalently
to proteins. FABPs proved to be good chiral inducers as protein scaffold, probably
because of the good encapsulation of the organocatalyst into the protein cavity. This
observation was an incentive for us to test ALBP for covalent coupling of transition
metal complexes of phosphorus and nitrogen containing ligands, which are very
attractive for the synthesis of artificial metalloenzymes, as they are able to catalyse
efficiently a variety of important homogeneous catalytic reactions.
The maleimide reagents display high selectivity toward thiol modification at neutral pH.
The reaction rates of maleimides with sulfhydryls at pH 7 is reported to be 1000 greater
than the reaction with amines.43 Chemoselective modification of papain and of the
protein tHisF-C9AD11C (a thermostable enzyme from Thermotoga maritime) via
Michael addition to the maleimide double bond of a Pd complex of N-(di(pyridine-2-
yl)methyl)maleimide (Figure 3a) was reported by Reetz and co-workers.16 The protein
tHisF-C9AD11C was also used as host for covalent incorporation of a Rh-complex of 5-
maleimido-1,10-phenanthroline (Figure 3b) via Michael addition to the maleimide
group.44 The catalytic properties of the resulting artificial metalloenzymes were tested in
hydrogenation reactions, but low activities and enantioselectivities were obtained.16,44
2
Figure 3 (a) Pd complex of N-(di(pyridine-2-yl)methyl)maleimide coupled via Michael addition to
papain and tHisF-C9AD11C;16 (b) Rh-complex of 5-maleimido-1,10-phenanthroline coupled via Michael
addition to tHisF-C9AD11C;44
Considering the high affinity of maleimides towards thiol modification, I used this
method to explore the efficient, site selective incorporation of metal complexes of
nitrogen and phosphane ligands intro three different protein scaffolds: ALBP, Δ98Δ and 
AppA mutants. The choice of proteins was determined, as mentioned in Chapter II, by
their different cavity structure and by a different degree of catalyst encapsulation.
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Various routes for covalent incorporation of Pd and Rh metal complexes of phosphane
and nitrogen ligands into structurally diverse proteins were explored. Site selective
incorporation of metal complexes of phosphane ligands for the efficient synthesis of
artificial metalloenzymes has become feasible recently.1-3 A Rh complex formed
through coordinating a phosphane ligand, precoupled to a protein via hydrazone
ligation, to a Rh precursor was reported by our group.3 In addition, I report herein
coupling of a preformed Rh–complex of an aldehyde functionalized phosphane to a
hydrazide modified protein, via hydrazone ligation. Synthesis of artificial
metalloproteins containing metal complexes of 5-maleimido-1,10-phenathroline could
be accomplished via Michael addition of cysteine to 5-maleimido-1,10-phenathroline.
IV.2 Results and discussion
IV.2.a Metal complexes of phosphane ligands
The first approach to incorporate phosphane ligands into proteins was by coupling CDI
activated phosphane-carboxylic acids to the unique cysteine of a protein. By applying
this approach, covalent mono-modification of ALBP with phosphane 4 and covalent
mono-modification of Δ98Δ with phosphanes 2-5 (Chapter II) was obtained. These
results prompted us to explore subsequent incorporation of transition metal complexes
of these phosphanes into the two proteins. Catalysts comprised of phosphane ligands
coordinating Rh or Pd have been used for synthetically important transition-metal
catalysed transformations like hydrogenation, hydroformylation and allylic substitution.
With these types of reactions in mind, I set out to synthesise Rh and Pd based artificial
metalloenzymes.
Figure 4 Structures of phosphane-carboxylic acids 2-5
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Two methods were tested in order to achieve selective cysteine modification with
transition metal complexes in presence of the multiple functional groups of protein.
I initially explored in-situ formation of transition metal complexes of the phosphane-
modified proteins, by adding the metal precursor to the proteins modified with
phosphane ligands. [Pd(η3-C3H5)Cl]2, [Pd(η3-C3H5)(THF)2]BF4, and [Rh(cod)(MeCN)2]
BF4 were tested for potential coordination to the phosphane ligand 4 coupled to
proteins. However, the modified ALBP and Δ98Δ proved to be unstable in presence of 
these metal precursors. Formation of a precipitate soluble in 8M GuCl (a common
denaturating reagent which facilitates solubilization of precipitated proteins) was
observed after the metal addition. In each case, only species corresponding to the
unmodified proteins were observed by LC-MS (ES+). Additives to prevent protein
precipitation (glycerol, NaCl, MgCl2), or the use of a co-solvent (acetonitrile) to
improve the solubility of modified protein did not solve the problem.
A possible cause of protein precipitation is structural modification and subsequent
instability induced by metal coordination to donor sites present in the protein. To avoid
this, I tried to couple preformed metal-complexes of ligands 4 and 5 to the unmodified
proteins. First, preformed Pd-4 metal complexes, synthesized from [Pd(η3-C3H5)Cl]2 or
[Pd(η3-C3H5)(THF)2]BF4 and CDI activated ligand 4 (Scheme 1) were coupled to ALBP
and Δ98Δ. Once again formation of a yellow precipitate soluble in 8M GuCl was 
observed during the coupling reaction. Protein precipitation was observed also in
presence of the previously mentioned additives (glycerol, NaCl, MgCl2). Moreover, at
the end of the coupling reactions of preformed Pd-4 metal complexes less than 25% of
the initial amount of protein was present in solution (Bradford assay), for both proteins
tested. No species having the mass corresponding to the protein modified with
phosphane ligand or with the metal complex were observed by LC-MS (ES+).
Scheme 1 Synthesis of Pd-(η3-C3H5) complexes of p-(diphenylphosphane)benzoic acid
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Coupling of CDI activated carboxylic acid-phosphanes to proteins in buffered solutions
did not lead to protein precipitation for any of the proteins investigated. Therefore the
preliminary hypothesis was that the instability of modified proteins in presence of
transition metal complexes is caused by possible subtle structural modifications
resulting from coupling of these complexes. To determine if the instability of the
proteins is caused by the metal precursor or by the metal complex, the stability of the
apo-proteins in presence of several metal precursors: [Pd(η3-C3H5)Cl]2, [Pd(η3-
C3H5)(THF)2]BF4, Pd2(dba)3, Na2PdCl4 and [Rh(cod)MeCN]BF4 was investigated.
Both apo-proteins, ALBP and Δ98Δ, were stable in presence of all the tested metal 
precursors. In all situations, the small amount of precipitate observed after
centrifugation of the apo-proteins and metal complexes mixtures was not soluble in 8M
GuCl and the amount of residual proteins in supernatant was higher than 70%.
Therefore I concluded that even though covalent coupling of the carboxylic acid-
phosphane 4 to ALBP and Δ98Δ does not induce structural changes leading to protein 
precipitation, coupling of Rh and Pd metal complexes of 4 to the two proteins induces
their precipitation.
Chelating bidentate phosphane ligands can form structurally well defined transition
metal complexes. In addition, they display better selectivities in several metal catalysed
reactions, compared to mono-phosphane ligands. For this reason I synthesized the Pd
complex 6 and the Rh complex 7 of the CDI activated bidentate phosphane ligand 5 and
I attempted to couple them to Δ98Δ. Coupling of CDI activated ligand 5 to ALBP was
not successful, probably because of the large steric requirements of this ligand, but also
because of the enclosed cavity of ALBP, partially blocked by the -helical lid (see
Chapter II). Consequently, coupling of these two metal complexes could be obtained for
Δ98Δ, but not for ALBP. CDI activated ligand 5 was coupled to Δ98Δ, however 
incomplete conversion to the monomodified protein with 5 was obtained (see Chapter
II).
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Scheme 2 Synthesis of Pd-(η3-C3H5) complexes of CDI activated diphosphane ligand 5
Complex 6 was synthesized by reacting CDI activated ligand 5 with [Pd(η3-C3H5)Cl]2.
The attempt to couple the complex 6 to Δ98Δ resulted in addition of the allyl group to 
the protein. A mass corresponding to the allyl modified protein was observed by LC-
MS (ES+), but not other masses corresponding to the apo-protein or of the protein
modified with the metal complex were observed (Figure 5).
Figure 5 LC-MS (ES+) spectrum o
Rh complex 7 was synthesized by rea
(Figure 6) and was coupled to Δ98Δ
observed by LC-MS (ES+) (Figure 7)
when free ligand 5 was coupled to Δ9
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could be caused also by the large steric requirements of complex 7. Alternatively, the
instability of the Rh-modified protein could be a cause as the coupling results were not
reproducible regarding the coupling efficiency. Less than 50% of the initial amount of
Δ98Δ was present in solution after the coupling reaction with complex 7 (Bradford
assay), suggesting again the instability of the modified protein in solution.
Figure 6 Structure of the Rh(acac) complex of CDI activated ligand 5
Figure 7 LC-MS (ES+) spectrum of the reaction mixture of Δ98Δ with the complex 7
Next I considered the synthesis of Pd-complexes of phosphane sulfides. N-(4-
(diphenylphosphane sulfide)benzyl) maleimide was successfully coupled to ALBP and
Δ98Δ, but attempts to subsequently remove the S protecting group failed (see Chapter 
II).
Axially chiral P,S and S,S heterodonor ligands have previously been shown to be
suitable ligands for asymmetric Pd catalysed allylic substitution reactions.45-47 Inspired
by these studies, I attempted to synthesize in-situ the Pd complex of N-(4-
(diphenylphosphane sulfide)benzyl) maleimide coupled to Δ98Δ, using [Pd(η3-
C3H5)Cl]2 as metal precursor. After treating the phosphane sulfide modified protein
with the metal-precursor, no species having the mass of the protein modified with the
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metal complex were observed by LC-MS (ES+). Attempts to determine whether
palladium was coordinated to the phosphane sulfide by 31P-NMR required higher
concentration of the protein, which led to precipitation of the protein in presence of the
metal precursor. Therefore from the preliminary results I could not conclude if
coordination of the metal to the N-(4-(diphenylphosphane sulfide)benzyl) maleimide
occurred or not.
After incorporation of the BH3 protected click-phosphanes into ALBP, Δ98Δ and AppA 
(see Chapter II), the next attempt was to synthesize the corresponding transition metal-
hybrids. Previous studies reported synthesis of low oxidation state catalytic systems
from phosphane borane complexes. In particular, Rh(I) and Pd(0) phosphane complexes
were synthesized from Rh(III) or Pd(II) salts by making use of the reductive properties
of the borane protecting group.48-49 Inspired by these studies, I explored the synthesis of
Pd(0) and Rh(I) complexes of click-phosphane 8 using Pd(OAc)2 and RhCl3 as metal
precursors (Scheme 3). To avoid reduction of the maleimide double bond by the BH3
protecting group, the metal complexes synthesis was performed in presence of acrylic
acid as BH3 trapping agent.
Scheme 3 Attempt of synthesis of the Rh(I) complex of BH3 protected click phosphane from a Rh(III)
precursor. (a) 50%MeOH:50%THF, 1h, 70°C
31P NMR analysis of the crude reactions indicated BH3 deprotection of the phosphane
and possible formation of the Pd or Rh metal complexes, without reaching complete
conversion of the BH3 protected phosphane to the corresponding metal complex. About
a third part of the BH3 protected phosphane remained unreacted, as detected by 31P
NMR. The presence of unreacted phosphane suggests a possible coordination of the
nitrogen atom of the triazole ring to the metal centre. From the 1H NMR spectra of the
crude reactions it was not possible to conclude whether the maleimide double bond was
intact.
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The potential problem of the nitrogen atom coordinating to the metal centre may be
avoided by synthesizing the metal complex of diphenyl(propargyl)phosphane, followed
by coupling of the preformed metal complex to the corresponding N-(p-azidophenyl)-
maleimide via a click-reaction.50
Difficulties were encountered in characterization of the Pd and Rh complexes of the
click heterodonor ligands, probably due to the presence of several possible isomeric
structures, stemming from coordination of the N atom of the triazole ring to the metal
centre. Therefore I explored the Rh(I) complex synthesis of the ligand 11, aiming to
obtain a well defined metal complex by coordinating the ligand 11 as a tridentate P-N-P
ligand (Scheme 4). Again RhCl3 was used as metal precursor for the synthesis of the
metal complex. No evidence was obtained for the presence of an intact maleimide
double bond after the attempts to synthesis of the Rh complex 9 and the Pd complex 10.
Therefore, to prevent the possible reduction of the maleimide double bond by the BH3
group, I used acrylic acid as BH3 trapping agent. To achieve a possible P,N coordination
to Rh, the ligand:metal ratio used was 1:1.
Scheme 4 Attempt of synthesis of the Rh(I) complex of a BH3 protected diphosphane from a Rh(III)
precursor in presence of acrylic acid as BH3 trapping agent
The preliminary analysis of the crude reaction indicates that BH3 decomplexation and
Rh-complex formation was successful, but the maleimide double bond was reduced.
Therefore the resulting metal complex was unsuitable for protein modification. A
solution could be the use of more efficient BH3 trapping agents, e.g. cyclooctadiene.49
Following the successful incorporation of free phosphane ligands into proteins via
hydrazone ligation (see Chapter II), I attempted to coordinate transition metals to the
phosphane modified proteins. In situ formation of a Rh complex of p-
(diphenylphosphane)benzaldehyde coupled via hydrazone linkage to the sterol carrier
protein 2 like domain of MFE (SCP-2L V83C) was previously reported. The Rh
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complex was formed by treating the phosphane modified SCP-2L V83C with one
equivalent of Rh(acac)(CO)2, and the metal complex formation was confirmed by mass
spectrometry and 31P-NMR.3
Preliminary results indicate successful incorporation of a preformed Rh complex of p-
(diphenylphosphane)benzaldehyde to AppA Y21C. The Rh complex was formed by
reacting one equivalent of Rh(acac)(CO)2 with two equivalents of p-
(diphenylphosphane)benzaldehyde and it was coupled to the AppA Y21C pre-modified
with 3-(N-maleimido)propionic acid hydrazide.
Formation of a Rh complex having two monodentate phosphane ligands coordinating to
the metal centre was preferred because of a resulting well defined, stable structure of the
preformed metal complex.
LC-MS (ES+) spectrum of the crude reaction showed masses corresponding to the
protein modified with the phosphane ligand (a), with the phosphane oxide (b), with the
Rh-monophosphane complex (c) and in addition, with the Rh-diphosphane complex (d)
(Figure 8).
The att
step pro
couplin
(diphen
two dif
this gen
a partic
a differ
Future
comple
prelimi
comple
0
100
%Calculated
mass (Da)
LC-MS mass
found (Da)
Rh+CO (c)-(a) 130 129.5
p-diphenylphosphino benzaldehyde (d)-(c) 290 289.5
(a) 15850.5 15848.8
(b) 16866.5 15864.4
(c) 15980.4 15978.3191
Figure 8 LC-MS (ES+) of AppA Y21C modified with the Rh complex 19
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IV.2.b Metal complexes of N-containing ligands
Coupling of a metal complex of 2,2’-bipyridine-5-carboxylic acid via thioester bond
formation was not successful. No protein modification was obtained when I tried to
couple the [η6-(p-cymene)Ru(N∩N)(OH2)](OTf)2 complex, having as (N∩N) bidentate 
chelating ligand the NHS activated 2,2’-bipyridine-5 carboxylic acid, to ALBP.
Efficient and selective incorporation of two maleimide functionalized N-ligands into
three structurally different protein hosts was successful (see Chapter III). Subsequently,
I explored the synthesis of artificial metalloproteins containing Cu(II) and Ru
complexes of these N-ligands.
Selective incorporation of the Cu(II) complex of 1,10 phenanthroline into ALBP
(lacking the His-tag sequence) was previously reported by Distefano and co-workers.
Their results indicated ALBP as a robust scaffold for incorporation of this particular
metal complex and as a good chiral inducer.5 More recently, DNA hybrid catalysts
containing Cu(II) complexes of 1,10-phenanthroline were used for Diels-Alder51 and
Michael reactions52 in water. The cationic arene Ru complexes containing chelating
1,10-phenanthrolines were active catalysts for transfer hydrogenation reactions.53 Based
on that, I explored the synthesis of artificial metalloproteins containing Cu(II) and
cationic p-cymene Ru complexes of 1,10-phenanthroline.
In addition, I studied the possible influence of the His-tag sequence on ALBP and Δ98Δ 
stability by comparing my results with those reported by Distefano for ALBP and
IFABP lacking the His-tag sequence. I investigated the Cu(II) complex formation of 5-
maleimido-1,10-phenantroline precoupled to ALBP and Δ98Δ. After selective covalent 
incorporation of 5-maleimido-1,10-phenanthroline into ALBP and Δ98Δ (see Chapter 
III), the corresponding Cu(II) complexes were synthesized following the protocol
reported by Distefano and co-workers, by adding Cu(II) to a solution of modified
protein. Metal complex formation was confirmed by fluorescence spectroscopy and the
results obtained were in concordance with the results reported by Distefano and co-
workers for ALBP and IFABP mutants.5,19
The fluorescence emission spectrum of unmodified ALBP has an emission maximum at
340 nm, attributed to tyrosine and tryptophan residues. Compared to that, the spectrum
of ALBP modified with 5-maleimido-1,10-phenanthroline has the emission maximum
at 340 nm substantially reduced, likely due to quenching by phenanthroline, and has
also an additional emission maximum at around 420 nm attributed to the phenanthroline
fluorophore. Both the phenanthroline fluorescence as well as the protein fluorescence
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were quenched after addition of Cu(II) to the modified protein solution. Addition of
EDTA to the solution of protein modified with the Cu(II) complex resulted in Cu(II)
removal by EDTA and partial returning of phenanthroline fluorescence (Figure 9).
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Figure 9 Fluorescence emission spectra of: (a) ALBP, (b) ALBP modified with 5-maleimido-1,10-
phenanthroline, (c) ALBP modified with the Cu(II) complex of 5-maleimido-1,10-phenanthroline (d)
ALBP modified with the Cu(II) complex of 5-maleimido-1,10-phenanthroline in presence of excess
EDTA.
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Figure 10 Difference fluorescence spectrum obtained by subtracting: (a) the fluorescence spectra of
Δ98Δ from the spectra of Δ98Δ modified with 5-maleimido-1,10-phenanthroline; (b) the fluorescence 
spectra of Δ98Δ modified with Cu(II)-5-maleimido-1,10-phenanthroline from the spectra of Δ98Δ 
modified with Cu(II)-5-maleimido-1,10-phenanthroline in presence of excess EDTA.
Perturbation of the phenanthroline fluorophore coupled to 98 in presence of CuSO4
was proven by comparing two fluorescence difference spectra. One spectrum was
a
b
c
d
a.
b.
194
obtained by subtracting the spectrum of 98 from the spectrum of 98 modified with
5-maleimido-1,10-phenanthroline and the second one by subtracting the spectrum of
98 modified with the Cu(II) complex of 5-maleimido-1,10-phenanthroline from the
spectrum of 98 modified with the same Cu(II) complex in presence of excess EDTA.
A similar shape was observed in both cases, in agreement with the results reported by
Distefano and co-workers.19 When the fluorescence properties of three IFABP mutants
modified covalently with 1,10-phenanthroline were explored, the results indicated the
IFABP mutants as less amenable for this sort of analysis. Only one modified mutant,
IFABP L72C, exhibited significant phenanthroline fluorescence.19 Δ98Δ is a genetically 
engineered variant of IFABP, which lacks the N-terminal 1-28 amino acids and the last
five amino acids belonging to the C-terminus.54 Belonging to the IFABP class, it is
expected that the differences in the fluorescence spectra of apo and modified-Δ98Δ to 
be less evident regarding the phenanthroline fluorescence.
Although the His-tag sequence was present for both proteins, ALBP and Δ98Δ, the 
formation of the metal complex did not induce protein instability. These results show
that the stability of an artificial metalloenzyme construct depends on the protein scaffold
as well as on the metal and the ligand type. Several subtle interactions between metal
complex and protein could lead to an unstable construct.
Figure 11 Structures of 3-(N-maleimido)-(N,N-bis(2-picolyl))-propanamide) (13), 5-maleimido-1,10-
phenanthroline (14) and 3-(N-maleimido)-propionic acid (15)
After successful incorporation of the Cu(II)-1,10 phenanthroline into ALBP and Δ98Δ, I 
tried to incorporate [η6-(p-cymene)Ru(N∩N)Cl]Cl and [η6-(p-cymene)Ru(N∩N)(OH2)]
(OTf)2 complexes, with N∩N being either the bidentate chelating ligand 3-(N-
maleimido)-(N,N-bis(2-picolyl))-propanamide) or 5-maleimido-1,10-phenanthroline.
This type of complexes has the advantage of being stable, soluble and catalytically
active in aqueous conditions.53
Figure 12 Possible structure of the η6-(p-cymene)Ru complex of 13
When metal complex 16 was allowed to react with ALBP and AppA Y21C, LC-MS
(ES+) spectra showed only the peaks corresponding to the proteins modified with 3-(N-
maleimido)-propionic acid (Figure 18), which is the product of hydrolysis of the amide
bond of 13. The metal complex 16 was formed in dichloromethane and was also
detected in the reaction mixture (LC-MS (ES+)). However it is possible that the amide
bond becomes more labile upon coordination of the central N atom to Ru centre and in
aqueous conditions 15 is released as a result of hydrolysis.
Figure 13 LC-MS (ES+) spectrum of the
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was decreasing in time, being replaced by the peaks corresponding to the protein
modified with complex 18 (17128.7) and the protein modified with the maleamic acid
adduct of complex 17 (17166.1). To prove that the complex 18 is formed upon
hydrolysis of the complex 17 coupled to ALBP in aqueous conditions, I synthesized and
coupled the derived complex 18, which is stable in water. This metal complex was
successfully incorporated into ALBP and into the two AppA mutants: Y21C and Q63C
(Table 1).
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Figure 14 η6-(p-cymene)Ru complexes of 5-maleimido-1,10-phenanthroline
Figure 15 LC- MS (ES+) of ALBP modified with complex 17
Table 1 ALBP and AppA chemical modification with Ru complex 18
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ALBP-17 17150.8 17145.9
17166.1
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Mass (Da)
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ALBP 16604.8 16604.2
ALBP -18 17131.3 17130.5
AppA Q63C 15430.1 15430.5
AppA Q63C -18 15956.6 15956.9
AppA Y21C 15395.1 15394.9196
AppA Y21C -18 15921.6 15921.7
Incomplete modification of the three proteins with the Ru-complex 18 was obtained
(Figure 16). Conversion was estimated at 62% for ALBP, 44% for AppA Y21C and
32% for AppA Q63C. These results were obtained after correction of the LC-MS data
for the differences in ionization efficiency between the modified and unmodified
proteins, which was estimated by adding half of equivalent of unmodified protein to the
crude reaction mixture.
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therefore the addition of a mass of 16 Da caused by oxidation of a methionine residue of
the protein should also be considered, instead of addition of water to the metal complex.
IV.3 Conclusions
Artificial metalloenzymes can be synthesized via covalent incorporation of transition
metal complexes (Rh, Pd) of phosphane ligands into proteins.1,3 However, the success
of the approach might be influenced by several factors like the metal precursor, the class
of phosphane ligand (mono- or diphosphane) and most important, the protein scaffold.
Pd and Rh metal complexes of phosphane ligands proved to induce protein instability
for the particular proteins tested (ALBP and Δ98Δ). A possible cause could be the 
presence of the His-tag sequence attached at the N-terminus of ALBP and at the C-
terminus of Δ98Δ, displaying high affinity toward metal coordination. Future work on 
attaching the phosphane metal complexes after the enzymatic cleavage of the His-tag of
AppA, ALBP and Δ98Δ might reveal different coupling results.   
Herein I report a general method for incorporation of phosphane complexes into
proteins, applicable for a wide protein structure and catalyst space. By using this
method, the potential incompatibilities between a particular organometallic catalyst and
a protein scaffold could be surpassed by varying the protein space. In particular, even if
incorporation of Pd and Rh complexes was not compatible with ALBP and Δ98Δ 
protein structures, the approach has been successful for other protein scaffolds (PYP1
and MFE SCP-2L V83C3).
A careful selection of the metal complexes and of the protein hosts is required. Robust
proteins, displaying high stability over a wide range of pH, but also soluble and stable in
organic solvents, could be a good choice.
Covalent coupling of Cu and Ru complexes of N-ligands to proteins proved to be less
troublesome regarding the stability of modified proteins (for the particular case of the
proteins studied in this work). Efficient and selective covalent modification of three
protein scaffolds with Cu and Ru complexes of 5-maleimido-1,10phenathroline was
obtained. Artificial metalloproteins containing Ru complexes of 1,10-phenanthroline
have not been reported before. Both Cu and Ru hybrids are stable in buffered solutions
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and are suitable to be tested for reactions catalysed by complexes of 1,10-
phenanthroline (Michael additions,52 Diels-Alder reactions,55 transfer hydrogenation56-
57).
IV.4 Experimental
IV.4.1 General methods
Chemicals were purchased from Aldrich, Fluka and Strem Chemicals and were used as
received. NMR spectra were recorded at room temperature on Bruker Avance 400 and
300 spectrometers. Positive chemical shifts (δ) are given (in ppm) for high-frequency 
shifts relative to a TMS reference (1H and 13C). 13C spectra were measured with 1H
decoupling. Multiplicities are indicated by: s (singlet), d (doublet), dd (doublet of
doublets) and m (multiplet). All reactions involving phosphanes were performed under
an argon atmosphere using degassed solvents and standard Schlenk techniques.
Fluorescence measurements were performed using a Varian Cary Eclipse Fluorescence
Spectrophotometer.
Protein stability (apo and modified proteins) was quantified by Bradford assay and
SDS-PAGE.
Proteins chemical modification was assessed by LC-MS (ES+). The protein sample (20
μL, 5 pM/μL) was desalted on-line through a XTerra MS C8 2.1 × 10 mm column, 
eluted with an increasing acetonitrile concentration (2 % acetonitrile, 98 % aqueous 1 %
formic acid to 98 % acetonitrile 2 % aqueous 1 % formic acid and delivered to an
electrospray ionisation mass spectrometer (LCT, Micromass, Manchester, U.K.) which
had previously been calibrated using myoglobin. An envelope of multiply charged
signals was obtained and deconvoluted using MaxEnt1 software to give the molecular
mass of the protein.
The sequence of ALBP reported by Bernlohr et al58 was used as reference for the mass
of ALBP C1A his-tagged mutant. For the mass of the 98 mutant, the 98 sequence
reported by Delfino et al54 was used as reference and for the mass of AppA mutants the
AppA sequence reported by Laan et al59 was used.
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[Rh(cod)(CH3CN)2]BF4 – was prepared according to a literature procedure60 and it was
kindly provided by Dr Wouter Laan (University of St Andrews).
[Pd(η3-C3H5)(THF)2]BF4 – was synthesized according to a literature procedure61 and it
was kindly provided by Dr Wouter Laan (University of St Andrews).
Attempts for in-situ formation of the Pd(η3-C3H5)-4-protein complexes
ALBP
45 nmol (0.45 eq) of [Pd(η3-C3H5)Cl]2 in 4.5 μl of dimethylformamide was added 
dropwise to a degassed solution of 100 nmol of ALBP-4 (1 eq.) in bicine (50 mM, 5 ml,
pH 8.5), in a Schlenk tube. The reaction mixture was stirred at room temperature for 16
hours. The unreacted palladium was removed by centrifugation (49,000 g, 4°C, 10 min).
The supernatant was transferred to a centrifugal concentrator (Amicon Ultra 15, 10,000
MWCO), diluted to 10 ml with degassed Tris·HCl (50 mM, pH 8) and concentrated to 
0.5 ml. This step was repeated four times after which the protein solution was
concentrated to 1 ml and stored at 4C.
The attempt to form in-situ the Pd complex of ALBP-4 using [Pd(η3-C3H5)(THF)2]BF4
as metal precursor was performed as described for [Pd(η3-C3H5)Cl]2. 90 nmol (0.9 eq.)
of [Pd(η3-C3H5)(THF)2]BF4 in 1.8 μl of tetrahydrofuran was used for metal complex 
formation.
Δ98Δ 
The attempts to form in-situ the Pd(η3-C3H5)-4-Δ98Δ complexes starting from [Pd(η3-
C3H5)Cl]2 and [Pd(η3-C3H5)(THF)2]BF4 and Δ98Δ-4 were performed as described for
ALBP-4.
Attempts for in-situ formation of the Rh-4-protein complexes
ALBP
100 nmol (1 eq.) of [Rh(cod)(MeCN)2]BF4 in 2 μl of acetonitrile was added dropwise to 
a degassed solution of 100 nmol of ALBP-4 (1 eq.) in bicine (50 mM, 5 ml, pH 8.5), in
a Schlenk tube. The reaction mixture was stirred for 16 hours at room temperature. The
unreacted rhodium was removed by centrifugation (49,000 g, 4°C, 10 min). The
supernatant was transferred to a centrifugal concentrator (Amicon Ultra 15, 10,000
MWCO), diluted to 10 ml with degassed Tris·HCl (50 mM, pH 8.0) and concentrated to 
0.5 ml. This step was repeated four times after which the protein solution was
concentrated to 1 ml and stored at 4C.
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Δ98Δ 
The attempt to form the Rh complex of Δ98Δ-4 starting from [Rh(cod)(MeCN)2]BF4
was performed as described for ALBP-4.
The attempts for in-situ formation of the Rh and Pd 4-protein complexes were also
performed in presence of the following common additives used to prevent protein
precipitation: 10% glycerol; 80mM MgCl2; 500 mM NaCl; 25% acetonitrile; 10%
glycerol and 500mM NaCl; 10% glycerol and 80 mM MgCl2; 10% glycerol, 500mM
NaCl and 80mM MgCl2.
CDI activation of ligands 4 and 5 – was performed as described in Chapter II.
Synthesis of activated 4-Pd(η3-C3H5)Cl
50 μmol (2.6 eq.) of CDI activated ligand 4 in 1 ml of dimethylformamide was added to
19 μmol (6.9 mg, 1 eq.) of [Pd(η3-C3H5)Cl]2. The yellow reaction mixture was left at
room temperature for 30 min., after which the solution was used for protein
modification.
Synthesis of activated 4-Pd(η3-C3H5)(THF)
50 μmol (1.3 eq.) of CDI activated ligand 4 in 0.5 ml of dimethylformamide was added
to 38 μmol (1 eq.) of [Pd(η3-C3H5)(THF)2]BF4 in 0.5 ml of tetrahydrofuran. The yellow
reaction mixture was left at room temperature for 30 min., after which the solution was
used for protein modification.
Attempts to couple the activated 4-Pd(η3-C3H5)Cl to ALBP
2.5 μmol (25 eq.) of activated [4-Pd(η3-C3H5)Cl] was added slowly to a degassed
solution of 100 nmol of ALBP (1 eq.) in 5 ml Tris·HCl (50 mM, pH 8), in a Schlenk
tube. The reaction mixture was stirred for 16 hours at room temperature. The unreacted
palladium complex was removed by centrifugation (49,000 g, 4°C, 10 min). The
supernatant was transferred to a centrifugal concentrator (Amicon Ultra 15, 10,000
MWCO), diluted to 10 ml with degassed Tris·HCl (50 mM, pH 8) and concentrated to 
0.5 ml. This step was repeated four times after which the protein solution was
concentrated to 1 ml and stored at 4C.
Attempts to couple the activated 4-Pd(η3-C3H5)Cl to Δ98Δ 
A solution of 100 nmol of Δ98Δ (1 eq.) in Tris·HCl (50 mM, 5 ml, pH 8) was degassed 
by purging with argon for 8 hours, in a Schlenk tube. The disulfide bridges were
reduced using 6-fold molar excess TCEP (12 μl of stock solution of 50 mM in water). 
The reduction reaction proceeded for 1 hour at room temperature. While stirring, 2.5
μmol (25 eq.) of activated [4-Pd(η3-C3H5)Cl] was added slowly. The reaction mixture
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was stirred for 16 hours at room temperature. The unreacted palladium complex and
TCEP were removed by centrifugation (49,000 g, 4°C, 10 min). The supernatant was
transferred to a centrifugal concentrator (Amicon Ultra 15, 10,000 MWCO), diluted to
10 ml with degassed Tris·HCl (50 mM, pH 8) and concentrated to 0.5 ml. This step was 
repeated four times after which the protein solution was concentrated to 1 ml and stored
at 4C.
Attempts to couple the activated 4-Pd(η3-C3H5)THF to ALBP – was performed as
described for the activated 4-Pd(η3-C3H5)Cl.
Attempts to couple the activated 4-Pd(η3-C3H5)THF to Δ98Δ – was performed as
described for the activated 4-Pd(η3-C3H5)Cl.
Synthesis of the complex 6
50 μmol (2.2 eq.) of CDI activated ligand 5 in 1 ml of dimethylformamide was added to
22.5 μmol (8.2 mg, 1 eq.) of [Pd(η3-C3H5)Cl]2. The yellow reaction mixture was left at
room temperature for 30 min., after which the solution was used for protein
modification.
Attempt to couple the complex 6 to Δ98Δ - was performed as described for the
activated [4-Pd(η3-C3H5)Cl].
Synthesis of the complex 7
20 μmol (1 eq.) of CDI activated ligand 5 in 0.4 ml of dimethylformamide was added to
18 μmol (4.64 mg, 0.9 eq.) of [Rh(acac)(CO)2]. The yellow reaction mixture was left at
room temperature for 30 min., after which the solution was used for Δ98Δ modification.  
Coupling of the complex 7 to Δ98Δ - was performed as described for the activated [4-
Pd(η3-C3H5)Cl].
Attempt to synthesize the Pd complex of N-(4-(diphenylphosphane sulfide)benzyl)
maleimide coupled to Δ98Δ 
The synthesis of this Pd complex was attempted based on a reported literature
procedure.47
0.45 μmol (0.16 mg, 0.9 eq.) of [Pd(η3-C3H5)Cl]2 in 9 μl of tetrahydrofuran was added 
dropwise to a degassed solution of 1 μmol (2 eq.) of Δ98Δ modified with N-(4-
(diphenylphosphane sulfide)benzyl) maleimide in Tris·HCl (50 mM, 50 ml, pH 7), in a 
Schlenk tube. The reaction mixture was stirred for 4 hours at room temperature. The
unreacted palladium was removed by centrifugation (49,000 g, 4°C, 10 min). The
supernatant was transferred to a centrifugal concentrator (Amicon Ultra 15, 10,000
MWCO), concentrated to 2 ml, diluted to 10 ml with degassed Tris·HCl (50 mM, pH 7) 
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and concentrated again to 2 ml. This step was repeated four times after which the
protein solution was concentrated to 1 ml and stored at 4C.
Attempt to synthesize the Rh complex 9
The synthesis of this Rh complex was attempted based on a reported literature
procedure.49
30 μmol (13.57 mg, 3 eq.) of click-compound 8 and 10 μmol (2.62 mg, 1 eq.) of RhCl3
were dissolved in 5 ml of anhydrous mixture methanol: tetrahydrofuran (1:1). The
reaction mixture was heated at reflux for 1 hour. After cooling, the solvent was removed
under reduced pressure and the residue was analysed by NMR spectroscopy.
31P {1H} NMR (121 MHz, MeOD): δ=17.1 (br), 38.64 (dd, J=108.12, 16.99), 46.82 (dd, 
J=110.04, 16.97) ppm
Attempt to synthesize the Rh complex 9 in presence of acrylic acid – was performed
in similar conditions as described above. 100 μmol of acrylic acid (7.2 mg, 10 eq.) was 
added to the reaction mixture before refluxing.
Attempt to synthesize the Pd complex 10
The synthesis of this Pd complex was attempted based on a reported literature
procedure.49
30 μmol (13.57 mg, 2 eq.) of click-compound 8 and 15 μmol (3.36 mg, 1 eq.) of 
Pd(OAc)2 were dissolved in 1 ml of anhydrous tetrahydrofuran and the reaction mixture
was stirred at room temperature for 30 min. Formation of a pale yellow precipitate was
observed after the first 10 min. The solvent was removed under reduced pressure and
the residue was analysed by NMR spectroscopy.
31P {1H} NMR (162 MHz, DMSO): δ=16.25 (br), 16.87 (br), 19.60 (br), 20.08 (br) 
ppm.
Synthesis of 11
bis(2-(diphenylphosphane)ethyl)amine hydrochloride
This compound was synthesized according to a literature procedure62 and was kindly
provided by Marzia Nuzzolo (University of St. Andrews).
Borane protected bis(2-(diphenylphosphane)ethyl)amine hydrochloride
The borane protection of bis(2-(diphenylphosphane)ethyl)amine hydrochloride was
done based on a reported literature procedure.63 A Schlenk tube containing the
solution of bis(2-(diphenylphosphane)ethyl)amine hydrochloride (1.08 mmol,
517.55 mg, 1 eq.) in tetrahydrofuran (8 ml) was placed on ice-bath and a 2M
solution of BH3SMe2 (2.27 mmol, 1.14 ml, 2.1 eq.) in tetrahydrofuran was slowly
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added via syringe, under stirring, into the ice cooled flask. After that the solution
allowed to reach room temperature and the stirring was continued for another 10
minutes, when the reaction was complete, according to the 31P NMR spectrum of the
crude. The excess of BH3SMe2 was removed by adding toluene and evaporating the
solvent under vacuum, process repeated 3 times. The product was obtained as a
white solid. Yield 100%.
1H NMR (400 MHz, CDCl3): δ=10.2 (s, br, 1H, NH), 7.50-7.37 (m, 12 H, ar), 7.70-
7.62 (m, 8H, ar), 3.10 (m, 2H, CH2), 2.81 (m, 2H, CH2), 1.30-0.53 (br, 3H, BH3)
ppm. 31P {1H} NMR (162 MHz, CDCl3): δ=12.92 ppm. 11B {1H} NMR (128 MHz,
CDCl3): δ=-40.1 ppm. 
3-(N-maleimido)propionyl chloride – was synthesized according to a literature
procedure 64 and was used for the next step without further purification.
Synthesis of 11
The synthesis of the compound was done according to a modified literature procedure
62. A Schlenk tube containing a mixture of borane protected bis(2-(diphenylphosphane)
ethyl)amine (1.8 mmol, 924.25 mg, 1 eq.) and triethylamine (7.8 mmol, 786.14 mg, 1.1
ml, 4.25 eq.) in dichloromethane (15 ml) was placed on ice-bath and the 3-(N-
maleimido)propionyl chloride (2.0 mmol, 377.22 mg, 1.1 eq.) in dichloromethane (1.5
ml) was added dropwise, under stirring, into the ice cooled flask. The solution allowed
to reach room temperature and the stirring was continued for another 16 hours at room
temperature. After that the solution was treated with 2M HCl (2x25 ml), the organic
phase was dried over MgSO4, filtered and concentrated under reduced pressure. The
residue was purified by silica gel flash chromatography (10% ethyl acetate in
dichloromethane) to afford 11 as white solid. Yield: 70% (793.7 mg).
1H NMR (400 MHz, CDCl3): δ= 7.76-7.61 (m, 8H, ar), 7.50-7.33 (m, 12H, ar), 6.64 (s, 
2H, CH=CH maleimide), 3.81-3.68 (t, J=7.36 Hz, 2H, CH2), 3.54-3.40 (m, 2H, CH2),
3.33-3.20 (m, 2H, CH2), 2.63-2.30 (m, 6H, CH2), 0.50-1.44 (m, 6H, BH3) ppm. 13C
NMR (100.6 MHz, CDCl3): = 170.4 (2xCO), 169.8 (1xCO), 134.3 (CH=CH
maleimide), 132.0 (d, J=6.4, ar), 131.9 (d, J=6.4, ar), 131.7 (d, J=1.2, ar), 131.5 (d,
J=1.2, ar), 129.2 (d, J=10.0, ar), 129.0 (d, J=10.0, ar), 128.6 (d, J=55.6, ar),127.8 (d,
J=55.6, ar), 43.1 (d, J=6.9, CH2), 41.5 (d, J=4.8, CH2), 33.9 CH2, 31.5 CH2, 25.3 (d,
J=34.5, CH2), 23.7 (d, J=34.5, CH2) ppm. 31P {1H} NMR (162 MHz, CDCl3): δ=12.4, 
11.9 ppm (br). 11B {1H} NMR (128 MHz, CDCl3): δ= -39.8 ppm (br). HRMS (FTMS 
+): m/z calc. for C35H41B2N2O3P2 (M+H+): 621.2785; found: 621.2780.
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Attempt to synthesize the Rh complex 12
50 mmol (31 mg, 1 eq.) of ligand 11, 0.3 mmol (20.57 μl, 6 eq.) of acrylic acid and 50 
mmol (13.16 mg, 1eq.) of RhCl3 were dissolved 10 ml of dry methanol. The mixture
was heated at reflux for 1 hour. After cooling the solvent was removed under vacuum
and the orange residue was analysed by NMR spectroscopy. 1H NMR (300 MHz,
MeOD): no peak at 6.68 corresponding to the CH=CH of maleimide; 31P {1H} NMR
(121 MHz, MeOD): δ=52.73 (dd, J=127.4, J=23.58), 44.12 (dd, J=119.9, J=23.35).  
ESI-MS (ES+) m/z= 697.03 – corresponding to the compound having chemical formula
C35H36N2O3P2Rh. ([M] C35H34N2O3P2Rh requires 695.5)
Synthesis of complex 19
2
2
78 μmol (22.5 mg, 2 eq.) of p-(diphenylphosphane)benzaldehyde in 0.65 ml anhydrous
dimethylformamide was added to 39 μmol (19 mg, 1 eq.) of Rh(acac)(CO)2. The yellow
reaction mixture was left at room temperature for 30 min., after which the solution was
used for protein modification.
Coupling of complex 19 to AppA Y21C modified with 3-(maleimido)propionic acid
hydrazide
0.25 μmol (5 eq.) of complex 19 in 4.2 μl of dimethylformamide was added dropwise to 
a degassed solution of 50 nmol of AppA Y21C (1 eq.) modified with 3-(N-
maleimido)propionic acid hydrazide in potassium phosphate buffer (50 mM, 1 ml, pH
7), in a Schlenk tube. The reaction mixture was stirred for 5 hours at room temperature.
The unreacted rhodium complex was removed by centrifugation (49,000 g, 4°C, 10
min). The supernatant was transferred to a centrifugal concentrator (Amicon Ultra 15,
10,000 MWCO), diluted to 10 ml with degassed potassium phosphate buffer (50 mM,
pH 7) and concentrated to 0.5 ml. This step was repeated four times after which the
protein solution was concentrated to 1 ml and stored at 4C.
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Cu(II) complex formation of 5-maleimido-1,10-phenantroline modified proteins
(ALBP and Δ98Δ) was performed according to a reported literature procedure.5,19
Fluorescence spectroscopy of apo- and modified proteins (ALBP and Δ98Δ) with 5-
maleimido-1,10-phenanthroline and with the corresponding Cu(II) complexes was
performed according to a reported literature procedure.5,19
Complex 16 – was synthesized based on a reported literature procedure53 and was
kindly provided by Dr. Bianca Munoz (University of St Andrews).
Coupling of complex 16 to ALBP
A solution of 50 nmol of ALBP (1 eq.) in Tris·HCl (50 mM, 1 ml, pH 8) was degassed
by purging with argon for 8 hours, in a Schlenk tube. While stirring, 2.50 μmol (50 eq.) 
of complex 16 in 50 μl of water was added slowly. The reaction mixture was stirred for 
5 hours at room temperature. To remove the excess modification reagent, the reaction
mixture was transferred to a centrifugal concentrator (Amicon Ultra 15, 10,000
MWCO), diluted to 10 ml with degassed Tris·HCl (50 mM, pH 8.0) and concentrated to 
0.5 ml. This step was repeated four times after which the protein solution was
concentrated to 1 ml and stored at 4°C.
Coupling of complex 16 to AppA Y21C
A solution of 50 nmol of AppA (1 eq.) in buffer (Tris·HCl 50 mM, 1 ml, pH 7)
containing 3M imidazole was degassed by purging with argon for 8 hours, in a Schlenk
tube. While stirring, 2.50 μmol (50 eq.) of complex 16 in 50 μl of water was added 
slowly. The reaction mixture was stirred for 5 hours at room temperature. To remove
the excess modification reagent, the reaction mixture was transferred to a centrifugal
concentrator (Amicon Ultra 15, 10,000 MWCO), diluted to 10 ml with degassed
Tris·HCl (50 mM, pH 7.0) and concentrated to 0.5 ml. This step was repeated four times 
after which the protein solution was concentrated to 1 ml and stored at 4°C.
Figure 18 LC-MS (ES+) spectrum o
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1H NMR (400 MHz, D2O): δ= 0.68 (d, J = 5.1 Hz, 6H, iso-CH3), 1.98 (s, 3H, CH3), 2.31
(sept, J = 5.1 Hz, 1H, CH), 5.99 (d, J = 4.7 Hz, 2H, C6H4), 6.21 (d, J = 4.7 Hz, 2H,
C6H4), 7.01 (s, 2H, CH maleimide), 7.95 (m, 2H, CH= phen), 8.06 (s, 1H, CH= phen),
8.49 (d, J = 6.51, 1H, CH= phen), 8.69 (d, J = 6.2, 1H, CH= phen), 9.84 (d, J = 3.9, 2H,
CH= phen),. 13C NMR (100.6 MHz, D2O): =17.6 (CH3), 20.93 (CH(CH3)2), 20.96
(CH(CH3)2), 30.43 (CH(CH3)2), 83.3 (CH-C6H4), 86.5 (CH-C6H4), 86.6 (CH-
maleimide), 101.6 (C-C6H4), 103.9 (C-C6H4), 126.6 (CH= phen), 127.0 (CH= phen),
127.2 (C= phen), 128.4 (C= phen), 128.7 (CH= phen), 130.08 (C= phen), 135.30 (C=
phen), 136.3 (C= phen), 140.7 (CH= phen), 145.9 (C= phen), 146.6 (C= phen), 156.1
(CH= phen), 156.9 (CH= phen), 171.31 (C=O), 171.36 (C=O).19F{1H}NMR (, D2O,
ppm) -79.37 (CF3SO3).
MALDI-TOF m/z found: 529.084 (M.W. C26H25N3O3Ru = 528.56)
Coupling of complex 18 to ALBP– was performed as described for complex 16.
Coupling of complex 18 to AppA Y21C
50 nmol protein (1 eq.) was maintained for 4 hours in buffer (Tris·HCl 50 mM, 1ml) 
containing 3M imidazole, at pH 7.0 and was further dialysed against Tris·HCl (50 mM, 
pH 7.0) to remove the imidazole and degassed by purging with argon for 8 hours. 2.50
μmol (50 eq.) of 18 in 50 μl of D2O was added to the degassed protein solution (1 ml)
after dialysis. The reaction mixture was stirred at room temperature for 5h. To remove
the excess modification reagent, the reaction mixture was transferred to a centrifugal
concentrator (Amicon Ultra 15, 10,000 MWCO), diluted to 10 ml with degassed
Tris·HCl (50 mM, pH 7.0) and concentrated to 0.5 ml. This step was repeated four times 
after which the protein solution was concentrated to 1 ml and stored at 4°C.
Coupling of complex 18 to AppA Q63C – was performed as described for AppA
Y21C.
Coupling of complex 18 to AppA Y21C in presence of 3M imidazole
50 nmol protein (1 eq.) in buffer (Tris·HCl 50 mM, 1ml) containing 3M imidazole, at 
pH 7.0, was degassed by purging with argon for 8 hours. 2.50 μmol (50 eq.) of 18 in 50
μl of D2O was added to the degassed protein solution. The reaction mixture was stirred
at room temperature for 5h. To remove the excess modification reagent, the reaction
mixture was transferred to a centrifugal concentrator (Amicon Ultra 15, 10,000
MWCO), diluted to 10 ml with degassed Tris·HCl (50 mM, pH 7.0) and concentrated to 
0.5 ml. This step was repeated four times after which the protein solution was
concentrated to 1 ml and stored at 4°C.
Coupling of complex 18 to AppA Q63C in presence of 3M imidazole– was
performed as described for AppA Y21C.
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Figure 22 LC-MS (ES+) of AppA Y21C - 18
Figure 23 LC-MS (ES+) of AppA Y21C - 18 after addition of 0.5 equiv. of apo-protein
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Figure 24 MALDI MS/M
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MALDI-MS/MS analysis of the peptide at m/z 1448
The peptide Leu131-Lys138-18 was selected for MS/MS and the cysteine modification
was confirmed.
The MS/MS analysis was acquired to a maximum of 3000 laser shots or until the
accumulated spectrum reached a S/N ratio of 35. All MS/MS data were acquired using 1
keV collision energy.
The combined MS and MS/MS data were analysed, using GPS Explorer (Applied
Biosystems) to interface with the Mascot 2.1 search engine (Matrix Science, London,
UK), against the UniProt (Swiss-Prot and TREMBL combined) database (April 2009).
No species restriction was applied. The data was searched with tolerances of 100 ppm
for the precursor ions and 0.5 Da for the fragment ions, trypsin as the cleavage enzyme,
assuming up to one missed cleavage, carbamidomethyl modification of cysteines as a
fixed modification and methionine oxidation selected as a variable modification.
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